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ABSTRACT 
 
The expression of cancer testis antigens (CTAgs) is normally restricted to spermatogenic 
cells of the testis but is also present in many cancers including testicular germ cell tumours 
(TGCTs). CTAg-specific T cell responses have been identified in patients with other solid 
tumours, and here we identified CTAg-specific T cells in TGCT patients. MAGEA family-
specific T cell responses were detected in 21/49 patients with a magnitude of up to 0.149% 
of total peripheral blood mononuclear cells. Responses to multiple MAGEA antigens were 
frequently detected in seminoma patients irrespective of tumour stage. Conversely, 
NSGCTT patients only developed responses towards MAGEA3, which were strongly 
associated with disease progression. Longitudinal analysis revealed that the magnitude of 
MAGE-specific immune responses diminished over time by up to 95%, which correlated 
with the removal of tumour antigens. MAGE-specific CD8 T cells demonstrated cytotoxic 
potential against endogenously presented antigen.  
 
Tumour infiltrating T cells were antigen experienced, recently activated, oligoclonal 
populations; many of which expressed the inhibitory molecules, TIM-3 and PD-1. 
Proliferation and cytokine secretion was suppressed in vivo but was rescued with in vitro 
stimulation, indicative of an exhausted T cell phenotype.  
 
Our findings have significant implications in the development of novel CTAg-specific 
immunotherapy in patients with cancer.  
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CHAPTER 1: INTRODUCTION 
 
The Immune System 
The immune system of higher mammals has evolved into a complex system in order to 
effectively protect the body against a wide range of pathogenic microorganisms and 
abnormal self, such as cancerous cells (Delves and Roitt, 2000). The immune system 
comprises of many specialised cell types and soluble factors, which work in unison to 
protect the body against internal and external threats. The immune response is self-
regulating to circumvent excessive inflammation that would otherwise lead to tissue 
damage. It also discriminates against self and non-self, thereby only targeting foreign 
bodies  and  not  the  body’s  own  cells;  unless  these  have  been  altered  as  in  the  case  of  cancer.  
The inability of the immune system to distinguish between self and non-self can lead to 
the development of autoimmune disease. The   immune   system   consists   of   ‘innate’   and  
‘adaptive’ immunity, which work together to ensure rapid and efficient removal of 
invading pathogens. This project focuses primarily on T cell immunology, and the 
introduction focuses predominantly on the mechanisms of adaptive immunity, with a brief 
overview of innate immunity. 
 
Innate Immunity 
The innate immune response represents the most ancient form of immunity, in 
evolutionary terms. It involves the recognition of conserved features of pathogens via 
pattern recognition receptors, such as the Toll- like receptors (TLRs), expressed on the cell 
surface (Hoffmann et al., 1999). Neutrophils and macrophages are the most important 
phagocytic cells that patrol the body and destroy pathogens (Underhill et al., 1999). Other 
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important cells such as mast cells, basophils and eosinophils release inflammatory 
mediators such as histamine and proteolytic enzymes. The inflammatory environment 
recruits other innate cells such as dendritic cells to the site of pathological insult. 
 
The innate immune system provides rapid responses, but the huge diversity of pathogens 
means the innate response may be ineffective or overwhelmed by the invading organism. 
The innate response is vital for the activation of the adaptive immune response and 
minimises the damage by pathogens while the adaptive immune response is developing.  
 
Adaptive Immunity 
The adaptive immune response can take several days to develop and therefore this 
response alone is ineffective at protecting against pathogens. However, the adaptive 
immune response has several advantages over the innate response. Firstly, when an 
antigen is encountered more than once, each subsequent encounter is more rapid and 
more efficient. This vital feature of adaptive immunity is known as immunological 
memory. Secondly, the adaptive response is highly specific for a particular antigen and is 
long lived. The greater specificity and selectivity of an adaptive immune response is 
attributable to the vast repertoire of receptors that are somatically generated as the cell 
develops. This process allows each cell to have a unique specificity for recognition of 
pathogens or abnormal cells that have evaded the innate immune system (Arstila et al., 
1999). 
 
The adaptive immune system encompasses two major types of lymphocyte subsets that 
originate from a common lymphoid progenitor in the bone marrow. Each lymphocyte 
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expresses a unique receptor on the cell surface that is specific for a single antigen. When a 
naive lymphocyte recognises its cognate antigen for the first time, along with appropriate 
stimulatory signals, it proliferates creating a clonal population of effector cells specific for 
that particular antigen. Once the infection has been resolved, the majority of clonally 
expanded cells die; the antigens that originally provoked a response are no longer at levels 
required to sustain it (Callan et al., 2000). However, a population of memory lymphocytes 
remain. This enables a rapid response against the possible reoccurrence of the pathogen. 
The two major types of lymphocytes are B lymphocytes (B cells) and T lymphocytes (T 
cells). 
 
B Cells 
B cells use their surface bound immunoglobulin protein to recognise foreign antigens on 
extracellular pathogens. When a B cell encounters and binds its cognate antigen with high 
affinity, it proliferates and the daughter cells differentiate into antibody-secreting plasma 
cells or B memory cells. Activated B cells undergo isotype subclass switching and somatic 
hypermutation of complementarity determining regions (CDR) to generate high affinity 
antibodies (Brack et al., 1978). The high affinity soluble antibodies released by the plasma 
cells are of the same specificity to the parent B cell from which they were derived. Secreted 
antibodies either neutralise the function of the pathogen or induce opsonisation whereby 
the pathogen is ingested by phagocytes. Bound antibodies also act as a receptor for the 
first component of the complement system and initiate activation of the classical 
complement cascade leading to destruction of the target antigen. Memory B cells persist in 
bone marrow conferring long-term immunity to that particular antigen.  
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T Cells 
There are two major subtypes of T cells. Firstly, CD8 cytotoxic T cells, which when 
stimulated, directly kill virally infected cells or abnormal cells such as tumour cells. 
Secondly, CD4 helper T cells, which, during the adaptive immune response, activate other 
cells. Precursors of T cells (thymocytes) migrate from the bone marrow to the thymus 
where they mature and undergo selection processes. This ensures they are able to bind 
self-major histocompatibility complex (MHC) molecules (positive selection), yet not react 
strongly to self- antigens (negative selection) (Klein et al., 2009). 
 
TCR Gene Rearrangement within the Thymus 
During T cell development, thymocytes migrate through defined microenvironments of 
the thymus and rearrange their T Cell Receptor (TCR) genes. Predominantly, T cells 
express  TCRs  comprising  an  α  and  a  β  chain,  which   form  a  heterodimer   that  recognises  
antigenic peptides bound to MHC molecules.  The  α  chain is encoded by the variable (V) 
and  joining  (J)  segments,  whereas  the  β  chain  is  encoded  by  the  variable  (V),  the  joining  (J)  
and an additional segment, the diversity (D) segment (Davis, 1990). Initially, the  β  chain  
rearranges (Saint-Ruf et al., 1994), and is subsequently expressed alongside the  α  chain  and  
CD3 complex (Mallick et al., 1993). TCRs are associated with the CD3 complex, which is 
expressed by all T cells and is required for TCR surface expression and subsequent 
signalling (Reinherz et al., 1982). The  α  chain  gene   is  subsequently  rearranged   to   form  a  
functional   αβ   TCR (Petrie et al., 1993). The vast diversity of the TCR is due to the 
availability of numerous gene segments which can be differentially combined, as well as 
additional junction diversity where single nucleotide changes are introduced during gene 
rearrangement (Krangel, 2009). Ultimately, this leads to a large number of CD4 and CD8 
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double-positive (DP) thymocytes with a diverse   repertoire   of   unique   αβ   TCRs with 
random specificity. 
 
Central Tolerance 
During maturation, thymocytes express a unique TCR on their surface. Importantly, 
thymocytes are unable to recognise antigen on their own. Instead they recognise antigens 
bound to MHC molecules. The TCR affinity for self-peptide:MHC (pMHC) complexes 
determines a thymocytes fate from this point forward. DP thymocytes expressing TCRs 
that do not bind self-pMHC complexes die by delayed apoptosis by a process termed 
“death  by  neglect”.  Those  with  a low affinity for self-pMHC receive pro-survival signals 
and differentiate into CD4 or CD8 single-positive (SP) thymocytes in the thymic cortex by 
a process termed positive selection. However, those with a high-affinity TCR for self-
pMHC complexes are removed by apoptosis, in a process called negative selection. 
Medullary thymic epithelial cells (mTECs) play a crucial role in thymic tolerance in that 
they express a large number of tissue-specific self-antigens (TSAs) (Derbinski et al., 2001) 
under the regulation of the autoimmune regulator (AIRE) (Anderson et al., 2002). They 
induce apoptosis of tissue specific antigen (TSA)-specific thymocytes in the thymic 
medulla. Combined, these processes render developing T cells non-reactive to self and 
prevent the generation of autoimmune disease. Cells that survive the selection process 
leave the thymus and enter the bloodstream or the lymphatic system. This process of 
central tolerance is outlined in Figure 1. 
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Peripheral Tolerance 
While central tolerance is able to remove the majority of self-reactive T cells, some low 
avidity self-reactive T cells escape this process. Peripheral tolerance is developed when T 
cells have completed maturation within the thymus and have entered the periphery, and is 
vital for the prevention of autoimmune disease (Caspi, 2006). Peripheral tolerance is 
achieved  by  a  variety  of  mechanisms  including  organisation  of  ‘immune-privileged’  sites  
such as that of the testis. The localised inhibitory mechanisms at play within the human 
testis are detailed later in this chapter. Tolerance within these sites is mediated by passive 
mechanisms, for example, restricted access to specific sites, e.g. blood-testis barrier. In 
addition, tolerance is actively mediated by the generation of an immune-suppressive 
environment through the production of regulatory cytokines such as TGF-β   and   IL-10. 
Moreover, expression of inhibitory ligands, such as Fas ligand and PD-L1, in tissue such as 
testis could induce cell cycle arrest or apoptosis in infiltrating T cells.  
 
Antigen recognition by a T cell without subsequent costimulation generally results in T 
cell anergy, or hypo-responsiveness. This is particularly relevant to self-reactive T cells 
that escape central tolerance due to a low avidity interaction between TCR and pMHC 
(Redmond and Sherman, 2005). In addition, chronic exposure to antigen without 
costimulation can lead to activation-induced cell death (reviewed in (Walker and Abbas, 
2002)). Moreover, if immature DCs process and present antigen without subsequent 
maturation, they do so in a tolerogenic manner (Dhodapkar et al., 2001). Probably the most 
pertinent mechanism by which peripheral tolerance is mediated is through the action of 
CD4+FoxP3+ regulatory T cells (Tregs). The absolute requirement for Tregs to protect the 
host from autoimmune disease suggests these cells play a crucial role in maintaining self- 
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Figure 1. The generation of central tolerance in the thymus. 
Common lymphoid progenitors arise in the bone marrow and migrate to the thymus. Early 
committed T cells lack expression of T-cell receptor (TCR), CD4 and CD8, and are termed double-
negative (DN; no CD4 or CD8) thymocytes. As the thymocytes travel through the cortex they 
express the pre-TCR, which is composed of the non-rearranging pre-Tα   chain   and   a   rearranged  
TCRβ-chain. Thymocytes then become double positive (DP) replacement of the pre-TCRα-chain 
with  a  newly  rearranged  TCRα-chain  occurs,  yielding  a  complete  αβTCR.  The  thymocytes  are  then  
able to interact with cortical epithelial cells that express MHC class I and class II molecules 
associated with self-peptides. The fate of these DP thymocytes depends on signalling that is 
mediated by interaction of the TCR with these self-peptide–MHC ligands. The lack of pro-survival 
signalling results in apoptosis (death by neglect). In the medulla, too much signalling due to high 
avidity binding of self-antigens can induce pro-apoptotic signalling (negative selection). The 
appropriate, intermediate level of TCR signalling initiates effective maturation (positive selection). 
Thymocytes that express TCRs that bind self-peptide–MHC-class-I complexes become CD8 T cells, 
whereas those that express TCRs that bind self-peptide–MHC-class-II ligands become CD4 T cells. 
Mature cells leave the thymus and enter peripheral lymphoid tissues. SP, single positive. Adapted 
from (Germain, 2002) with consent (licence number: 3251880264723) 
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tolerance in the periphery (Sakaguchi et al., 2006). Importantly, many of these mechanisms 
outlined here are subverted in the course of tumour development, promoting tumour 
immune evasion and subsequently tumour growth.  
 
Antigen Processing and Presentation 
Antigens are derived from many sources including invading pathogens and self-proteins. 
T cells can only recognise antigens that are presented on the cell surface via MHC 
molecules. In humans, MHC molecules are also known as human leukocyte antigens 
(HLA), which are polygenic and very polymorphic. Consequently, there is huge variation 
in the exact peptides presented by the MHC (Horton et al., 2004). We all inherit multiple 
MHC class I genes (HLA-A, B and C) that present peptides to CD8 T cells, and MHC class 
II genes (HLA-DR, DP and DQ), which present antigenic peptides to CD4 T cells. The 
mechanism by which peptide processing occurs is different depending on whether 
peptides are presented on MHC class I or MHC class II. In general, antigens presented by 
MHC class I molecules are derived from endogenous proteins, whereas exogenous 
proteins taken up by endocytosis are presented by MHC class II. The concept of exogenous 
antigen presentation to CD8 T cells via the MHC class I pathway is known as ‘cross-
presentation’   (Bevan, 1976). This latter concept is particularly important in the context of 
tumour immunology. The details of all three pathways are summarised below (Figure 2).  
 
MHC Class I Antigen Presentation Pathway 
MHC class I molecules are expressed on almost all nucleated cells and allow the cell to 
display peptides from endogenously synthesised proteins. These proteins are degraded by 
the proteasome into small peptides of around 9 amino acids in length and are then 
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transported into the endoplasmic reticulum by transporter associated with antigen 
processing (TAP) (Cresswell et al., 2005). Here, peptides are loaded into the MHC class I 
molecules and translocated to the cell surface with the help of chaperone proteins (Rock et 
al., 1994, Bouvier, 2003). In the context of tumour immunology, CD8 T cells are able to 
survey the host cell proteome for the presence of tumour-associated and tumour-specific 
proteins, then target these abnormal cells accordingly. 
 
MHC Class II Antigen Presentation Pathway 
The constitutive expression of MHC class II is restricted to professional antigen presenting 
cells (APCs), including B cells, macrophages and dendritic cells (DCs). However, MHC 
class II expression can be induced in other cell types, including fibroblasts and certain 
tumours (Steimle et al., 1994, Guermonprez et al., 2003). Peptides processed and 
subsequently presented by MHC class II are usually derived from exogenously acquired 
proteins following internalisation, i.e. those contained within endolysosomal 
compartments (Rudensky et al., 1991, Watts, 2004). Peptides with a size of around 15 
amino acids are loaded onto nascent MHC class II molecules, and transported to the 
surface for recognition by CD4 T cells. Evidence suggests endogenously expressed 
proteins can also be presented by MHC class II molecules (Dengjel et al., 2005, Schmid et 
al., 2007). 
 
Cross Presentation 
Professional APCs are able to present exogenous antigens to CD8 T cells, in a process 
called ‘cross-presentation’   (Bevan, 2006). This phenomenon is extremely relevant in the 
context of tumour antigen presentation as it enables CD8 T cells to elicit a cytotoxic recall 
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response against tumour cells without requiring costimulation. Specifically, it allows a 
CD8 T cell response to be generated against an antigen that would otherwise be 
inaccessible to the MHC class I processing pathway. Proteins are potentially released from 
cells undergoing apoptosis or chemotherapy-induced-necrosis and endocytosed by 
neighbouring cells (usually DCs). This mechanism allows exogenous proteins to enter the 
MHC class II pathways. Importantly, mechanisms exist whereby extracellular proteins can 
enter the MHC class I pathway. Such mechanisms include DCs transporting endocytosed 
antigen from the endosome directly into the cytosol where it is degraded by the 
cytoplasmic proteasome. Peptides are then transported by TAP into the ER, and 
translocate to the cell membrane bound to MHC class I molecules, in a process similar to 
the classical MHC class I pathway (Ackerman and Cresswell, 2004, Nierkens et al., 2013). 
In addition, antigens can be degraded in the cytosol and imported into the recycling 
endosome by TAP molecules present in the endosomal membrane, where loading occurs 
on recycling MHC class I molecules (Albert et al., 1998). Another such mechanism is the 
degradation of antigens by endosomal proteases whereby these antigens are loaded onto 
MHC class I molecules in the endosomes, in a proteasome independent and TAP-
independent manner (Gromme et al., 1999). 
 
Alternative methods of cross presentation have been described which use mechanisms 
such as macroautophagy and trogocytosis, as well as the manipulation of gap junctions 
between DCs and tumour cells. Autophagy is an intracellular process, which degrades 
long-lived and misfolded proteins during cellular stress. Inhibition of autophagy results in 
the absence of cross presentation (Li et al., 2008). Trogocytosis is a process whereby MHC  
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Figure 2. Antigen presentation pathways in APCs. 
APCs have functional MHC class I and MHC class II presentation pathways. MHC class I molecules 
present peptides that are derived from proteins degraded mainly in the cytosol. MHC class II 
molecules acquire peptides that are generated by proteolytic degradation in endosomal 
compartments i.e. exogenous proteins. DCs have a unique ability to deliver exogenous antigens to 
the MHC class I pathway   by   ‘cross-presentation’.   TAP, transporter associated with antigen 
processing. Adapted from (Villadangos and Schnorrer, 2007) with consent (licence number: 
3251880596676) 
 
class I peptide complexes are transferred from the tumour to the DCs, allowing efficient 
presentation of tumour antigens to CD8 T cells and their subsequent activation (Wakim 
and Bevan, 2011, Wolfers et al., 2001). Tumour antigenic peptides could be transferred 
from the tumour cells to DCs via channels in gap junctions (Neijssen et al., 2005). Several 
publications demonstrate the transfer of peptides from apoptotic cells and tumour cells to 
DCs (Pang et al., 2009, Saccheri et al., 2010). Moreover, the transferred peptides were 
efficiently presented on MHC class I molecules and triggered activation of specific CD8 T 
cells. 
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Antigen Presenting Cells and Costimulation 
Professional APCs are able to process antigen with great efficiency and induce complete 
activation of naive T cells that have not previously encountered cognate antigen. 
Immature DCs scout peripheral tissues and take up antigen at sites of infection or within a 
tumour mass. They migrate to secondary lymphoid organs where they mature and present 
captured epitopes to T cells. 
 
APCs provide a second costimulatory signal at the point of TCR:pMHC interaction (Itano 
and Jenkins, 2003). This synergistic signalling by costimulatory molecules is necessary for 
optimal T cell proliferation and differentiation. Mature DCs are the most effective APC 
since costimulatory molecules are constitutively expressed following activation (Inaba et 
al., 1990), however, upon stimulation, B cells and macrophages can upregulate 
costimulatory molecules to act as professional APCs (Barker et al., 2002). The B7 
superfamily of costimulatory molecules interact with CD28 on the surface of T cells. CD28 
binding partners include CD80 (B7-1) and CD86 (B7-2), which are expressed on APCs. 
CD28 costimulation augments T-cell activation, and induces both T cell proliferation and 
IL-2 production. TCR engagement with pMHC in the absence of costimulation leads to a 
state of T cell anergy. Anergic T cells are characterised by their inability to secrete IL-2 and 
diminished proliferative capability, however their anergic state can be reversed due to 
their expression of CD25 (IL-2 receptor) (Schwartz, 2003). 
 
After successful activation, proliferation and differentiation of naive T cells following 
TCR:pMHC interaction with costimulation, the requirement for costimulation is lost. 
Consequently, exposure to antigen alone is adequate for subsequent T cell activation. 
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Importantly, a high proportion of CD8 T cells express NKG2D on their surface, which can 
act to augment TCR-dependent activation when bound to its corresponding ligand 
(Roberts et al., 2001). In contrast, CTLA-4 is upregulated on the surface of activated CD4 T 
cells, which upon ligation of CD80 and CD86, can result in cell cycle arrest, and 
termination of the T cell response. Both CTLA-4 and CD28 have the same binding 
partners, but CTLA-4 transmits an inhibitory signal whereas CD28 transmits a stimulatory 
signal (London et al., 2000). These concepts have significant implications for the function of 
tumour-specific T cells, whereby costimulation would not be provided directly by the 
tumour cell initiating the response. T cell fate under different conditions of TCR 
engagement is illustrated in Figure 3. 
 
T cell Memory and Activation 
Activated T cells clonally expand and differentiate into effector T cells. During 
differentiation, T cells demonstrate extensive heterogeneity in the expression of molecules 
such as cytokines, chemokine receptors and costimulatory molecules. After the initial 
immune response, a small proportion of these cells persist as either effector memory (TEM), 
or central memory (TCM) T cells (Lanzavecchia and Sallusto, 2005, Tanchot et al., 1997). A 
highly differentiated memory subset of CD8 T cells (TEMRA) can also develop, however 
this population is less common in CD4 T cells. The fate of naive T cells is not decided prior 
to cell division as they have the capacity to produce effector and memory T cell progeny 
following activation (Stemberger et al., 2007). Memory cells persist at low frequencies for 
many years by an equilibrium of homeostatic proliferation and cell death (Gourley et al., 
2004). 
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Figure 3. T cell fate under different conditions of TCR engagement. 
Simultaneous recognition of a specific pMHC complex by the TCR, and of CD80 or CD86 
by the costimulatory receptor CD28 results in T-cell activation, cytokine production, 
proliferation and differentiation. In the absence of CD28 costimulation, T cells become 
anergic or undergo apoptosis. After T-cell activation and upregulation of cytotoxic T-
lymphocyte antigen 4 (CTLA-4), its ligation with the TCR results in cell-cycle arrest and 
termination of T-cell activation. Adapted from (Alegre et al., 2001) with consent (licence 
number: 3251880862396). 
 
 
T cells can be separated into four major subsets based on the expression of chemokine 
receptor CCR7, and the CD45 high molecular weight isoform, CD45RA (Sallusto et al., 
1999). These subsets are termed naive (CCR7+CD45RA+), TEM (CCR7- CD45RA-), TCM 
(CCR7+CD45RA-), and the highly differentiated CD8 TEMRA (CCR7-CD45RA+). The 
expression of CCR7 is essential for the ability of naive and TCM cells to circulate through 
lymph nodes and sample the environment for cognate antigen. The expression of CCR7 
ligands, CCL19 and CCL21, in lymph nodes enables the migration of these cells into this 
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area (Rot and von Andrian, 2004). TCM have the ability to differentiate into effector cells 
upon antigen stimulation, but lack immediate effector function. In contrast, TEM 
downregulate CCR7 expression and upregulate the expression of tissue homing 
chemokine receptors e.g. CXCR3, enabling them to patrol peripheral tissues, including 
tumour sites. Upon antigen recognition, these cells are able to respond immediately with 
full effector function. TEMRA cells are produced primarily due to chronic viral-antigen 
stimulation, and re-express the CD45RA isoform. In this thesis, the detection of activated T 
cells ex vivo was required, and the markers used to distinguish activated cells from resting 
cells are outlined below. 
 
T cell stimulation causes the upregulation of several cell surface molecules including CD69 
and CD38. CD69 is a very early activation marker that is expressed on T cells within an 
hour of TCR:pMHC engagement. Moreover, it is the earliest known inducible cell surface 
glycoprotein acquired during T cell activation (Hara et al., 1986). CD38 is an ADP-ribosyl 
hydrolase expressed at variable levels on hematopoietic cells. It is highly expressed by 
subsets of thymocytes (Tenca et al., 2003) and antigen stimulated T cells (Sandoval-Montes 
and Santos-Argumedo, 2005, Shubinsky and Schlesinger, 1997).  
 
T cells respond to antigen by secreting cytokines and/or directly lysing target cells. The 
appropriate mechanism(s) depends on the T cell subtype being stimulated and the 
environment in which activation occurs. Cytotoxic CD8 T cells directly kill infected, 
abnormal and cancerous cells which display antigenic peptides through MHC class I on 
their surface. Two populations of CD4 helper T cells exist, namely Th1 and Th2. Both of 
these populations recognise peptides in the context of MHC class II on APCs (Mosmann 
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and Coffman, 1989). Classification into these distinct subsets is based on the cytokines 
secreted by the cells. Antigen dose and cytokines present in the environment when the 
cells are activated dictates the pathway the cells will follow (Rogers and Croft, 1999). Once 
naive Th0 cells have been polarised into Th1 or Th2 cells, commitment is not reversible, 
even under opposing polarising conditions (Murphy et al., 1996). 
 
Helper CD4 T cell Response 
The role of CD4 T cells in the adaptive immune response is to orchestrate and promote the 
function of other effector cells. This is achieved by the secretion of soluble factors 
including cytokines and chemokines. In addition, activation-induced expression of Fas 
ligand by CD4 T cells can mediate apoptosis in tumour cells expressing Fas.  
 
Th1 cells are polarised by IL-12 and type I interferons through induction of the 
transcription factors STAT4 and T-bet (Cho et al., 1996).  They  secrete  IFNγ  and  TNFα,  in  
order to instigate delayed-type hypersensitivity responses effective in the clearance of 
virally infected or cancerous cells. These inflammatory cytokines mediate the activation of 
phagocytes and the induction of opsonising and compliment activating antibodies. 
Furthermore, Th1 associated cytokines augment the cytotoxic T cell response by 
supporting CD8 T cell activation and up-regulating MHC class I expression on APCs.  
 
Th2 cells are polarised by the induction of STAT-6 and GATA3 (Rengarajan et al., 2000). 
They secrete IL-4, IL-5, and IL-13 and are important for the control of extracellular 
pathogens and allergies by mediating humoral immune responses. Additional CD4 T cell 
subsets have also been described. For example, Th17 cells, which secrete IL-17 and are 
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associated with many autoimmune diseases (Harrington et al., 2005, Park et al., 2005), and 
FoxP3+ Tregs, which play a crucial role in the suppression of immune responses (Asano et 
al., 1996, Takahashi et al., 1998). 
 
Cytotoxic CD8 T cell response 
CD8 T cells induce apoptosis in target cells by the release of cytolytic granules, which 
contain perforin and granzyme (Lieberman, 2003). Perforin binds to the target cell 
membrane and polymerises to form a transmembrane pore which allows granzyme to 
enter (Keefe et al., 2005). Granzyme consists of proteases that trigger caspase dependent 
apoptosis (Russell and Ley, 2002). Interaction between Fas ligand, expressed by CD8 T 
cells, and Fas receptor, expressed by the target cell, is another mechanism by which CD8 T 
cells mediate their cytotoxic effects. Engagement of these two molecules induces apoptosis 
of the target cells (Rouvier et al., 1993). Furthermore, activation of CD8 T cells induces the 
production of the effector   cytokines   IFNγ  and  TNFα.   Secreted   IFNγ   can   synergise  with  
TNFα   to   activate   macrophages   and   recruit   them   to   sites   of   inflammation.   In   addition, 
target cells up-regulate MHC class I molecules, increasing the likelihood of transformed 
cells being recognised by CD8 T cells (Zhou, 2009). 
 
NK Cells 
NK cells link the innate and adaptive arms of the immune system and have important 
anti-viral and anti-tumour functions. NK cells are large granular lymphocytes, derived 
from the common lymphoid progenitor, which circulate in lymphoid organs and 
peripheral tissues (Cooper and Caligiuri, 2004). 
 
18 
 
Activating and Inhibitory Receptors 
NK cells can be activated by stimulation via their activating receptors or by the lack of 
signal through their inhibitory receptors (Hamerman et al., 2005). Primarily, inhibitory 
receptors are specific for highly polymorphic MHC molecules, which enable them to 
mediate   ‘missing   self-recognition’- the ability to respond to self-cells that have lost 
expression of MHC class I molecules (Ljunggren and Karre, 1990). In addition, activating 
receptors expressed by NK cells, such as NKG2D, can bind ligand which is barely 
detectable in resting conditions but frequently expressed upon cellular stress. Such ligands 
include MICA and members of the ULBP family. Moreover, DNA lesions associated with 
tumour development activate the DNA damage response (DDR), resulting in the 
upregulation of NKG2D ligands and the subsequent killing of cancerous cells (Gasser et 
al., 2005). In summary, tumour cells can downregulate the necessary antigens identifying 
them as   ‘self’   and   also   upregulate   activating   ligands,   leading   to   NK   cell   mediated  
cytotoxicity. 
 
NK Cell Subsets 
NK cells are defined as a population of lymphocytes which express CD56, but are negative 
for CD3 and are subdivided into two subsets, namely CD56lowCD16+ and CD56hiCD16-. NK 
cells found in peripheral blood are predominantly the CD56lowCD16+ subset, accounting 
for approximately 90% of circulating NK cells. This subset has a greater cytolytic potential 
in the resting state, expressing high levels of cytotoxic granules, compared to the 
CD56hiCD16- subset. CD56hiCD16- NK cells are enriched in secondary lymphoid tissues 
and  demonstrate   superior  production  of   inflammatory  cytokines   including   IFNγ,  TNFα,  
and GM-CSF (Cooper and Caligiuri, 2004). 
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NK cells direct their cytotoxic effects in two ways. Firstly, NK cells constitutively express 
cytotoxic granules and are capable of inducing apoptosis in target cells via a MHC-
independent   mechanism.   Secondly,   CD16   (FcγRIIIA   immunoglobulin   Fc   receptor)  
expression allows NK cells to target cells to which a humoral response has been mobilized 
and to lyse cells through antibody-dependent cellular cytotoxicity (ADCC) (Tarkkanen et 
al., 1986). Moreover, the lysis of target cells directed by NK cell cytotoxicity could lead to 
cross-presentation of antigens released from target cell by a subset of DCs. This in turn 
could lead to activation of CD8 T cells and subsequent anti-tumour responses (Krebs et al., 
2009). Importantly, both NK cell subsets may be recruited by chemokines to sites of 
inflammation following tumour formation. 
 
Human Testis Structure and Function 
The testis has two key functions: the generation of gametes (spermatozoa) and the 
production and controlled release of androgens, predominantly testosterone. The 
formation of the testis is controlled by the expression of the SRY gene, which directs the 
embryonic gonads into the testis development pathway by activating male-specific 
transcription factors. In humans, the primordial germ cells derived from pluripotent stem 
cells proliferate and migrate from the endoderm of the yolk sac into the undifferentiated 
gonad by the fourth week of gestation. Histological development of the testis is largely 
completed by the end of the third month of gestation (Shalet, 2009). 
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Histology of the Human Testis 
The pubertal testis is a highly complex organ incorporating many specialised cell types 
including germ cells, Leydig cells and Sertoli cells. The testis is compartmentalised 
histologically and functionally, with androgen production and spermatogenesis being 
confined to separate regions. Spermatogenesis takes place in the seminiferous tubules and 
testosterone is synthesised by Leydig cells interspersed between the tubules. Germ cells 
are in intimate contact with Sertoli cells, which extend from the basal lamina toward the 
lumen of the tubules and constitute the main structural element of the seminiferous 
epithelium. They provide developmental signals and growth factors for germ cell 
differentiation. Surrounding the tubules are myoid peritubular cells that provide 
structural support and peristaltic properties to transport the immotile spermatozoa along 
the tubule. Tight junctions between neighbouring Sertoli cells generate the blood-testis 
barrier (BTB), dividing the seminiferous tubules into distinct compartments to protect the 
developing germ cells from the immune system. Immune cells such as macrophages, 
dendritic cells, mast cells, and T cells also reside in the interstitial space located between 
the tubules (Hedger, 1997, Rival et al., 2006). Macrophages are the largest population of 
immune cells located in the testis. These cells are derived from peripheral blood 
monocytes and migrate into the testis, where they mature (Frungieri et al., 2002). T cells 
constitute approximately 10 to 20% of the immune cells present in the human testis 
(Pollanen and Niemi, 1987). Natural killer cells and dendritic cells are also present within 
the interstitial space, but at relatively low numbers (Hedger, 2011). Testis morphology and 
cells likely to be involved in immune privilege is summarised in Figure 4. 
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Figure 4. Morphology and immune privilege in the human testis. 
Sertoli cells traverse the entire radius of the seminiferous tubules. Spermatogonia and more 
differentiated germ cells are in intimate contact with Sertoli cells at all stages of maturation. The 
myoid peritubular cells surround and protect the seminiferous tubules, and together with tight 
junctions between adjacent Sertoli cells form an impermeable physical barrier. This barrier forms 
the  basis  of  the  ‘blood–testis  barrier’,  although  immune  modulatory  mechanisms play a 
fundamental part in protecting the germ cells from immune mediated damage. The interstitial 
space located between the tubules contains the Leydig cells and immune cells such as macrophages, 
dendritic cells and T cells. Since immune cells exist in such close proximity to highly antigenic germ 
cells, an immune response would be generated without appropriate tolerance mechanisms 
(Adapted from (Immunopaedia.org, 2010) with permission).  
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Spermatogenesis 
Spermatogonial stem cells reside at the luminal side of the basal membrane, where they 
develop into highly specialised haploid spermatozoa by a tightly regulated process termed 
spermatogenesis. Spermatogenesis is a series of processes that produce an exceptionally 
large number of spermatozoa from a finite population of stem cells. This involves the 
mitotic proliferation of spermatogonial stem cells to form spermatogonia. DNA replication 
and differentiation of these cells generate primary spermatocytes. Two successive meiotic 
divisions follow to form haploid spermatids. Spermiogenesis completes the maturation 
process in the seminiferous tubules to produce highly differentiated spermatozoa. Sperm 
are then transported through the rete testis into the epididymis where they are 
concentrated and further matured ready for ejaculation.  
 
Regulation of spermatogenesis is a complex interplay of endocrine and paracrine signals 
and involves the synthesis and release of gonadotropin releasing hormone (GnRH) from 
the anterior hypothalamus. In turn, GnRH stimulates the synthesis and secretion of follicle 
stimulating hormone (FSH) and luteinising hormone (LH) from the anterior pituitary 
gland. Both FSH and LH are released into circulation in bursts and act synergistically in 
spermatogenesis. Although the exact mechanisms are not fully understood, FSH binds to 
its receptor on Sertoli cells and activates several signalling pathways (Walker et al., 1995), 
(Sharma et al., 1994). The Sertoli cells stimulated by FSH produce a paracrine factor that 
prevents apoptosis of differentiated spermatogonia. The survival of these cells amplifies 
the basal level of germ cell production, which is maintained by testosterone secreted by 
Leydig cells following the binding of LH (Plant and Marshall, 2001). 
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Testicular Immune Privilege  
During the process of spermatogenesis, a multitude of surface and intracellular proteins 
are expressed, which should be seen as foreign and eradicated accordingly. Surprisingly, 
these are tolerated by the testis and immunogenicity of these antigens is not diminished 
(Tung et al., 1981, Suescun et al., 1994). 
 
Sertoli cells play a pivotal role in immunological privilege. Highly specialised tight 
junctions between adjacent Sertoli cells form a blood-testis barrier (BTB), which restricts 
and regulates the passage of large molecules through the intercellular spaces (Cheng and 
Mruk, 2002) (Figure 4). This process creates a unique microenvironment for the developing 
germ cells and ensures that the composition of the tubular fluid differs considerably from 
that of the interstitium (Tuck et al., 1970, Setchell, 1990). Importantly, mitotically active 
spermatogonia reside in the basal compartment that is not protected by the BTB, whilst the 
rest of the germ cells can be found in the immune privileged apical compartment (Rival et 
al., 2006). The majority of immunogenic germ cells are sequestered behind this barrier, 
physically protected from the immune system (Li et al., 2009). However, the 
spermatogonia lie within the non-immune privileged basal compartment suggesting that 
other mechanisms must be used to protect these cells from the host immune system (Yule 
et al., 1988, Saari et al., 1996). Moreover, the BTB is incomplete in the rete testis, a location 
where immense numbers of spermatozoa exist yet no immune response is provoked (Dym 
and Romrell, 1975, Koskimies et al., 1971). In addition, all cell types required to initiate an 
immune response are present in the interstitial space surrounding the tubules including 
APCs, T cells and NK cells (Hedger, 1997). Significantly, antibodies and lymphocytes 
specific for spermatogenic antigens can be found in the peripheral blood of fertile men 
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(Turek and Lipshultz, 1994). Finally, immunisation with testicular auto-antigens or passive 
transfer of testicular auto-antigen-specific T cells can disrupt immune privilege (Tung et 
al., 1987). It is therefore clear that the BTB alone cannot account for all the manifestations 
of testicular immune privilege. 
 
Immune privilege is due to the failure of antigen recognition or the lack of a response 
following antigen exposure in the testis. MHC class I is expressed at low levels by 
seminiferous epithelium, which enables developing germ cells to avoid direct recognition 
by T cells. The immunoregulatory MHC antigen HLA-E is expressed by spermatogenic 
cells (Fiszer et al., 1997), which exerts an inhibitory effect on CD8 T cells and NK cells. 
Inactivation and deletion of antigen-specific T cells contributes to successful testicular 
immune privilege. In general terms, activated T cells can be regulated and subsequently 
deleted by the Fas-mediated signalling pathway (Ju et al., 1995). FasL is expressed by 
Sertoli cells and may be responsible for the death of activated CD8 T cells, thus 
suppressing adaptive immunity in a highly localised manner (Sanberg et al., 1996, Bellgrau 
et al., 1995). A protective effect of FasL has been demonstrated in studies involving 
melanoma cells (Hahne et al., 1996), and allogeneic colon carcinoma cells (Arai et al., 1997), 
however, other studies show increased FasL expression on certain tumour cell lines which 
in fact provoke an inflammatory response (Allison et al., 1997, Miwa et al., 1998). Testicular 
immune privilege is also mediated by the tryptophan-metabolising enzyme indoleamine 
2,3 dioxygenase (IDO). IDO inhibits T cell mediated immunity and stimulates regulatory T 
cells (Fallarino et al., 2009).  
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Immune privilege is also mediated by antigen-specific control mechanisms within the 
testis. Injection of soluble antigens into the testis produces specific suppression of T cell 
responses against such antigens (Ditzian-Kadanoff, 1999, Verajankorva et al., 2002). In 
addition, activated and memory CD8 T cells directed against pancreatic islet allografts in 
the mouse testis are targeted for destruction when they enter the testis environment. 
Moreover, graft specific Treg cells are produced altering the balance between memory and 
regulatory T cells (Nasr et al., 2005). As summarised in (Meinhardt and Hedger, 2011), 
these studies indicate a switch from a response that is associated with cell-mediated 
immunity, to a response that is principally immunoregulatory and tolerogenic. A 
substantial proportion of interstitial macrophages demonstrate an immunoregulatory 
phenotype, characterised by an increase in suppressive functions and a reduction in pro-
inflammatory cytokine secretion (Kern et al., 1995, Hedger, 2002).  
 
As well as their role in the establishment of the BTB, Sertoli cells are central to testicular 
immune privilege in other ways. Immunoprotection of allografts and xenografts in the 
testis is provided by Sertoli cells (Mital et al., 2011). FasL, IDO and constitutively expressed 
TGFβ are all produced by Sertoli cells and have been implicated in graft survival (Bellgrau 
et al., 1995). In addition, Sertoli cells express inhibitors of complement (Lee et al., 2007), 
secrete inhibitors of granzyme B (Bladergroen et al., 2001, Sipione et al., 2006) and express 
PD-L1 (Cheng et al., 2009), all of which negatively regulate a cytotoxic T cell response. The 
production of macrophage-migration-inhibitory factor (MIF) by Leydig cells (Okuma et al., 
2005), may also contribute to immune privilege by inhibiting the destructive potential of 
NK cells and cytotoxic CD8 T cells (Apte et al., 1998, Abe et al., 2001). 
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The roles of Sertoli cells, Leydig cells and testicular immune cells in creating immune 
privilege are still not fully understood. However, it is apparent that multiple factors are 
involved and what is most important is the balance between the suppression of an 
immune response to protect the spermatogenic cells from attack and the ability to initiate 
an immune response to protect against infection and cancer.  
 
Testicular Germ Cell Tumours 
Testicular cancer is a relatively rare cancer with an unusual age-distribution. It occurs 
predominantly in young and middle-aged men and is the most common cancer in men 
aged 15-44 years. Although the incidence of testicular cancer is low throughout the world, 
it is estimated to have nearly doubled in the last 40 years in the USA (McGlynn et al., 2003), 
Europe and the UK (Toledano et al., 2001, Swerdlow et al., 1998). It is evident that this 
increase has occurred mainly in younger men, predominantly the white Caucasian 
populations in industrialised countries such as Western and Northern Europe (Statistical 
Information Team, 2007). Notably, testicular cancer is rare in non-Caucasian populations 
especially in Eastern Asia and Western Africa (GLOBOCAN, 2002). Despite the significant 
rise in incidence, mortality from testicular cancer has fallen considerably. The decline in 
mortality has been noticeable since the 1970s, correlating with the introduction of better 
cancer management, in particular the therapeutic platinum-based chemotherapy regimens 
used for metastatic germ cell tumours. Unlike many other cancers, testicular cancer has a 
high cure rate, even in patients with metastatic disease. 
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Figure 5. Development of testicular germ cell tumours from spermatogenic precursors 
The process of spermatogenesis (top) and the hypothesised route to tumour transformation 
(bottom) are illustrated. The premalignant carcinoma in situ (CIS) is thought to develop from an 
undifferentiated gonocyte, but CIS does not develop into an invasive overt TGCT until after the 
onset of puberty. Then, CIS may transform into a seminoma or NSGCTT.  Embryonal carcinoma 
(EC) is the most undifferentiated form of a NSGCTT. EC cells are pluripotent, and usually 
differentiate further into somatic tissues like teratomas (TER), and extra-embryonic tissues, like 
choriocarcinomas (CHC) and yolk sac tumour (YST). Sometimes, seminoma and various NSGCTT 
elements co-exist within the same tumour mass and are known collectively as mixed germ cell 
tumours (mGCT). 
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Risk Factors 
The reasons behind the increased occurrence of testicular cancer are not fully understood 
but the rapid increase over a short period of time would suggest that critical changes in 
environmental factors are contributing to the development of these tumours. It has been 
postulated that increased maternal age and high oestrogen levels in utero may affect foetal 
germ cells and disrupt germinal epithelium (Richie, 2005, Group, 1994b, Group, 1994a, 
Coupland et al., 1999). A high prevalence of cryptorchidism, testicular maldescent, and 
infertility has been associated with an increased risk of developing testicular cancer. Other 
risk factors include inguinal hernias, hydrocele and a family history of testicular cancer, 
which suggests that defects in urological development and genetic predisposition may 
contribute to observed incidence (Tollerud et al., 1985, Rapley et al., 2000). A variety of 
genetic abnormalities have been described in testicular cancer, such as the isochromosome 
12p (Oliver, 1997).  Patients  with  Klinefelter’s  syndrome  (47XXY)  or  XY  dysgenesis  have  a  
higher risk of developing testicular cancer (Nichols et al., 1987, Levin, 2000). In addition, 
associations between a sedentary lifestyle or immunosuppression and testicular cancer 
have also been proposed, but there is no clear consensus from these studies (Leibovitch et 
al., 1996, Garner et al., 2003). 
 
Pathology  
Over 95% of testicular tumours originate from germ cells. Histologically, testicular germ 
cell tumours (TGCT) have two main subtypes - pure seminoma (45%) and non-
seminomatous germ cell testicular tumours (NSGCTT) (55%). NSGCTTs may remain 
undifferentiated as embryonal carcinoma, or subsequently undergo extra-embryonic 
differentiation to form yolk sac tumours, choriocarcinomas, and mature teratomas. In 
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addition, NSGCTTs can include elements of seminoma to generate mixed germ cell 
tumours (mGCT). The tumour transformation process is summarised in Figure 5. 
NSGCTTs tend to occur on average ten years earlier than seminomas. It is recognised that 
seminomas have a indolent clinical course, whereas NSGCTTs behave more aggressively. 
 
TGCT develop from a malignant transformation of a non-invasive lesion called carcinoma 
in situ (CIS), which is influenced by hormones at or after puberty (Rajpert-De Meyts et al., 
1996, Rajpert-De Meyts and Skakkebaek, 1994). These lesions are found growing within 
seminiferous tubules and express transcription factors commonly expressed by embryonic 
stem cells, suggesting a pluripotent gonocyte origin. Despite a common origin, testicular 
cancers are histologically, pathologically and clinically distinct. 
 
Presentation, Diagnosis and Staging 
The classic presentation of a TGCT is a hard painless mass within the testis. Further 
diagnosis involves a testicular ultrasound and baseline measurements of tumour markers 
including Alpha-fetoprotein (AFP), human chorionic gonadotropin (HCG), and lactate 
dehydrogenase (LDH). AFP is an embryonic protein expressed by yolk sac elements of a 
tumour but not by pure seminoma, whereas HCG is secreted by both seminomas and non-
seminomas. LDH is also a germ cell tumour product but is less tumour-specific and is 
generally used to monitor treatment (Andreyev et al., 1993, von Eyben et al., 2001).  
 
Following positive diagnosis of a TGCT, a radical inguinal orchidectomy is performed. 
Between 5 and 10% of TGCTs are present at an extragonadal site, predominately at the 
retroperitoneum or mediastinum. Due to predictable patterns of lymphatic or 
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haematogenous spread, staging of the tumour is completed by an abdominal CT scan or 
chest x-ray. The tumour is assigned a stage on the basis of primary tumour size, the 
involvement of regional lymph nodes, the presence of distant metastases and the levels of 
various serum tumour markers (Fizazi et al., 2004).  
 
Treatment 
At University Hospital Birmingham, TGCT patients receive a stage specific treatment 
regime, as outlined in Figure 6. Stage 1 seminoma patients receive carboplatin 
monotherapy. A few patients, for whom chemotherapy is inappropriate or who decline it, 
may be offered radiotherapy. Stage 2A seminoma patients are treated with retroperitoneal 
radiotherapy or a combination of cisplatin and etoposide. Tumours categorised as Stage 2B 
or above are treated with four cycles of the same combination therapy. Stage 1 NSGCTT 
patients receive active surveillance or 2 cycles of the combination therapy 
bleomycin+etoposide+cisplatin (BEP). Patients receiving only surveillance have a 
recurrence rate of 15 – 20% but this is reduced to <2% with adjuvant chemotherapy. Stage I 
NSGCTT patients who exhibit lymphovascular invasion (LVI) receive two cycles of BEP.  
Higher stage NSGCTTs are separated into prognostic groups and treated accordingly. 
These patients are usually treated with 3-4 cycles of BEP chemotherapy followed by 
surgical resection of residual masses (Heidenreich et al., 2009).   
 
The well-documented improvements in mortality from the mid-1970s appear to coincide 
with the introduction of cisplatin as a therapeutic agent for metastatic TGCTs. 
Chemotherapy regimens based on cisplatin were subsequently developed along with 
improvements in tumour imaging and developments in surgery for residual disease. 
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Figure 6. The stage specific treatment regimen for TGCTs at the University Hospital Birmingham Testicular Cancer Centre. 
Flow diagram illustrating the treatment plans according to tumour type and stage. Designed and approved by Paul Hutton, UHB, UK. 
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Cancer Immunology 
The expression of immunogenic tumour antigens on the surface of tumour cells can 
mediate an adaptive immune response. Tumour growth suggests that either anti-tumour 
immunity is suppressed, or that it is insufficiently induced to destroy the cancer. This may 
be due to the inhibition of activation and differentiation, or induction of tumour-specific 
immune cell dysfunction, as well as the down-regulation of MHC on tumour cells. 
 
Immune Mediated Tumour Destruction 
The expression of tumour antigens on a transformed cell provokes an immune response, 
which generally involves the recognition and elimination of emerging tumour cells by 
lymphocytes (Dunn et al., 2002, Swann and Smyth, 2007). Many tumour antigens have 
been shown to induce cytotoxic T cell responses in vitro and in vivo and can be divided into 
several subgroups. Firstly are antigens that are products of mutated proto-oncogenes or 
tumour suppressor genes, such as the cell cycle regulator p53 (Goh et al., 2010) and caspase 
8 (Mandruzzato et al., 1997). Secondly are atypical or over-expressed normal cellular 
proteins including HER-2 and AFP (Ioannides et al., 1993). Third are viral proteins, such as 
those derived from human papillomavirus, which can be processed and presented on the 
surface of a virus- induced cancerous cell (Ostrand-Rosenberg, 2004). Finally, cancer testis 
antigens (CTAgs), which are expressed exclusively in germ cells of the testis and various 
malignancies but are silent in normal somatic tissue (Caballero and Chen, 2009b). It is 
highly likely that the immunogenicity of these antigens is due to the lack of central 
tolerance during T cell development. 
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In addition, NK cells, which express NKG2D, can respond to transformed cells expressing 
NKG2D ligands, such as MICA/B and ULBPs (Guerra et al., 2008).  Endogenous   ‘danger’  
signals are induced early during tumour development (Matzinger, 1994). These include 
DNA,   heat   shock   proteins   and   IFNα,   which   promote   the   induction   of   adaptive   anti-
tumour immune responses (Gallucci and Matzinger, 2001). Furthermore, healthy, non-
malignant cells surrounding the tumour are often damaged due to tumour growth and 
invasion, and as a result display substances such as hyaluronan fragments on their surface. 
This allows the recruitment of immune cells to the tumour site (Sims et al., 2010).  
 
Intratumoural Immune Responses and Prognosis 
Solid tumours often contain immune cell infiltrates consisting predominantly of tumour 
infiltrating lymphocytes (TILs). T cells are the main effector cell type of the adaptive 
immune response involved in the destruction of a tumour cell, in particular cytotoxic CD8 
T cells. The infiltration of CD8 T cells, Th1 CD4 T cells and the presence of 
proinflammatory cytokines have been associated with improved prognosis (Prestwich et 
al., 2008, Ghiringhelli et al., 2009). The majority of tumour antigens described are restricted 
to presentation through MHC class I and are therefore recognised by CD8 T cells 
(Rosenberg, 2001). Interestingly, the distribution of CD8 T cells within particular tumour 
types is a determinant of prognosis in colorectal cancer, ovarian cancer, breast cancer and 
glioblastoma (Naito et al., 1998, Sato et al., 2005, Pages et al., 2005a, Yoshimoto et al., 1993, 
Palma et al., 1978). The presence of infiltrating NK cells is also associated with a 
favourable prognosis in several cancers (Ishigami et al., 2000, Takanami et al., 2001, Coca et 
al., 1997).  
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It is important to note that not all infiltrating lymphocytes have a beneficial effect on anti-
tumour responses. TILs in this category would include the immunosuppressive cells types 
including Tregs and myeloid derived suppressor cells (MDSC) (Khaled et al., 2013). Tregs 
can be found in tumour draining lymph nodes (Munn and Mellor, 2006) as well as the 
tumour tissue itself (Woo et al., 2002), where they suppress the anti-tumour immune 
responses. Tregs can inhibit effective anti-tumour immunity by directly or indirectly 
inhibiting CD8 T cells, NK cells, NKT cells and B cells (Taams et al., 2001). Specifically, 
Tregs inhibit the proliferation of tumour-specific T cells restricting activation and 
subsequent effector functions of CD8 T cells (Shevach, 2002). An increased proportion of 
Tregs within tumours has been associated with poor prognosis in several tumours (Wolf et 
al., 2005, Petersen et al., 2006). The depletion of Tregs augments the effectiveness of T cell 
therapy (Antony and Restifo, 2005).  
 
The important role played by the immune system in tumour development and patient 
prognosis is evident in immune comprised transplant patients, as these patients have an 
increased risk of developing certain tumours (Sheil et al., 1997, Birkeland et al., 1995).  
 
Immunoediting Model 
Despite the diverse range of immune mechanisms which target transformed cells, the high 
prevalence of cancer would indicate that the immune response is unable to sufficiently 
control its growth and spread (Dranoff, 2009). This has led to an updated hypothesis 
termed  immunoediting,  based  on  Burnet’s  immunosurveillance  model,  but  incorporates  a  
selection pressure in certain tumour cells, favouring escape from immune destruction 
(Dunn et al., 2002, Dunn et al., 2004a). 
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Cancer immunoediting is an extrinsic tumour suppressor mechanism that engages 
following cellular transformation and only when intrinsic tumour suppressor mechanisms 
are unsuccessful at controlling these transformed cells. The model is split into three 
sequential phases termed elimination, equilibrium and escape. The elimination phase 
focuses  on  the  continual  eradication  of  newly  forming  tumour  cells  that  express  ‘danger’  
signals (Gallucci and Matzinger, 2001) by an anti-tumour immune response. If successful, 
this process leads to the complete destruction of early tumours before they are clinically 
apparent. Over time, a proportion of cancer cells may acquire mutations generating a 
cancer cell variant that is not destroyed in the elimination phase and consequently enter 
the equilibrium phase, in which its outgrowth is prevented by immunologic mechanisms. 
During the equilibrium phase, elimination of transformed cells continues and 
consequently results in the selection of mutated cells. If the immune system is too 
overwhelmed by tumour development, immunological control is lost and the balance is 
shifted towards tumour growth. These cells are now said to have entered the escape phase. 
In addition, spontaneous generation of poorly immunogenic cancer cells may enter 
directly into the escape phase. Tumour cells in this phase may accumulate together and 
cause clinically apparent disease (reviewed in (Schreiber et al., 2011)) 
 
Mechanisms of Tumour Escape 
Cancer cells can evade the immune system using a combination of strategies. The well 
documented down regulation of MHC class I on tumour cells stops the cell from 
presenting tumour antigens and in turn reduces the ability of CD8 cytotoxic T cells 
recognise and lyse the cell (Bubenik, 2004). This may occur due to the downregulation or 
mutation of   β2M,   or   by   modifications   to   TAP, therefore disrupting the MHC class I 
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processing pathway (Benitez et al., 1998), (Bai et al., 2003). A reduction in the CD4 T cell 
response has also been described, which is due to the disruption in the formation and 
expression of MHC class II peptide complexes (Marsman et al., 2005). Tumour cells are 
able to inhibit the initiation or activation of a specific immune response. In particular, they 
fail to induce the maturation of DCs and in essence induce anergy in tumour specific T 
cells resulting in their failure to recognise the tumour as foreign (Kowalczyk, 2002). In 
addition, the expression of IDO by tumour cells leads to a depletion of tryptophan in the 
tumour microenvironment, thus inhibiting T cell proliferation (Avril et al., 2010). During 
tumour-induced angiogenesis, the disrupted interaction between lymphocytes and the 
tumour microvasculature has been shown to interrupt the infiltration of immune cells into 
the tumour (Ryschich et al., 2002).  
 
The secretion of immune suppressive cytokines, such   as   TGFβ   from   tumour   cells, can 
contribute to an immunosuppressive microenvironment and is usually associated with 
poor prognosis (Moses, 2010).  TGFβ  can  modulate   the  activity  and  secretion  of   IFNγ  by  
NK cells, which is required for successful clearance of tumour cells involving Th1 CD4 T 
cells.   There   are   numerous   additional   roles   for   TGFβ   in   cancer   immunosuppression that 
involve both innate and effector immune cells (Flavell et al., 2010).   Importantly,   TGFβ  
directly inhibits CTL function by suppressing the expression of several cytolytic genes, 
including  the  genes  encoding  IFNγ,  granzyme  B  and  FasL  (Thomas and Massague, 2005). 
The sustained release of the anti-inflammatory cytokine IL-10 favours tumour escape from 
immune surveillance by stimulating cancer cell proliferation and inhibiting apoptosis 
(Alas et al., 2001, Kawamura et al., 2002). Ectopic expression of FasL in tumour cells is 
another means of immune escape since it encourages apoptosis of Fas-expressing activated 
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T cells that infiltrate the tumour tissue (Strand et al., 1996). Moreover, down regulation, 
genetic mutations or epigenetic gene silencing of Fas in tumour cells results in the inability 
of immune cells to induce apoptosis in these cells (Butler et al., 1998, Real et al., 2001). 
Furthermore, cytotoxic killing mechanisms can be inhibited, for example, the impaired 
binding of perforin to the tumour cell surface reduces the ability of granzyme B to 
penetrate the cell membrane (Lehmann et al., 2000).  
 
Introduction to Cancer Testis Antigens 
CTAg expression is limited to germ cells of the testis (Boon T, 1997) and many tumours. In 
particular, CTAgs are predominantly expressed by spermatogonia but are also expressed 
by cells in the later stages of spermatogenesis (Takahashi K, 1995, Jungbluth AA, 2002, 
Gjerstorff MF, 2006, Jungbluth AA, 2001, Jungbluth AA, 2000). In brief, CTAgs can be 
divided into two groups, those produced by genes on the X chromosome, named CT-X 
antigens, and those produced by genes on autosomes, termed non-CT-X antigens 
(Caballero and Chen, 2009a). 
 
Importance of CTAgs in Cancer 
More than 40 CTAg families have been described (Scanlan MJ, 2002, van der Bruggen P, 
1991), but the biological function for many is unknown. The CTAg families with known 
functions are mainly the non-CT-X antigens which play important roles in 
spermatogenesis and cancer, including the MAGEA family. MAGEA1 is a transcriptional 
repressor and is thought to repress the expression of differentiation genes (Laduron et al., 
2004). Within healthy testis it prevents differentiation of spermatogonia in order to 
maintain a population of cells for continuous spermatogenesis. Expression of MAGEA 
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family genes by tumour cells can cause resistance to TNF-mediated cytotoxicity (Park et 
al., 2002). In addition, MAGEA expression confers resistance to chemotherapy drugs 
including doxorubicin (Glynn et al., 2004). MAGEA2 suppresses the activation and 
function of p53, resulting in resistance to the chemotherapeutic drug etoposide (Monte et 
al., 2006). MAGEA3 is able to suppress p53-dependent apoptosis (Yang et al., 2007). Certain 
members  of  the  GAGE  family  are  able  to  suppress  the  apoptotic  functions  of  Fas  and  IFNγ  
(Cilensek et al., 2002). 
 
Expression Patterns of CTAgs 
CTAg expression varies between different tumours. For example, melanoma appears to 
have the greatest frequency of expression, with lung and breast cancer also demonstrating 
high expression levels (reviewed in (Matthew et al., 2002) (Ugur et al., 1998)). In addition, 
NY-ESO-1 is very rarely found in the absence of MAGEA3 suggesting CTAgs are co-
expressed and their regulation is part of a coordinated gene expression programme. 
Peripheral tolerance to CTAgs is not established as the germ cells of the testis are located 
within an immune privileged site (Bart et al., 2002) and do not express HLA molecules  on 
their surface (Fiszer D, 1998). This makes CTAgs an ideal target for vaccination-based 
therapy  which  would  stimulate  the  patient’s   immune  system  and  induce  an  anti-tumour 
response. 
 
Regulation of CTAgs 
A universal mechanism for CTAg expression in germ cells and cancer is suggested by the 
lower levels of CpG methylated DNA within gene promoters of germ cells compared to 
somatic tissues (Reik et al., 2001) and the inclination towards genome-wide demethylation 
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in cancer (De Smet C, 1996). Hypomethylation of CpG islands is the most widely accepted 
mechanism for activation of CTAg expression in cancerous cells (reviewed in (Simpson et 
al., 2005)). Treatment with DNA methyl-transferase 1 inhibitor, 5-aza-2-deoxycytidine, 
leading to the progressive loss of DNA methylation, induces MAGE expression and 
apoptosis in cancer cells (Weiser et al., 2001). Histone deacetylase inhibitors, in 
combination with 5-aza-2-deoxycytidine, or independently, can also induce the expression 
of NY-ESO-1 and MAGE (Shigeki et al., 1996). Nevertheless, methylation states and histone 
deacetylation   alone   doesn’t   explain   the   non-coordinated pattern of CTAg expression in 
certain cancers (Jungbluth et al., 2000). It has been hypothesised that the expression of 
CTAgs in cancer cells results from the activation of a gametogenic differentiation program 
which aids the successful development of the tumour (Old, 2001).  
 
Spontaneous Immune Responses to CTAgs 
A range of immunogenic tumour antigens recognised by CD8 T cells (Boon and Old, 1997, 
Kawakami and Rosenberg, 1997, Robbins et al., 1997) or antibodies (Stockert et al., 1998, 
Scanlan et al., 1998) have been described. The MAGE family encode tumour–specific 
antigens, which have been shown to be presented by MHC class I molecules (Traversari et 
al., 1992, Van den Eynde and Boon, 1997, van der Bruggen et al., 1991). Furthermore, 
MAGEA1, MAGEA3 and NY-ESO-1 induce coordinated humoral and cell mediated 
immune responses (Caballero and Chen, 2009a, Marie et al., 1999, Scanlan et al., 1999).  
 
Making the Most of a CTAg-specific Response 
 CTAgs are excellent targets for cancer vaccines as they are expressed in many tumour 
types but are absent in healthy tissue. A clinical trial which vaccinated with a known 
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MAGEA3 immunogenic peptide revealed tumour regression in 7 out of 25 patients even 
though a large CD8 T cell population was not present (Marie et al., 1999). Interestingly, 
CD8 T cells play a role in tumour regression in animal models (Coulie, 1997) and peptide 
based vaccination strategies have shown promise in some cancer patients (Khazaie et al., 
2009). A vaccination approach using peptide and recombinant MAGEA3 and NY-ESO-1 
has been developed for treatment of melanoma. These vaccines induce regression of 
individual melanoma nodules but infrequently lead to complete tumour regression (Jager 
et al., 2006, Marchand et al., 1999). A more recent study described synergistic effects and a 
beneficial clinical outcome when combining NY-ESO-1 with CTLA-4 blockade (Yuan et al., 
2008), suggesting tumour-specific T cells are inhibited through regulatory receptors on 
their cell surface. 
 
Expression of Cancer Testis Antigens in Testicular Germ Cell Tumours 
The expression of MAGEB1, MAGEB2, MAGEA1, GAGE, NY-ESO-1 and/or CAGE has 
been described in seminoma. Interestingly, these CTAgs are not expressed in teratomatous 
elements and only 18% of NSGCTTs expressed one or more of these CTAgs (Yuasa et al., 
2001). This suggests that TGCTs have different developmental pathways and may arise 
from different precursor cells. Previous research conducted by Hara et al., 1999 supports 
the conclusion that the expression of MAGE genes are more frequent in seminoma than in 
NSGCTT and suggested that seminomas share numerous traits with normal germ cells of 
the testis. Additional studies have confirmed protein expression of numerous MAGEA 
family members in seminoma (Cheville and Roche, 1999, Aubry et al., 2001, Nonomura et 
al., 1999). Studies using immunohistochemistry show NY-ESO-1 expression primarily in 
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carcinoma in situ and spermatocytic seminoma, but a lack of expression during tumour 
progression (Satie et al., 2002).  
 
Role of the Immune System in Testicular Germ Cell Tumour Destruction 
T cell tolerance to peptides derived from CTAg proteins is not generated in healthy 
individuals as these antigens do not cross the BTB and are not expressed in tissues at other 
sites. Therefore CTAg-specific T cell are present in the periphery which may have the 
ability to detect CTAg expression by tumours (Boon and van der Bruggen, 1996). To our 
knowledge, there are no reported studies describing in detail, the presence of CTAg-
specific T cell responses in patients with testicular cancer.  
 
As discussed previously, chemotherapy treatment results in high cure rates of TGCTs, 
however, some chemotherapeutic agents cause damage to the testis, most notably the BTB 
(Pereira and Garcia e Costa, 2007). Consequently, chemotherapy-associated damage may 
break down testicular immune privilege and expose remnants of CTAg expressing cells to 
the immune system. As a result, the immune system may encounter these antigens and 
subsequently prime anti-tumour immune cells which may then be involved in the 
elimination of residual disease post orchidectomy. In addition, the development of TGCTs 
may also break down testicular immune privilege (Fink et al., 2006), allowing the priming 
of cytotoxic CD8 T cells specific to antigens derived from germ cells and/or tumour cells. 
Taken together, it is conceivable that CTAg-specific T cells would be detectable in these 
patients, and may serve as a primary anti-tumour protective mechanism, or aid the 
destruction of residual tumour cells. 
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HYPOTHESIS 
Chapter one of this thesis focuses on the hypothesis that T cells within testicular tumours 
contain clonally expanded, antigen-experienced populations. It also deals with the 
hypothesis that T cells and NK cells in TIL have been reversibly anergised or rendered 
dysfunctional within the tumour, but regain their function upon removal from this 
suppressive environment. The second chapter concerns the hypothesis that cell mediated 
immune responses are generated towards TGCTs. Specifically, CTAg expression in TGCTs 
provokes a T cell mediated immune response, which is detectable in peripheral blood of 
TGCT patients, but not in healthy controls.  
 
AIMS 
The aims of this work were:  
x To investigate the memory phenotype, activation status and clonality of T cells 
infiltrating TGCTs, and possible regulatory mechanisms at play that may influence 
T cell function 
x To investigate the functional capabilities of T cells that infiltrate testicular tumours 
following their removal from a potentially suppressive environment 
x To determine whether other immune cells are present at the tumour site and how 
they may function  
x To investigate the presence of CTAg-specific immunity in TGCT patients, and to 
study the kinetics of these responses following the removal of tumour burden 
x To examine the functional capacity of CTAg-specific T cells isolated from 
peripheral blood of TGCT patients 
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CHAPTER 2: MATERIALS AND METHODS 
 
Patients 
Fresh human biopsies of TGCT tissue, adjacent normal testis tissue, and 50 ml heparinised 
blood and 6 ml clotted blood were obtained from patients undergoing radical 
orchidectomy at the New Queen Elizabeth Hospital, Birmingham, UK. Fresh tissue 
specimens were acquired immediately after surgical removal, and provided directly by the 
histopathology department. 
 
Up to 30 ml heparinised blood and 6 ml clotted blood were also obtained from patients 
prior to adjuvant chemotherapy and at regular intervals following treatment. The follow-
up samples coincide with mandatory clinic visits at the Cancer Centre, University 
Hospitals Birmingham, UK. Between 50-80 ml of blood was donated by healthy 
volunteers, which were used as controls.  
 
Written informed patient consent and local ethical committee approval (South 
Birmingham research ethics committee LREC reference 09/H1207/161, study reference 
RRK3953) were obtained prior to sample collection. Patients were 18 years or above, and 
competent to give full informed consent. Patients were excluded from the study if they 
were known to be infected with HIV, HBV or HCV. 
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Patient Characteristics  
Blood samples used in this study were collected from 74 TGCT patients prior to 
chemotherapy. Tumour tissue was collected from 10 patients, and healthy testicular tissue 
from 7 patients. Matched blood and tissue samples were obtained from 8 patients. Tumour 
type and tumour stage of samples obtained are summarised in Table 1. Blood samples 
from 14 healthy controls were age- and gender-matched to TGCT patients. Each patient is 
assigned a patient ID, consisting of a unique number and the patients initials. Further 
information about all patients recruited into this study including  the  patients’  age,  tumour  
type, staging and chemotherapy regime, can be found in the appendix Table 29. 
 
 
Table 1. Summary of Blood and Tissue Samples Obtained From TGCT Patients 
* patients with metastatic disease where primary tumour tissue was collected
 
 
 
 
Tumour Type 
(Stage) 
n 
Blood 
 
Tissue 
PBMC Serum 
 
Tumour Normal 
   NSGCTT        14 12 11  3 1 
           Localised 5 4 4 
 
1 1 
           Metastatic 9 8 7  2* - 
   Embryonal Carcinoma 2 1 1  0 1 
   mGCT 11 9 10  3 0 
           Localised 10 8 9 
 
3 - 
        Metastatic 1 1 1 
 
- - 
   Seminoma  48 46 43  6 3 
       Stage I 39 37 35 
 
6 3 
       Stage II-IV 9 8 8 
 
- - 
             Total 75 68 65  12 5 
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Cell Culture Media and Solutions  
Wash media  
RPMI 1640 (Gibco BRL)  
100 U/ml Penicillin (Gibco BRL)  
100  µμg/ml Streptomycin (Gibco BRL)  
 
GM media  
RPMI 1640 (Gibco BRL)  
100 U/ml Penicillin (Gibco BRL)  
100 µμg/ml Streptomycin (Gibco BRL)  
2mM Glutamine (Gibco BRL)  
10% Foetal Calf Serum (SBS Biologicals) 
 
TCL media  
RPMI 1640 (Gibco BRL)  
100 U/ml Penicillin (Gibco BRL)  
100 µμg/ml Streptomycin (Gibco BRL)  
2 mM Glutamine (Gibco BRL)  
10% Human Serum (HD Supplies) 
 
Freezing media 
Foetal Calf Serum (SBS Biologicals)  
10% DMSO (Sigma)  
 
 
MACS buffer (sterile filtered) 
1 x PBS (University of Birmingham)  
0.5% Bovine serum albumin (Sigma)  
2 mM EDTA (Sigma)  
 
TCC media  
RPMI 1640 (Gibco BRL)  
100 U/ml Penicillin (Gibco BRL)  
100 µμg/ml Streptomycin (Gibco BRL)  
2 mM Glutamine (Gibco BRL)  
5% Human Serum (HD Supplies)  
5% Foetal Calf Serum (SBS Biologicals) 
 
ELISA coating buffer 
1 x PBS (University of Birmingham)  
0.1M Na2HPO4 (Sigma)  
adjust to pH 9 with 0.1 M NaH2PO4 
 
TBE Buffer 
89 nM Tris HCL  
89 nM Boric Acid  
3 mM EDTA 
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ELISA blocking buffer 
1 x PBS (University of Birmingham)  
1% Bovine serum albumin (Sigma)  
0.05% Tween 20 (Sigma) 
 
ELISA Wash buffer (PBS-T) 
1x PBS  
0.05% Tween 20  
 
ELISA stop buffer 
1M HCL 
 
Sample Buffer (Laemmli) 
0.0625M Tris-HCl pH 6.8 
 2%SDS, 
 10% glycerol,  
5% 2- mercaptoethanol 
1M DTT. 
 
 
 
 
DMEM-C 
100 U/ml Penicillin (Gibco BRL)  
100 µμg/ml Streptomycin (Gibco BRL)  
2 mM Glutamine (Gibco BRL)  
10% FCS   
 
10 x HLA-typing PCR buffer 
670 mM Tris base (pH 8.8) 
166mM ammonium sulphate 
1% Tween-20 
 
HLA-typing TDMH mix 
2.6 x PCR buffer 
460 mM dNTPs 
6.25 mM MgCl2 
 
10x gel electrophoresis loading buffer  
16g sucrose,  
0.25% (w/v) Bromophenol Blue  
40ml dH2O 
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Peptides 
Single peptides were synthetic 9mer peptides generated using 9-fluorenylmethoxy-
carbonyl chemistry. They were dissolved in DMSO to a final concentration of 5 mg/ml. 
The MAGEB1 peptide library consisted of a series of 15mer peptides, overlapping by 11 
amino acids, covering the entire MAGEB1 protein sequence. The lyophilised peptides 
were resuspended in DMSO to a final concentration of 5 mg/ml. The MAGEA1, A3, A4 
and NY-ESO-1 overlapping peptide mixes, and the CEFT peptide pool, where purchased 
from JPT, Germany. Each vial contained 25 µμg of each overlapping peptide and was 
dissolved in a minimal volume of DMSO.   
 
Isolation of TIL from Tumour Tissue 
Between 4 and 10 mm3 of tumour tissue was washed twice in RPMI media then cut with 
fine scissors into 1 mm3 pieces followed by non-enzymatic disaggregation. Briefly, tissue 
pieces were forced through a 70 µμm  filter  to  remove  tissue  aggregates.  The  resulting  single  
cell suspension was layered over LymphoprepTM density gradient solution (NycoMed) and 
centrifuged at 800 x g for 30 minutes (brake off). The buffy layer at the density gradient 
interface was carefully removed and washed in RPMI media and centrifuged at 600 x g for 
10 minutes. The final cell suspension contained predominantly lymphocytes, as 
determined by light microscopy. On average, approximately 5 x 103 lymphocytes were 
harvested from each 1 mm3 of tumour tissue. 
 
Isolation of PBMC from Whole Blood 
PBMCs were isolated from 10 to 40 ml of heparinised venous blood under sterile 
conditions. Heparinised blood was mixed at a ratio of 1:1 with RPMI media and layered 
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over LymphoprepTM density gradient solution (NycoMed) at a ratio of 2:1, and centrifuged 
at 800 x g for 30 minutes at room temperature (brake off). The PBMCs at the density 
gradient interface were carefully removed with a transfer pipette, transferred into fresh 
RPMI media, and centrifuged at 600 x g for 10 minutes. This wash step removes any 
residual serum proteins that were in the buffy layer. Cells were washed again in RPMI 
media and centrifuged at 600 x g for 10 minutes. The final wash was performed in TCL 
media and centrifuged at 300 x g for 10 minutes. This relatively slow spin removes 
contaminating platelets that may interfere with downstream assays. The number of 
lymphocytes was determined using a haemocytometer. Cells were used immediately for 
assays or cryopreserved, as described below. 
 
Isolation of Patient Serum from Clotted Blood 
Whole blood collected in vacutainers containing clotting factor were centrifuged at 800 x g 
for 5 minutes. The supernatant containing serum proteins devoid of blood cells and 
clotting factors were transferred to a 2ml cryovial. Serum was frozen at -80°C for later use. 
 
Cryopreservation of Purified TIL and PBMC 
Cell suspensions were pelleted by centrifugation at 300 x g for 10 minutes, and 
resuspended in ice cold Freezing media. Cells were frozen at -80°C in a Mr Frosty 
(Nalgene) containing isopropanol to allow cooling at a constant rate of 1°C per minute. 
Cells were then transferred to liquid nitrogen (-180°C) after 24 hours, for long term 
storage. 
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Thawing of Cryopreserved TIL and PBMC 
Cryopreserved cells were removed from liquid nitrogen and placed in a water bath at 
37°C. When completely thawed, cells were immediately transferred to pre-warmed TCL 
media and washed by centrifuging at 280 x g for 10 minutes before resuspension in an 
appropriate volume for downstream assays. 
 
Maintenance of Healthy Donor LCLs and HT-29 Cell Line 
All cells were grown in a humidified incubator at 37°C, 5% CO2. LCLs were generated 
from healthy donor PBMCs. They were grown in GM media, which was replenished twice 
weekly. HT-29 colorectal adenocarcinoma cell lines were grown in tissue culture flasks 
and maintained in DMEM-C media. Cell lines were passaged when 80% confluent by 
removing media, washing cells with sterile PBS, and trypsinising with Trypsin- EDTA to 
detach adherent cells from the flask. Trypsin was neutralised with the addition of fresh 
DMEM-C media, centrifuged at 500 x g for 5 minutes, resuspended in an appropriate 
volume of DMEM-C media and transferred to a new flask.   
 
Flow Cytometry  
Flow cytometric analysis was carried out using a BD LSRII machine with BD FACS DIVA 
acquisition software (Version 6.1.3; BD Biosciences). Further offline analysis was 
performed with either FACS DIVA or FlowJo analysis software (TreeStar). The use of 
multi-colour flow cytometry requires compensation techniques to account for spectral 
overlap of fluorochromes. This was achieved by running anti mouse IgG-CompBeads (BD) 
stained separately with each fluorochrome conjugated antibody. The auto-compensation  
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function was used to effectively compensate spectral overlap. Cells were gated using FSC-
H vs. FSC-A to identify single cells; single lymphocytes were then identified by their FSC-
A and SSC-A properties. Dead cells were gated out using Propidium Iodide (PI). Live T 
cells were identified as PI- CD3+ cells. T-helper cells and T-cytotoxic cells were determined 
by surface expression of CD4 or CD8, respectively. Cells bearing both CD4 and CD8 were 
excluded. NK cells were determined by gating on CD3- CD56+ cells and divided into 2 
subsets by differential expression of CD56 and CD16.  
 
Characterisation of Lymphocyte Subsets by Cell Surface Staining  
PBMCs or TIL were resuspended in 100 µμl MACS buffer at a final concentration of 0.5-
1x107 cells/ml. Cells were surface stained for 20 minutes at 4°C, as previously described, 
with various combinations of antibodies as detailed in Table 2. Cells were washed once in 
MACS buffer and resuspended in an appropriate volume for cytometric analysis. At least 
50,000 lymphocytes were recorded based on size and granularity using a FSC vs. SSC 
scatter plot. 
 
PMA/Ionomycin Stimulation  
PBMC or TIL were resuspended at a concentration of 1x106 /ml in TCL media. To a 96w 
round bottom plate, 100 µμl of each cell suspension with or without 0.02 µμg/ml  PMA,   2 
µμg/ml  Ionomycin  was  added.  The  cells  were  incubated  at  37°C,  5%  CO2. After 1 hour, 100 
µμl  of  TCL  media  containing  10 µμg/ml  Brefeldin-A, and 1.25 µμg/ml  Monensin  was  added  to  
each well. Cells were incubated for a further 5 hours at 37°C, 5% CO2. Cells were 
subsequently washed ready for intracellular cytokine staining. 
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Table 2. Anti-human antibodies to cell surface markers used for cell phenotyping 
Target 
Antigen Conjugate Stock Dilution Clone Source 
CD3ε APC-Cy7 50µμg/ml 1:20 HIT3a Biolegend 
CD4 PerCP-Cy5.5 200µμg/ml 1:50 FU50 Biolegend 
CD8α AmCyan 0.1mg/ml 1:20 SK1 BD 
CD56 PE-Cy7 50µμg/ml 1:30 1:HOD56 Biolegend 
CD16 PE 0.1mg/ml 1:30 B73.1 eBioscience 
CD45RA 
CCR7 
eFluor-450 
PE 
0.1mg/ml 
25µμg/ml 
1:20 
1:20 
HI100 
3D12 
eBioscience 
eBioscience 
TIM-3 
PD-1 
PE 
PerCP-efluor710 
25µμg/ml 
25µμg/ml 
1:20 
1:20 
F38 2E2 
MIH4 
eBioscience 
eBioscience 
CD107a 
CD161 
NKG2D 
FITC 
eFluor-488 
APC 
0.1mg/ml 
50µμg/ml 
0.1mg/ml 
1:50 
1:20 
1:20 
H4A3 
HP-3G10 
D11 
BD 
eBioscience 
eBioscience 
γδTCR FITC 
FITC 
0.8mg/ml 
- 
1:20 
1:20 
B1.1 
VIT4 
eBioscience 
CD4 Miltenyi 
CD69 Alexa-fluor-647 0.4mg/ml 1:20 FN20 Biolegend 
CD38 PE-Cy7 0.3mg/ml 1:20 HIT-2 eBioscience 
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Intracellular Cytokine Staining  
Cells were then washed in MACS buffer and stained with appropriate surface antibodies 
at 4°C for 20 minutes. Cells were then washed in PBS and fixed with 2% 
paraformaldehyde at room temperature for 10 minutes. Cells were washed with MACS 
buffer, resuspended in the residual volume and permeabilised with 0.5% saponin at room 
temperature for 10 minutes. In the presence of 0.5% saponin, intracellular cytokine 
staining was subsequently conducted with IFNJ-AF700 and TNFα-PE-Cy7 for 30 minutes 
at room temperature. Cells were washed 2x in MACS buffer and resuspended in an 
appropriate volume for flow cytometric analysis. 
 
Combined Intracellular Cytokine and CD107a Staining of Peptide-Stimulated PBMC 
Multiparameter flow cytometry was used to simultaneously examine CD4 and CD8 T cells 
for intracellular expression of IFNγ and TNFα, and degranulation (CD107a surface 
expression) following stimulation with peptide. Cells were stimulated with either 10 
µμg/ml single peptide or 40 ng/ml overlapping peptides. PBMCs were resuspended at a 
concentration of 1x106 /ml in TCL media. To a 96w round bottom plate, 100 µμl of each cell 
suspension containing peptide(s) and 20 ng/ml CD107a-FITC (stimulated) or 20 ng/ml 
CD107a-FITC antibody only (unstimulated), was added. The cells were incubated at 37°C, 
5% CO2. After 1 hour, 100 µμl   of   TCL  media   containing   10 µμg/ml   Brefeldin-A, and 1.25 
µμg/ml  Monensin  was   added   to   each  well.  Cells  were   incubated   for   a   further   5   hours   at  
37°C, 5% CO2. Cells were then washed in MACS buffer and stained with CD3-APC-Cy7, 
CD4-PerCP-Cy5.5 and CD8-AmCyan at 4°C for 20 minutes. Cells were then washed in PBS 
and intracellular cytokine stained, as previously described.  
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CelltraceTM Violet Labelling of TIL 
TIL and PBMCs were resuspended at a concentration of 1x106 cells/ml in PBS. A 5 mM 
CelltraceTM Violet dye stock solution was prepared following the manufacturers 
guidelines. Briefly, 20 µμl of DMSO was added to one vial of CelltraceTM Violet reagent and 
mixed well by vortexing. The reconstituted CelltraceTM Violet was added to the cell 
suspension at a final concentration of 5 µμM and incubated for 20 minutes at 37°C, 5% CO2, 
with occasional agitation. Five times the original staining volume of TCL media was 
added to the cells and incubated for 10 minutes at 37°C to sequester any unbound dye 
remaining in solution. Cells were pelleted by centrifugation at 600 x g for 10 minutes then 
resuspended in pre-warmed TCL media at a concentration of 1x106 cells/ml. Cells were 
incubated for a further 15 minutes to allow acetate hydrolysis of CelltraceTM Violet 
molecules.  
 
CD3/CD28 Dynabeads® Proliferation Assay of TIL 
Following CelltraceTM Violet labelling of TIL, cells were incubated at a 1:1 ratio with 
Dynabeads® Human T-Activator CD3/CD28 beads (Invitrogen), in the absence of protein 
transport inhibitors, for 4-5 days at 37°C, 5% CO2. Beads were subsequently removed from 
the cell suspension by transferring cells to a 15ml Falcon tube and placing them in the 
EasySep® magnet for 5 minutes. Cells were decanted, washed in MACS buffer and 
centrifuged at 600 x g for 10 minutes. Cell pellets were resuspended in residual volume 
and stained with CD3-APC-Cy7, CD4-PerCP-Cy5.5 and CD8-AmCyan at 4°C for 20 
minutes. Cells were washed twice in MACS buffer and resuspended in an appropriate 
volume for flow cytometric analysis. 
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Generation of T cell Lines 
A panel of 8 peptides (Generon) from 5 CTAg gene families was chosen on the basis of 
having been previously identified as CD8 T cell epitopes that cover the most common 
HLA types, and HLA-peptide dextramers were available. The peptides, gene derivation, 
and MHC Class I restriction are detailed in Table 3. Freshly isolated PBMC were 
resuspended in 500 µμl of Wash media. If using cryopreserved PBMC, cells were thawed as 
previously described, resuspended at 1x106 /ml in TCL media and rested overnight in a 48 
well tissue culture plate (1x106 cells/well). The following morning, cells were washed in 
Wash media to remove serum proteins and resuspended in 500 µμl Wash media. Peptides 
were added either individually or in pools at a final concentration of 10  µμg/ml.  Cells were 
incubated at 37°C, 5% CO2 for 1 hour, with occasional agitation. Following peptide 
loading, cells were washed in TCL media and resuspended in 500 µμl TCL media 
containing 25 ng/ml IL-7 (Peprotech) and 2 ng/ml IL-15 (Peprotech). Each 500 µμl cell 
suspension was transferred to one well of a 48 well cell culture plate and incubated at 
37°C, 5% CO2. A further 500 µμl of TCL media supplemented with 50 U/ml IL-2 (Peprotech) 
was added on day 3. Cell cultures were fed twice weekly with TCL media containing 50 
U/ml IL-2, following the removal of half the spent media. A proportion of cells were 
subsequently harvested 10-12 days later for dextramer analysis. If peptide stimulated cells 
contained a dextramer positive population, these cells were set up for limiting dilution T 
cell cloning. 
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 Table 3. Detailed list of peptides used in T Cell Line assays. 
 
 
 
 
 
 
 
 
 
 
 
                   (#) HLA prevalence in England was determined using www.allelefrequencies.net,  
               as described in (Gonzalez-Galarza et al., 2011) 
 
 
 
 
 
 
 
 
 
 
Gene 
product 
HLA 
restriction 
HLA 
frequency(#) 
(%) 
Peptide                      
(aa Sequence) 
Position 
NY-ESO-1 A2 42.6 MLMAQEALAFL 1-11 
MAGEA1 A2 42.6 KVLEYVIKV 278-286 
B7 21.4 RVRFFFPSL 289-298 
MAGEA2 A2 42.6 YLQLVFGIEV 157-166 
MAGEA3 A1 29.1 EVDPIGHLY 168-176 
A2 42.6 KVAELVHFL 112-120 
MAGEA4 A2 42.6 GVYDGREHTV 230-239 
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HLA-Peptide Dextramer Staining 
Following peptide stimulation of T cell cultures, cells were washed in MACS buffer and 
stained with pMHC complexes (Dextramers; Immudex) at room temperature for 20 
minutes. Cells were washed in MACS buffer before antibody staining of surface markers. 
A negative HLA-matched dextramer was used that contained an irrelevant peptide. Cells 
that stained positive with this dextramer were classified as background and were 
subtracted from the CTAg-specific T cell frequency. This enabled us to determine a more 
accurate final frequency of a particular CTAg-specific T cell population. A result was only 
considered positive if a dextramer positive population was greater than 0.1% of the total 
frequency of CD8 T cells.  
 
Enrichment of Dextramer Positive CD8 T Cells 
Dextramer positive CD8 T cells were obtained by positive selection using MACS 
technology (Miltenyi Biotec) under sterile conditions. Antigen specific T cells were 
enriched using a manual magnetic cell sorting method using anti-PE magnetic beads and 
QuadroMACS (midi) separator. Anti-PE magnetic beads bind to PE-conjugated 
dextramers and enable high purity enrichment through MS columns. Cells were washed in 
MACS buffer and stained with dextramers as previously described. Cells are resuspended 
in 90 µμl  of  MACS  buffer  and  10  µμl  of  anti-PE beads was added. Cells were incubated for 30 
minutes at 4°C with occasional agitation. Following incubation, cells were washed to 
remove unbound beads and passed through 2 pre-equilibrated MS columns (double sort). 
Dextramer positive cells bind to the column and are eluted with MACS buffer. Enriched 
dextramers positive cells were pelleted by centrifugation at 300 x g for 10 minutes. Cells 
were resuspended in either MACS buffer for flow cytometric analysis to determine purity 
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of sort, or TCL media for limiting dilution cloning. The post purification flow cytometric 
analysis was used to determine dilutions required for cloning by limiting dilutions. 
Negative fractions were also collected and used as autologous feeder cells, as required.  
 
T Cell Cloning by Limiting Dilution 
CTAg-specific T cells were cloned using this method to enable further characterisation of 
their function. Feeder cells are required to provide stimulatory signals and growth factors 
that support the clonal expansion of isolated T cells. If autologous PBMCs (or negative 
fraction of MACS sort) were unavailable or insufficient, allogeneic PBMCs from 3 
apheresis  “cones”   (National  Blood  Service)  were  used  as  feeder  cells.  To  generate   feeder  
cells, PBMCs were stimulated overnight at 37°C, 5% CO2 in TCC media containing 5 µμg/ml 
PHA. The following morning, cells were washed thoroughly in TCC media before 
irradiation (40Gy). HLA-matched LCLs were also used and loaded with 10 µμg/ml relevant 
peptide prior to irradiation. The irradiated feeder cells were washed 3 times in TCC media 
and resuspended at 1x106/ml PBMC and 1x105/ml LCL. The mixture was supplemented 
with 20 U/ml IL- 2; 10 ng/ml IL-7; 8 ng/ml of both IL-15 and IL-21. To this cloning mix, T 
cells to be cloned were added to give concentrations of 0.3 cells, 1 cell and 3 cells per 100 
µμl/well.  The  resulting  mixes  were  added  to  96  well  round  bottom  tissue culture plates and 
incubated at 37°C, 5% CO2. On day 3, 100 µμl  of  TCC  media  supplemented  with  25  U/ml  IL-
2 was added to each well. Between days 14 and 28, the plates were monitored for clonal 
expansion. If enlargement of cell pellet was observed, the entire contents of that well were 
resuspended in 500 µμl TCC media containing fresh feeder cells and cytokines. The cell 
suspension was subsequently transferred to a well of a 48 well tissue culture plate. Cells 
were replenished with fresh TCC media containing 50 U/ml IL-2 twice weekly. If required, 
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cells were given irradiated feeder cells at the same cell concentrations as the original 
cloning procedure. Clones were screened by dextramer staining prior to further 
characterisation. If cells were dextramer positive, functional analysis was determined at 
least 7 days after the most recent addition of feeder cells. 
 
Stimulation Assay for IFNγ ELISA 
This assay was used to test the specificity and avidity of T cells through their ability to 
secrete IFNγ when co-cultured with antigen specific targets. Antigen specificity was 
confirmed with a range of targets consisting of peptide loaded LCLs and HT-29 colorectal 
adenocarcinoma cell line (endogenously presented MAGEA3 through HLA-A1). In 
addition, LCLs loaded with irrelevant peptide, HLA-mismatched LCLs loaded with test 
peptide, LCLs alone and T cells alone, were also used as controls. LCLs and T cells were 
washed twice in TCL media to remove any residual IFNγ present in tissue culture 
supernatant. LCLs were resuspended in TCL media at a concentration of 3x105 cells/ml; T 
cells were resuspended at 3x104 cells/ml in TCL media supplemented with 50 U/ml IL-2. T 
cells were seeded in triplicate in 96 well round bottom plates at a density of 3x103 per well. 
Targets were peptide loaded as required. For a peptide titration assay to determine the 
avidity of a T cell response, LCLs were loaded with 10 fold dilutions ranging from 10-5 to 
10-12 M peptide. Target cells were added to T cells at an Effector:Target (E:T) ratio of 1 to 
10. To determine the ability of T cells to respond to endogenously presented antigen, HT-
29 cells were added instead of peptide loaded LCLs at various E:T ratios. The plates were 
centrifuged at 300 x g for 5 minutes to enhance cell-to-cell contact, and then incubated at 
37°C, 5% CO2 overnight. The following morning, plates were centrifuged at 600 x g for 5 
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minutes and 150 µμl of supernatant was harvested. The cell culture supernatants were 
either assayed immediately or frozen at -80°C prior to IFNγ ELISA. 
 
IFNγ ELISA 
A   Maxisorp™   plate   (Nunc)   was   coated   with   0.75 µμg/ml   anti-human IFNγ   antibody  
(Pharmingen) in 50 µμl/well  Coating  Buffer.  The  plate was sealed and incubated overnight 
at 4°C. The plates were washed 5 times with 200 µμl PBS-T buffer, blotted, and then 200 µμl 
of ELISA Blocking Solution was added to each well. The plates were incubated for 2 hours 
at room temperature. The plates were then washed 3 times in PBS-T and 50 µμl   test  
supernatants, as well as standards (2000 pg/ml to 15 pg/ml IFNγ   in  doubling  dilutions)  
were added. The plate was washed 5 times as before then 50 µμl/well   of   0.75 µμg/ml 
biotinylated anti-human IFNγ   antibody   (Pharmingen) was added. The plate was 
incubated for 1 hour at room temperature. The plate was washed 5 times then 50 µμl/well  of  
1:1000 streptavidin-HRP (MabTech) was added, and incubated for 45 minutes at room 
temperature. The plate was washed extensively before 100 µμl/well of TMB substrate (Tebu 
Bio) was added. The plate was left in the dark at room temperature for up to 20 minutes. 
The reaction was stopped by the addition of 100 µμl  1M  HCl and the plate was read at an 
absorbance wavelength at 450nm. IFNγ levels of supernatants were calculated by 
reference to the standard curve. 
 
NK Cell Purification 
To examine the function of infiltrating NK cells, they were first purified using MACS 
technology, in sterile conditions. When TIL numbers were available, the cells were washed 
in MACS buffer and stained with anti-CD56-PE. Cells were washed in MACS buffer, 
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stained with anti-PE microbeads and positively selected using MS columns, as previously 
described. Following enrichment, cells were resuspended at 1x105/ml in TCL media 
containing 50 U/ml IL-2 and rested in a well of a 96 well tissue culture plate for up to 48 
hours at 37°C, 5% CO2. Following incubation, NK cells were used in the NK cell 
cytotoxicity assay, as described below.  
 
NK Cell Cytotoxicity Assay (CD107a Mobilisation Assay) 
To determine NK cell cytolytic potential, rested NK cells were plated into a 96 well round-
bottom tissue culture plate, at a final concentration of 1x105cells/ml of TCL media 
containing 20 U/ml IL-2. K562 or Daudi cells were subsequently added to each well at a 
concentration of 1x105cells /ml in TCL media containing 20ng/ml CD107a-FITC, to give a 
E:T ratio of 1:1. When cells were required at varying E:T ratios (range 10:1 to 1:10), NK 
cells were diluted accordingly. Cell-to-cell contact was improved by centrifuging the plate 
at 200 x g for 4 minutes. Cells were incubated at 37°C, 5% CO2. After 1 hour, Brefeldin-A 
and Monensin were added at a final concentration of 10 µμg/ml   and   1.25 µμg/ml,  
respectively. Following a further 5 hour incubation, cells were washed and surface stained 
with CD3-APC-Cy7, CD56-PE-Cy7 and CD16-PE. Where appropriate, cells were fixed and 
permeabilised, and stained for intracellular cytokines as previously described. Cells were 
subsequently analysed for CD107a levels and cytokine secretion by flow cytometry. NK 
cells cultured with TCL media alone (containing CD107a-FITC and protein transport 
inhibitors) were considered background and the value subtracted from each test sample. 
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Simultaneous Extraction of RNA and Protein from Human Tumour Tissue 
RNA isolation 
RNA and protein were isolated for semi-quantitative reverse transcription-polymerase 
chain reaction (RT-PCR) and Western blot analysis, respectively. RNA and Protein were 
simultaneously extracted using a phenol-chloroform method. Following precipitation, 
total RNA was purified further using an RNeasy Lipid Tissue Mini Kit (Qiagen). Between 
30 and 50 mg of snap-frozen tissue was placed in a tube containing 1 ml of QIAzol Lysis 
Reagent. The tip of a homogeniser probe was submerged into the tube and homogenised 
on ice for 1 minute on setting 5. Next, the homogenate was left to stand for 3 minutes at 
room temperature to allow foaming to subside. To ensure complete dissociation of 
nucleoprotein complexes, the suspension was incubated for a further 5 minutes at room 
temperature.  To  the  homogenate,  200  µμl  of  chloroform  was  added  and  shaken  vigorously  
for 20 seconds. To allow phase separation to occur, the sample was incubated for 10 
minutes at room temperature before centrifuging at 12,000 x g for 15 minutes at 4°C.  
 
Following centrifugation, the sample separates into 3 distinct phases: an upper aqueous 
phase containing RNA; an interphase; and a lower organic phase containing protein. The 
upper aqueous phase was transferred to an RNase-free tube and 1 volume of 70% ethanol 
was added, mixed thoroughly by vortexing, transferred to an RNeasy Mini spin column 
and centrifuged at 10,000 x g for 20 seconds. The organic phase containing protein was 
transferred to an eppendorf and placed on ice while the RNA purification procedure was 
completed. The RNA, now bound to the membrane of the RNeasy column was washed 
with Buffer RW1, followed by 2 washes with Buffer RPE. The RNA was then eluted from 
the membrane with 50 µμl of RNase-free water, and frozen at -80°C or used immediately for 
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generation of cDNA. RNA concentration was measured with a Nano-Drop 3300 (Thermo 
Scientific). Pure RNA samples would have an A260/A280 ratio of 2.0, and samples were 
rejected if a value of 1.7 or below were obtained, indicating unacceptable levels of 
contamination. For all reactions, 1 µg of RNA was prepared for reverse transcription by 
dilution with sterile DEPC-treated water. 
 
Protein Isolation 
Protein, contained within the organic fraction, was precipitated using alcohol 
precipitation. Firstly, DNA contamination was removed by the addition of 0.3ml of 100% 
ethanol per 1 ml QIAzol Lysis Reagent used. The tube was inverted 10 times, until a 
homogenous solution was achieved, before being incubated at room temperature for 5 
minutes. The solution was subsequently centrifuged at 2000 x g to pellet the DNA. The 
supernatant was further precipitated to isolate protein immediately, or stored at -80°C for 
later purification. Briefly, 1.5 ml of acetone was added per 1 ml QIAzol Lysis Reagent used 
for the initial homogenation. The sample was incubated for 10 minutes on ice before being 
centrifuged at 12,000 x g for 10 minutes at room temperature. Following centrifugation, the 
supernatant was discarded and the pellet, containing the protein, was washed 3 times in 
95% ethanol containing 0.3 M guanidine hydrochloride. During each wash, the solution 
was incubated for 20 minutes at room temperature before being centrifuged at 8000 x g for 
5 minutes at 4°C. After the third wash, the pellet was resuspended in 100% ethanol, 
incubated for 20 minutes at room temperature, and centrifuged at 10,000 x g at 4°C. The 
supernatant was removed and the protein pellet was air dried for 10 minutes before being 
resuspended in PBS containing 1% SDS. To aid pellet dissolution, the sample was 
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incubated at 50°C for 10 minutes. Following complete resuspension, protein concentration 
was determined using the BCA assay or stored at -80°C for downstream applications.   
 
Protein Concentration Determination by BCA Assay 
Protein levels in healthy testis and TGCT lysates were quantified using BCA assay as 
described in the manufacturers protocol (Pierce). Bovine serum albumin (BSA) standards 
were  prepared  from  a  2  mg/ml  stock  solution  and  ranged  from  0  to  2000  µμg/ml.  Twenty  
five µl of  each  sample/standard  and  200  µμl  of  Working  Reagent   (50:1,  Reagent  A:B)  was  
added to a 96 microplate well and mixed well on a plate shaker for 30 seconds. The plate 
was sealed and incubated for 30 minutes at 37°C. The plate was subsequently cooled to RT 
then absorbance was measured at 550nm. A standard curve was generated using the 
known standards and the equation of the line (linear) was used to determine the relative 
concentrations of each samples. 
 
Sample Preparation for SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE)  
Protein samples were denatured in Sample Buffer and boiled at 100°C for 5 minutes. Tubes 
were placed on ice for 3 minutes before being centrifuged at 10,000 x g for 5 minutes to 
remove insoluble material. Following centrifugation, tubes were left on ice until ready to 
load on gel. 
 
SDS-PAGE Gel Preparation and Running 
Protein samples were separated on homemade SDS-polyacrylamide gels assembled using 
Atto   apparatus   according   to   manufacturer’s   instructions.   Separating   gels   were   made 
containing 100mM Tris-HCl, 0.1% SDS, and 0.01% TEMED which were diluted with H2O 
64 
 
to give a 15% acrylamide gel, as outlined in Table 4.  Immediately before casting, a final 
concentration of 0.02% APS was added to initiate acrylamide polymerisation. The gel was 
poured and allowed to set at room temperature for 10 minutes. Isopropanol was layered 
on top of the separating gel to warrant level setting and to prevent the gel from drying out. 
The isopropanol was removed, stacking gel was poured above the separating gel and 
comb inserted. The gel was set following 15 minute incubation at room temperature. SDS-
PAGE running buffer was prepared as detailed in Table 5, and added to the upper and 
lower gel-tank reservoirs.  
 
The denatured samples (up to 50 µμg) were then loaded into each lane. A pre-stained, 
broad range molecular marker (NEB) was run simultaneously to allow determination of 
protein separation and molecular weight estimation. The gel was run at 100V through the 
Stacking gel then increased to 200V through the separating gel. The gel was run for 2 
hours or until the dye front (bromophenol blue) had migrated to the bottom of the gel. 
     
 
 
         Table 4. Separating and Stacking gel recipes. 
Separating gel 
components (15%) Volume 
Stacking gel 
components Volume 
    
30 % Acrylamide 3.75  ml 30 % Acrylamide 1.0 ml 
H20 1.34 ml H20 4.5 ml 
1M Tris Buffer pH 8.8 1.88 ml 1M Tris Buffer pH 6.8 1.9 ml 
SDS 10% (w/v) 100 µl SDS 10 % (w/v) 100 µl 
APS 10% (w/v) 100 µl APS 10 % (w/v) 100 µl 
TEMED 5µl TEMED 7.5 µl 
Total Volume 7.2 ml Total Volume 7.61 ml 
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             Table 5. SDS page Running buffer and Transfer buffer recipes. 
Running buffer (1x) Transfer Buffer (1x) 
    
Tris Base 1.5 g Tris Base 3.0 g 
Glycine 7 g Glycine 14.4 g 
SDS 0.5 g SDS  0.1 g 
  Methanol 200 ml 
Water Up to 500ml Water 800 ml 
Total Volume 500 ml Total Volume 1000 ml 
 
 
 
Western Blot Analysis 
Following electrophoresis, Western blotting was conducted by wet transfer electroblotting. 
SDS-PAGE   resolved   proteins   were   transferred   to   0.45   µμm   nitrocellulose   membrane.  
Briefly, gels, membrane, sponges and 3mm blotting filter paper were equilibrating in 
Transfer buffer. A single gel was laid onto a pre-cut nitrocellulose membrane, sandwiched 
between 4 pieces of 3 mm blotting paper and two blotting sponge pads, and placed in a 
transfer cassette (Bio-Rad). The assembled cassettes were inserted into a transfer tank filled 
with Transfer buffer. Proteins were transferred to the membrane overnight at 4°C at a 
constant 30V. Following transfer, the blots were stained with Ponceau S to allow visual 
inspection of protein transfer. Ponceau S was easily removed from the membrane by 3 
washes in PBS-T, with constant agitation. 
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Table 6. Antibodies used for western blot analysis. 
Target 
Antigen Host Isotype Stock Dilution Clone Source 
Secondary 
Antibody Stock Dilution Source 
GAPDH Rabbit IgG 200µμg/ml 1:3000 Polyclonal SCBT Anti-rabbit HRP 1mg/ml 1:1000 Invitrogen 
MAGEA1 Mouse IgG1 200µμg/ml 1:200 MA454 Thermo Anti-mouse HRP 1mg/ml 1:5000 Promega 
MAGEA3 Mouse IgG1 200µμg/ml 1:2000 1H1 Abcam Anti-mouse HRP 1mg/ml 1:5000 Promega 
MAGEA4 Rabbit IgG 1mg/ml 1:1000 Polyclonal Sigma Anti-rabbit HRP 1mg/ml 1:1000 Invitrogen 
PD-L2 Goat IgG 500µμg/ml 1:200 Polyclonal R&D Anti-goat HRP 1mg/ml 1:1000 Invitrogen 
MICA/B Goat IgG 200µμg/ml 1:1000 Polyclonal SCBT Anti-goat HRP 1mg/ml 1:1000 Invitrogen 
ULBP2 Mouse IgG2a 1mg/ml 1:200 MM0593-7F33 Abcam Anti-mouse HRP 1mg/ml 1:5000 Promega 
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Prior to detection, membranes were incubated with blocking solution (PBS containing 3% 
BSA and 0.05% Tween-20) for 1 hour to prevent primary antibodies binding non-
specifically. The membranes were washed in PBS-T for 5 minutes at room temperature 
before being probed overnight at 4°C with primary antibody (prepared in blocking 
solution). Post incubation, blots were subjected to 3 x 10 minute washes in PBS-T. 
Secondary horseradish peroxidase (HRP) conjugated antibodies were prepared in blocking 
solution and incubated with the membranes for 1-2 hours at room temperature. The blot 
was subsequently washed as described before. Primary and secondary antibody 
combinations are detailed in Table 6. Residual wash buffer was removed from the blot and 
a chemiluminescence substrate (ECL-Plus) was applied directly to the membrane for 2 
minutes. Proteins were visualised on the ChemiDoc system (Bio-Rad) using GeneTools 
software. Equal loading of samples was confirmed by blotting for GAPDH. Densitometry 
was performed using GeneTools software. 
 
Re-Probing of Western Blots 
To probe for different proteins using the same blot, the membranes were stripped using 
Restore™  Western  Blot  Stripping  Buffer  (Pierce)  for  15  minutes  at  room temperature, with 
constant agitation. The membranes were washed 3 times in PBS-T before incubation in 
blocking solution. The membranes were then ready for re-probing. 
 
Reverse Transcription of RNA 
QuantiTect reverse transcription kit (Qiagen) was used to reverse transcribe RNA to 
cDNA. Template RNA and kit components were thawed on ice, mixed by flicking the 
tubes and centrifuged briefly to collect residual liquid from the sides of the tubes. The 
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genomic DNA elimination reaction was  prepared  by  mixing  2  µμl  gDNA Wipeout Buffer, 1 
µμg  template RNA, and topped up with RNase-free  water  to  a  total  volume  of  14  µμl. The 
solution was incubated at 42°C for 5 minutes, and then placed immediately on ice. In a 
separate tube, the reverse-transcription master mix was   prepared   by   combining   1   µμl  
Quantiscript Reverse Transcriptase,  4  µμl  Quantiscript  RT  Buffer,  and  1  µμl  RT  Primer  Mix. 
The mixture was vortexed briefly and stored on ice. The entire genomic DNA elimination 
reaction (14  µμl) was added to the reverse-transcription master mix, and mixed by gentle 
pipetting. The reaction mixture was subsequently incubated at 42°C for 15 minutes for 
reverse transcription to occur, followed by 95°C for 3 minutes to inactivate the reverse 
transcriptase enzyme. The newly generated cDNA was used immediately for qRT-PCR 
reaction or stored at -20°C for later use. 
 
  
Quantitative Real Time Polymerase Chain Reaction (qRT-PCR) 
All qRT-PCR reactions were performed on an Applied Biosystems 7500 real-time PCR 
system using Sybr Green technology and QuantiTect Primer Assays (Qiagen). QuantiTect 
primers contain a mixture of forward and reverse primers at equal proportions, and are 
outlined in Table 7. The QuantiTect primers were reconstituted in 1.1 ml TE buffer, pH 8.0, 
and mixed by vortexing the tube 5 times, to give a 10x primer mix. For a single reaction of 
a gene of interest, 12.5 µμl of 2x QuantiTect SYBR Green PCR Master Mix,   2.5   µμl   of  
appropriate QuantiTect Primers, and RNase-free  water  up   to  20  µμl,  were  combined   in  a  
microcentrifuge tube. The reaction mixture was gently vortexed and dispensed into PCR 
plates. To each well 100ng of appropriate template   cDNA  (5  µμl  of 20 ng/µμl)  was  added, 
mixed by pipetting, and the plate was sealed and centrifuged at 300 x g for 3 minutes. The 
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plate was placed in the qRT-PCR machine and run with the following conditions: An 
initial PCR activation step for 15 minutes at 95°C, followed by 40 cycles of 30 seconds at 
94°C (denaturation), 30 seconds at 55°C (annealing), and 30 seconds at 72°C (extension). A 
melt curve analysis step was added at the end of the PCR run to verify the specificity of 
PCR products. A housekeeping gene (GAPDH) was always run alongside the genes of 
interest. Each sample was run in triplicate. The 2-ΔΔCt method was used to compare 
expression levels between tumour tissue and healthy testis tissue, and normalised to 
GAPDH. Fluorescence below the threshold after 40 cycles was classified as a negative 
result. 
 
DNA Extraction from Whole Blood 
DNA extraction from whole blood was carried out using the Qiagen DNeasy Blood and 
Tissue   Kit.   Briefly,   20   µμl   proteinase  K  was   pipetted   into   a   1.5  ml  microcentrifuge   tube.  
Between 50 and 100 µμl  anticoagulant-treated blood was added to the tube and adjusted to 
220  µμl  with  PBS.  The  suspension  was  mixed  before  adding  200  µμl  Buffer  AL  and  vortexing.  
The suspension was incubated at 56°C for 10 minutes,   and  200  µμl   absolute   ethanol  was  
added, mixed by vortexing briefly and pipetted into a DNeasy Mini spin column placed in 
a 2 ml collection tube. The tube was centrifuged at 6000 x g for 1 minute, and the flow-
through and collection tube was discarded. The spin column was placed in a new 2 ml 
collection tube and 500 µμl  Buffer  AW1 was added, centrifuged for 1 minute at 6000 x g, 
and flow-through and collection tube were discarded. The spin column was placed in a 
new  2  ml  collection  tube  and  500  µμl  Buffer  AW2  was  added,  centrifuged  for  3  minutes at 
20000 x g, and flow-through and collection tube were discarded. The spin column was 
transferred to a new 1.5 ml microcentrifuge tube, and DNA was eluted by adding 50 µμl  
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Buffer AE to the centre of the spin column membrane. The spin column was incubated for 
1 minute at RT, and then centrifuged for 1 minute at 6000 x g. The eluted DNA was used 
immediately for HLA-typing PCR or frozen at -20°C for long-term storage. 
 
HLA Typing by Endpoint PCR 
To verify HLA-type of patients with a positive dextramer response, patient and control 
DNA samples were used to identify those expressing HLA A1, A2 and B7, as previously 
described (Bunce et al., 1995). A PCR master mix containing 70.87 µμl   TDMH, 35 µμl  
nuclease-free  water,   2  µμM of each adenomatous polyposis coli control primers and 3.75 
units of Taq polymerase (Bioline) was prepared in a small eppendorf. For a no DNA 
control tube, 8.5 µμl  of  master  mix  was  removed.  One hundred ng of DNA/ reaction (1.5 µμg) 
was then added to the master mix, and was aliquoted into 0.2 ml domed PCR tubes that 
contained various primer combinations for each HLA type to be tested, as per Table 8. 
PCR was carried out using the following conditions:  60 seconds (96°C), 5 cycles of 25 
seconds (95°C), 45 seconds (70°C), 45 seconds (72°C) followed by 21 cycles of 25 seconds 
(95°C), 50 seconds (65°C), 45 seconds (72°C) followed by 4 cycles of 25 seconds (96°C), 60 
seconds (55°C) and 120 seconds (72°C), then 72°C for 10 minutes. At the end of the run, 
samples were held at 4°C before being run on an agarose gel. 
  
Agarose Gel Electrophoresis for HLA Typing PCR 
Agarose gels were made by adding 1% (w/v) agarose powder to 1xTBE buffer and heating 
in a microwave to dissolve the agarose. Agarose was cooled to 55°C before the addition of 
a final concentration of ~0.5 µμg/ml  ethidium bromide solution. The gel was then poured 
with an appropriate toothed comb. A 10x loading buffer was added to all samples before 
71 
 
loading into appropriate lanes in the gel. Agarose gels were immersed in 1xTBE buffer 
before samples were loaded and gels ran at 120V for approximately 55 minutes. The size of 
DNA fragments were assessed by comparing their migration to a 100 base pair DNA 
marker ladder (Invitrogen). Gels were examined and recorded using an ultraviolet 
transilluminator. 
 
 
Table 7. Primers used in qRT-PCR assay to determine expression levels of 
genes in TGCT and healthy testis tissue. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene Qiagen Primer Reference Amplicon Size  
   
MAGEA1 QT01669430 109bp 
MAGEA3 QT00064799 106bp 
MAGEA4 QT00008862 118bp 
NY-ESO-1 QT00088956 140bp 
MAGEB1 QT00012362 126bp 
PD-L1 QT00082775 72bp 
PD-L2 QT00089761 127bp 
ULBP1 QT00084532 108bp 
ULBP2 QT01026291 80bp 
ULBP3 QT00049728 121bp 
MICA QT00245112 120bp 
GAPDH QT00079247   95bp 
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                  Table 8. Primers for HLA typing. 
HLA Sense primer sequence Anti-sense primer sequence Final concentration 
(µμM) 
    
A1 5-CGACGCCGCGAGCCAGAA  5-AGCCCGTCCACGCACCG  3.3 
A2 5-GTGGATAGAGCAGGAGGGT  5-CCAAGAGCGCAGGTCCTCT  3.3 
B7.1 5-GGAGTATTGGGACCGGAAC  5-TACCAGCGCGCTCCAGCT  3.3 
B7.2 5-GAGCCTGCGGACCCTGCT  5-TACCAGCGCGCTCCAGCT  3.3 
    
Positive Control 5- ATGATGTTGACCTTTCCAGGG  5- TTCTGTAACTTTTCATCAGTTGC  2 
No DNA Control 5- ATGATGTTGACCTTTCCAGGG 5- TTCTGTAACTTTTCATCAGTTGC  2 
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IFNγ  ELISPOT 
PBMC used for the ELISPOT assay were removed from liquid nitrogen and thawed as 
previously described. Cells were resuspended and washed in TCC media and centrifuged 
at a reduced speed of 100 x g for 15 minutes to avoid cell clumping. Cell were resuspended 
in TCC media at a final concentration of 106 cells/ml, and rested overnight at 37°C, 5% CO2. 
Ninety six well Millipore Immobilon-P PVDF plates were activated for 30 seconds with 
70% Ethanol. Plates were then washed 3 times with sterile PBS and subsequently coated 
with 15 µμg/ml of anti-IFNγ  mAb   (clone:D1K,  Mabtech)  diluted   in  PBS  overnight  at  4°C.  
The following morning the plate was washed 5 times with PBS, then once with RPMI 1640 
and subsequently blocked for 1 hour with TCC media. During this blocking stage, rested 
cells were washed and counted. Trypan blue was used to disregard dead cells. Between 
250,000 and 300,000   PBMCs  were   added   to   duplicate  wells   in   100   µμl of TCC media, to 
which overlapping peptides were added at a final concentration of 1 µμg/ml of each 
peptide. The plate was incubated for 16-18 hours at 37°C, 5% CO2. Following incubation, 
cells were removed and the plates were washed 6 times with PBS-T.  Fifty  µμl  of  1 µμg/ml 
biotinylated anti-IFNγ-mAb (clone: 7-B6-1, Mabtech) diluted in PBS was added to the 
wells and incubated for 3 hours at RT. The plates were washed 6 times with PBS-T. Fifty µμl 
of streptavidin conjugated alkaline phosphatase was added to the wells for 1 hour at RT, 
and the plates were washed 6 times with PBS-T, and 4 times with PBS. The chromogenic 
substrate BCIP/NBT-plus was added to the wells and allowed to develop in the dark until 
dark spots emerged. The reaction was by washing the plate extensively with tap water and 
allowing it to dry in the dark overnight. The number of spots were read using an AID 
automated ELISPOT reader. Each spot is representative of one reactive IFNγ  secreting  T  
cell. Data  was  transformed  to  give  the  number  of  IFNγ  secreting  cells  per  106 PBMC. 
74 
 
Determination of TCRVβ  Repertoire by Flow Cytometry 
All TCRVβ-specific   antibody   reagents   were   part   of   the   TCRVβ   repertoire   kit   from 
Beckman Coulter. Detection of individual TCRVβ   families was carried out on TIL and 
autologous PBMC. Briefly, up to 1 × 105 cells were surface stained simultaneously with 
CD3-PE-Cy5 and a set of three antibodies (A-H), directed  against  TCRVβ families as listed 
in Table 9. Antibodies directed against TCR families were labelled with either FITC or PE, 
or dual labelled with PE and FITC. Flow cytometric analysis was performed on LSRII, as 
previously described. Cells were gated on the CD3+ population, and individual TCRVβ 
families were evaluated based on exclusive staining for either FITC or PE or dual staining 
of both. Thus, 24 individual   TCRVβ families were analysed, covering over 80% of the 
TCRVβ  repertoire, using only eight individual tubes. 
 
Data Handling and Statistical Analysis 
Statistical analysis was performed using GraphPad Prism version 5 (GraphPad Software). 
To determine differences between two groups, a non-parametric Mann-Whitney test was 
performed. A non-parametric Kruskal–Wallis test was used when comparing more than 2 
groups,   with   a   Dunn’s   multiple   comparison   post   hoc   test.   A   Wilcoxon   matched-pairs 
signed-rank test was used to compare non-parametric matched data. A linear regression 
was   performed   to   assess   the   relationship   between   two   variables.   Spearman’s   non-
parametric test was used to determine correlations. Normal distribution was assessed 
using the D’Agostino & Pearson test, where appropriate. The null hypothesis was rejected 
at a p value of <0.05. Confidence intervals of 95 -99.9 % were used. * indicates of p <0.05,  
** indicates p< 0.01, *** indicates p<0.001. 
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          Table 9.  Antibodies used  for  Vβ  clonality  analysis. 
 
 
 
 
 
 
 
Tube Vβ  Family Fluorochrome Clone Isotype (species) 
  
A 
Vβ  5.3 PE 3D11 IgG1 (mouse) 
  Vβ  7.1 PE + FITC ZOE IgG2a (mouse) 
  Vβ  3 FITC CH92 IgM (mouse) 
  
B 
Vβ  9 PE FIN9 IgG2a (mouse) 
  Vβ  17 PE + FITC E17.5F3 IgG1 (mouse) 
  Vβ  16 FITC TAMAYA1.2 IgG1 (mouse) 
  
C 
Vβ  18 PE BA62.6 IgG1 (mouse) 
  Vβ  5.1 PE + FITC IMMU157 IgG2a (mouse) 
  Vβ  20 FITC ELL1.4 IgG (mouse) 
  
D 
Vβ  13.1 PE IMMU222 IgG2b (mouse) 
  Vβ  13.6 PE + FITC JU74.3 IgG1 (mouse) 
  Vβ  8 FITC 56C5.2 IgG2a (mouse) 
  
E 
Vβ  5.2 PE 36213 IgG1 (mouse) 
  Vβ  2 PE + FITC MPB2D5 IgG1 (mouse) 
  Vβ  12 FITC VER2.32 IgG2a (mouse) 
  
F 
Vβ  23 PE AF23 IgG1 (mouse) 
  Vβ  1 PE + FITC BL37.2 IgG1 (rat) 
  Vβ  21.3 FITC IG125 IgG2a (mouse) 
  
G 
Vβ  11 PE C21 IgG2a (mouse) 
  Vβ  22 PE + FITC IMMU546 IgG1 (mouse) 
  Vβ  14 FITC CAS1.1.3 IgG1 (mouse) 
  
H 
Vβ  13.2 PE H132 IgG1 (mouse) 
  Vβ  4 PE + FITC WJF24 IgM (rat) 
  Vβ  7.2 FITC ZIZOU4 IgG2a (mouse) 
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General Introduction 
 
Tumour-infiltrating lymphocytes (TIL), particularly T cells, are found within the lesions of 
many types of human tumours including TGCTs. The contribution of the immune 
infiltrate in recognition and elimination of tumour cells is unclear for the majority of 
cancers. Numerous studies in a variety of cancer types have shown that tumour residing T 
cells express markers of activation and display a phenotype typical of effector memory 
differentiation (Pages et al., 2005b, Yoshino et al., 1992). In addition, previous literature has 
described the ability of CD8 T cells to recognise tumour cells via the expression of tumour-
specific antigens. Nevertheless, tumour progression is common especially in the case of 
TGCTs, suggesting immune escape mechanisms play an important role in tumour growth 
and survival.  
 
A detailed phenotypic and functional analysis of cells infiltrating TGCT lesions, and the 
knowledge of negative regulatory mechanisms at play within the tumour can help 
increase our understanding of tumour mediated immune evasion. This opens up the 
possibility of creating alternative immunotherapies, not only relevant for use in TGCTs, 
but also as a universal treatment for other cancers exhibiting a large lymphocytic infiltrate. 
Knowledge gathered from the identification and in-depth analysis of CTAg-specific T cells 
from TGCT patients would be relevant for other tumour types where CTAg expression is 
demonstrated. In addition, understanding the dynamics of a CTAg response would enable 
us to generate more effective T cell-mediated therapy regimens in the future.  
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CHAPTER 3: PHENOTYPE AND FUNCTIONALITY 
OF LYMPHOCYTES INFILTRATING TGCTs 
 
 
Introduction 
Since lymphocytes are abundant in TGCTs, particularly seminoma, the emphasis of 
previous studies has primarily concerned T cells and their potential anti-tumour function. 
In addition, earlier reports have predominantly used immunohistochemistry to examine 
the phenotype of infiltrating cells. Although this methodology allows the identification, 
localisation, and potential interaction of TIL with tumour cells in situ, phenotypic analysis 
is restricted and functionality is difficult to determine. 
 
Here, this chapter aims to further characterise the phenotype of T cells that are recruited 
into the TGCT, not only in seminoma, but within all TGCTs containing seminomatous 
elements. In particular, the memory phenotype of infiltrating T cells will be examined and 
compared to that of autologous peripheral blood derived T cells. Furthermore, the 
activation status of these T cell subsets will be investigated, along with the expression of 
inhibitory receptors known to negatively regulate an immune response. This will aid in 
our understanding of whether tumour infiltrating T cells retain effective anti-tumour 
functionality. This may be important in the context of developing T cell immunotherapies 
whereby blocking of such receptors may favour a successful cytotoxic immune response 
and thereby improve anti-tumour immunity.  
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The functionality of these cells with regard to cytokine secretion, proliferative ability and 
cytotoxic potential will be examined to determine the activity of these cells once removed 
from the tumour environment. The clonality of tumour infiltrating T cells will also be 
compared to that of autologous peripheral blood T cells (PBMC) to help determine 
whether antigen-specific expansion of T cells occurs within the tumour. Investigating the 
functional characteristics of these cells will increase our understanding of anti-tumour 
immunity in the context of TGCTs. 
 
Although the presence of T cells within TGCT lesions has been well documented, little is 
known about NK cells which infiltrate these tumours. Since all TGCTs are derived from 
undifferentiated primordial germ cells, it has been suggested that MHC expression on 
these cells may be low or absent. Consequently, T cell mediated immunity, in particular 
cytotoxic CD8 T cell responses, may be ineffective at targeting and subsequent killing of 
tumour cells. NK cells can target transformed cells without the need of prior sensitisation. 
The frequency, phenotype and function of NK cells within these tumours will therefore be 
examined. 
 
In this study, immune cells are analysed ex vivo, directly following mechanical tumour 
dissociation, an approach which allows a more informative examination of multiple 
phenotypic and functional attributes of TIL.  
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Results 
αβ  and  γδ  T cells Infiltrate TGCTs 
Following the isolation of lymphocytes from TGCT tissues by gentle mechanical 
dissociation, cells were stained with appropriate antibodies against cell surface antigens 
and analysed by flow cytometry. Cells were first gated to remove doublet cells, before 
gating on live lymphocytes. T cells were identified by their expression of CD3 and were 
subsequently  defined  by  differential  expression  of  CD4,  CD8  and  γδ  TCR. All three T cell 
subtypes were detected in TIL (Figure 7). 
 
The median CD4:CD8 ratio in TIL (n=7) is 1.12:1 (interquartile range [IQR]: 0.65-1.15) 
demonstrating CD4 and CD8 cells are present at approximately equal proportions. In 
PBMC, there is approximately twice as many CD4 T cells than CD8 T cells (median ratio: 
1.99 IQR: 1.26-3.04) demonstrating that TILs are significantly enriched for CD8 T cells 
(p=0.0156) (Figure 8a). 
 
γδ T cells were also present in TIL,  but  at  relatively  low  frequency  compared  to  αβ  T  cells   
(median: 3.07% of CD3+ T cells) (Figure 8b). There was no significant difference between 
the  proportion  of  γδ  T  cells  in  TIL  (3.07  IQR:  1.61-9.57) compared to PBMC (3.42 IQR: 1.54-
6.90) (p=0.5703).  
 
Overall, our results indicate that  αβ  T  cells  are  the  dominant  T  cell  population  infiltrating  
TGCT masses, with the tumour environment being enriched for CD8 T cells. 
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Figure 7.  Gating  strategies  for  identification  of  CD4,  CD8  and  γδ  T  cells. 
Cells were first gated to remove doublet cells (a), before gating on lymphocytes based on 
FSC-A and SSC-A properties (b). Live T cells were classified as being propidium iodide 
(PI) negative and CD3 positive cells (c). CD4 (green) and CD8 (red) T cells were gated from 
the CD3+PI- population (d). γδ  T  cells  (blue)  were  identified  as  γδ  TCR  positive  cells  from  
the CD3+ CD4- CD8- subset (e). Plots shown are representative of TIL isolated from TGCT 
tissue of a single individual. 
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Figure 8.  Proportion  of  CD4,  CD8  and  γδ TCR+ T cells in PBMC and TIL. 
The proportion of CD4 and CD8 T cells in matched PBMC and TIL was calculated, and 
expressed as a CD4:CD8 ratio (a). The   proportion   of   γδ   T   cells   was   determined   and  
expressed as a percentage of total CD3+ T cells (b). Each symbol represents an individual 
patient. Horizontal lines indicate the median. Data analysed by Wilcoxon matched-pairs 
signed-rank test, * denotes p<0.05.  
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CD4 and CD8 TIL Have an Effector Memory Phenotype 
The memory phenotype of CD4 and CD8 T cells from PBMC and TIL was determined by 
flow cytometry following antibody staining for CD45RA and the chemokine receptor 
CCR7. The expression of these markers classified cells into the following memory 
phenotypes: TEMRA (CD45RA+CCR7-), naive (CD45RA+CCR7+), effector memory (TEM, 
CD45RA-CCR7-) and central memory (TCM, CD45RA-CCR7+) T cells. Table 10 shows the 
distribution of CD4 (Figure 9) and CD8 (Figure 10) T cells in these memory subsets within 
both PBMC and TIL. The proportion of naive T cells was markedly lower in TIL compared 
with autologous PBMC (CD4 median 1.35% vs. 46.44%; CD8 median 2.22% vs. 30.49%). 
These changes were reciprocated by a significant enrichment of TEM in TIL compared to 
PBMC (CD4 median 78.22% vs. 20.54%; CD8 median 85.76% vs. 38.30%). In addition, the 
proportion of TEMRA cells in the CD4 compartment was significantly reduced. The same 
serves true for CD8 TEMRA although the decrease does not reach statistical significance. 
There was no significant difference in the proportion of CD4 and CD8 TCM cells isolated 
from tumour compared to PBMC. In conclusion, T cells with an TEM phenotype are the 
predominant tumour infiltrating cells. 
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Figure 9. Memory phenotype of CD4 T cells in matched PBMC and TIL. 
Expression of CCR7 and CD45RA on CD4 T cells was determined to show TEMRA 
(CD45RA+CCR7-), naive (CD45RA+CCR7+), effector memory (TEM, CD45RA-CCR7-), and 
central memory (TCM, CD45RA-CCR7+) T cells (a). Proportions of CD4 T cells in each 
memory subset are shown (b). Each symbol represents an individual patient. Horizontal 
lines indicate the median. Data analysed by Wilcoxon matched-pairs signed-rank test,  
** denotes p<0.01.  
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Figure 10. Memory phenotype of CD8 T cells in matched PBMC and TIL. 
Expression of CCR7 and CD45RA on CD8 T cells was determined to show TEMRA 
(CD45RA+CCR7-), naive (CD45RA+CCR7+), effector memory (TEM, CD45RA-CCR7-), and 
central memory (TCM, CD45RA-CCR7+) T cells (a). Proportions of CD8 T cells in each 
memory subset are shown (b). Each symbol represents an individual patient. Horizontal 
lines indicate the median. Data analysed by Wilcoxon matched-pairs signed-rank test, 
 ** denotes p<0.01.  
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Table 10. Memory phenotype of CD4 and CD8 T cells in matched PBMC and TIL. 
 CD4 (n=9)  CD8 (n=9)  
 PBMC TIL 
p 
PBMC TIL 
p 
 Median 25th 75th Median 25th 75th Median 25th 75th Median 25th 75th 
TEMRA 2.66 1.45 6.10 0.86 0.29 28.71 0.0039 12.01 3.74 40.15 5.94 1.40 9.58 0.1641 
Naive 46.44 24.12 60.69 1.35 0.66 10.71 0.0039 30.49 11.81 73.09 2.22 1.16 5.52 0.0039 
TEM 20.54 15.85 36.79 78.22 56.10 82.43 0.0039 38.30 15.56 54.52 85.76 64.69 93.18 0.0039 
TCM 26.43 20.74 34.71 20.22 11.21 32.43 0.2500 3.65 2.21 5.91 2.61 1.69 14.51 0.6523 
 Data expressed as median with 25th and 75th quartile. Significant differences are highlighted in bold type.  
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The Effector Memory T cell Compartment is Inflated in TGCT Patients  
We could reasonably hypothesise that T cells infiltrating the tumour may re-enter 
circulation and would therefore result in a systemic increase in tumour specific cells in 
peripheral blood. Since effector memory T cells are elevated in TIL, we investigated 
whether memory subsets were increased in the circulation of patients with testicular 
cancer, compared to healthy controls. TGCT patients and healthy donors were gender-
matched and age-matched, to enable effective comparison (Figure 11). We observed 
different proportions of peripheral blood memory subsets in TGCT patients, compared to 
healthy donors (Figure 12 and Table 11). Peripheral blood effector memory CD4 and CD8 
T cells were significantly elevated in TGCT patients. This effect was reciprocated by a 
statistically significant reduction in the proportion of naive T cells. We speculate that 
tumour development leads to the generation and expansion of tumour specific T cells that 
may enter circulation and subsequently inflate the peripheral blood memory T cell pool.  
 
Furthermore, we characterised the memory phenotype of peripheral T cells from a small 
cohort of seminoma patients before (n=10), two weeks (n=10) and three months (n=6) post 
chemotherapy. No significant difference was observed in the proportions of CD4 and CD8 
T cells within each memory subset shortly after chemotherapy (two weeks). However, 
three months post chemotherapy revealed decreased proportions of TEM cells and 
increased proportions of naive T cells for both the CD4 and CD8 T cell compartments 
within the circulation (Table 12, Table 13 and Figure 13). P values and significance 
between each time point for CD4 and CD8 T cells are outlined in Table 14. Together, our 
data suggest the removal of tumour burden and/or the onset of chemotherapy could lead 
to a reduction in anti-tumour specific immunity.  
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Figure 11. Age of healthy donors and TGCT patients. 
The age of healthy donors and TGCT patients is shown. There is no significant difference 
in the age of healthy donors and TGCT patients used in this study. Box represents 25th and 
75th percentile, line represents median, and whiskers represent 10-90 percentile. Data 
analysed by Mann-Whitney test.  
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Figure 12. Memory phenotype of peripheral blood CD4 and CD8 T cells of healthy 
donors and TGCT patients. 
Expression of CCR7 and CD45RA on CD4 (a) and CD8 (b) T cells was determined to 
define TEMRA, Naive, TEM and TCM subsets. Proportions of cells in each memory subset of 
healthy donors and TGCT patients were compared. Each symbol represents an individual 
patient. Horizontal line indicates the median. Data analysed by Mann Whitney test,  
* denotes p<0.05, ** denotes p<0.01. 
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Table 11. Memory phenotype of peripheral blood CD4 and CD8 T cells of healthy donors and TGCT patients. 
 CD4  CD8  
 Healthy (n=13) TGCT (n=15) 
p 
Healthy (n=13) TGCT (n=15) 
p 
 Median 25th 75th Median 25th 75th Median 25th 75th Median 25th 75th 
TEMRA 3.16 2.24 8.60 4.06 2.70 6.93 0.5804 15.70 6.96 20.29 17.69 8.08 29.06 0.6450 
Naive 57.96 46.29 62.30 43.36 34.34 48.36 0.0270 49.16 31.18 57.10 29.99 18.47 39.64 0.0341 
TEM 20.08 14.70 21.64 29.35 24.81 35.61 0.0099 32.26 14.59 41.71 46.05 34.81 54.59 0.0382 
TCM 19.21 12.48 28.23 22.37 18.64 35.18 0.2136 4.54 2.54 5.69 3.80 2.66 5.70 0.7125 
Data expressed as median (bold) with 25th and 75th quartile. Significant differences are highlighted in bold italic type.  
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Figure 13. Memory phenotype of peripheral blood CD4 and CD8 T cells of TGCT 
patients before and after chemotherapy. 
Expression of CCR7 and CD45RA on CD4 (a) and CD8 (b) T cells was determined to 
define TEMRA, Naive, TEM and TCM subsets. Proportions of cells in each memory subset at 
pre, 2wks and 3M post chemotherapy is shown. Each symbol represents an individual 
patient. Horizontal line indicates the median. Data analysed by Wilcoxon matched-pairs 
signed-rank test, * denotes p<0.05.  
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Table 12. Memory phenotype of peripheral blood CD4 T cells of TGCT patients before 
and after chemotherapy 
   Pre (n=10) 2wks (n=10) 3M (n=6) 
 Median 25th 75th Median 25th 75th Median 25th 75th 
TEMRA 4.03 2.46 6.95 4.24 2.69 8.01 5.69 3.57 8.64 
Naive 43.40 31.90 46.39 50.12 34.58 52.93 51.22 41.70 58.12 
TEM 29.69 25.32 32.83 23.27 18.28 32.44 23.64 16.35 27.27 
TCM 22.33 18.50 37.60 22.89 16.24 32.07 20.34 16.22 27.49 
     Data expressed as median (bold) with 25th and 75th quartile.   
   
 
Table 13. Memory phenotype of peripheral blood CD8 T cells of TGCT patients before 
and after chemotherapy 
 Pre (n=10) 2wks (n=10) 3M (n=6) 
 
Median 25th 75th Median 25th 75th Median 25th 75th 
TEMRA 15.61 11.16 20.86 17.18 10.43 21.70 21.00 12.48 28.70 
Naive 28.83 15.32 32.82 29.09 17.39 46.07 38.07 27.62 45.16 
TEM 53.83 36.42 62.23 49.03 32.34 63.69 34.42 24.10 52.67 
TCM 3.89 3.08 5.81 3.55 3.01 7.02 3.44 2.71 5.35 
    Data expressed as median (bold) with 25th and 75th quartile.  
 
 
Table 14. P values for memory phenotyping of peripheral blood T cells of TGCT 
patients before and after chemotherapy. 
 CD4 CD8 
 TEMRA Naive TEM TCM TEMRA Naive TEM TCM  
Pre vs. 2wks 0.1309 0.2324 0.2754 0.1602 0.6250 0.5566 0.7695 0.3223  
Pre vs. 3M 0.0313 0.0313 0.0313 0.0938 0.5625 0.0313 0.0313 0.3125  
2wks vs. 3M 1.000 0.3215 0.2188 0.3125 0.3125 0.5625 0.1563 0.5625  
  Significant differences are highlighted in bold italic type.  
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T Cells Infiltrating TGCTs Express Markers of Activation 
T cells isolated from TGCT tissue are predominantly TEM. This suggests tumour infiltrating 
T cells are antigen-experienced i.e. they have previously been activated by, and are 
responding to, cognate antigen presented through MHC complexes. Although these cells 
are antigen experienced, this alone does not indicate whether the recognition of antigen 
has occurred recently. By assessing the expression of activation markers on T cells from 
TIL, and comparing this to PBMC, we are able to determine whether these cells have been 
activated within the tumour. 
 
Expression of CD69 was examined on CD4 and CD8 T cells from PBMC and TIL by flow 
cytometry. CD69 is the earliest inducible cell surface glycoprotein acquired during T cell 
activation (Testi et al., 1994). Expression of CD69 was significantly increased on both CD4 
(p=0.0025) and CD8 T cells (p=0.0025) in TIL compared to PBMC (Figure 14 and Table 15). 
The median expression of CD69 on TIL was 46.70% and 44.56% of total CD4 and CD8 T 
cell subsets, respectively. In contrast, less than 1% of CD4 and CD8 T cells from PBMC 
expressed CD69. Expression levels of CD69 on γδ  T  cells were  similar  to  that  of  αβ  T  cells,  
with a median of 51.77% for TIL vs. 0.79% for PBMC. This data suggests that 
approximately half the T cell population infiltrating TGCT has very recently been 
activated, indicative of stimulation within the tumour. 
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Figure 14.  CD69  expression  on  αβ  and  γδ  T  cell  subsets  from  PBMC  and  TIL. 
Expression of CD69 was determined on CD4, CD8,  and  γδ  T  cells  by  flow  cytometry  and  
representative histograms are shown (a). Bar chart shows significant increase in CD69 
expression on all T cell subsets (b) in TIL (open bar) compared to PBMC (filled bar). Bars 
represent median. Error bars represent upper range. Data analysed by Mann-Whitney test, 
* *denotes p<0.01.  
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To corroborate the observation that T cells are activated, CD38 expression was also 
analysed on matched PBMC and TIL. CD38 expression on resting T cells is low but is 
highly expressed on activated T cells. The cell surface density of CD38 (median 
fluorescence intensity [MFI]) on CD4 and CD8 T cells was far greater on TIL (CD4: 1310, 
CD8: 1036) than on PBMC (CD4: 454, CD8: 406), in all patients analysed (Figure 15 and 
Table 15). A 4-fold increase in CD38 density was found on CD8 T cells in TIL compared to 
PBMC. Similarly, a 5-fold increase was observed for CD4 T cells in TIL. Differences in 
CD38 MFI of T cells from PBMC and TIL did however not reach statistical significance, 
likely due to small sample size (n= 3). It is clear from Figure 15a that the increase in MFI in 
TIL was primarily due to a large population of T cells expressing very high levels of CD38. 
This cell population was present in both the CD4 and CD8 compartments, but was 
completely absent on T cells from peripheral blood.  
 
Increased CD69 Expression on Peripheral Blood CD8 T Cells Following Chemotherapy  
A high proportion of tumour infiltrating T cells are activated, which led us to examine the 
expression of CD69 on peripheral blood T cells from TGCT patients (pre-treatment) 
compared to healthy controls. No difference in CD69 expression was apparent on either 
the CD4, CD8 or γδ  T  cell subsets from TGCT patients compared to healthy donors (Figure 
16a and Table 18). However, the proportion of CD8 and  γδ  T  cells expressing CD69 was 
increased shortly after (two weeks) chemotherapy (Figure 16b, Table 17 and Table 18), 
compared to levels prior to treatment. Although statistically significant, the overall 
increase in CD69 expressing cells is minimal, and therefore its biological significance 
unknown.  
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Figure 15. Expression of CD38 on T cells from TIL and autologous PBMC. 
Representative histograms show the expression of CD38 on CD4 and CD8 T cells in PBMC 
and TIL (a). CD38 MFI was calculated and is shown for CD4 and CD8 T cells in PBMC and 
TIL (b). Lines join PBMC and TIL from the same patient. Data analysed by Wilcoxon 
matched-pairs signed-rank test.  
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Table 15.  CD69  and  CD38  expression  on  αβ  and  γδ  T  cell  subsets  from  PBMC  and  TIL. 
 CD4   CD8  
 PBMC TIL 
p 
PBMC TIL 
p 
 Median 25th 75th Median 25th 75th Median 25th 75th Median 25th 75th 
CD69 
(n=6) 0.17 0.04 0.44 46.70 17.85 57.76 0.0025 0.52 0.12 1.00 44.59 17.16 62.38 0.0025 
CD38 
(n=3) 454 431 847 1310 1211 3451 0.2500 406 142 440 1036 905 2452 0.2500 
 
 
 
                                           γδ    
 PBMC TIL 
p 
 Median 25th 75th Median 25th 75th 
CD69 
(n=6) 0.79 0.19 1.56 51.77 26.08 71.23 0.0025 
 
Data expressed as median (bold) with 25th and 75th quartile. Significant differences are highlighted in bold italic type.  
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Figure 16. CD69 expression on peripheral blood T cells of healthy donors and TGCT 
patients at pre and post treatment. 
Expression of CD69 was determined by flow cytometry. Bar charts compare the 
proportion of CD69 expressing CD4, CD8 and   γδ   T   cells   in   healthy   donors   and   TGCT  
patients (a) Bars represent median. Error bars indicate upper quartile. Data analysed by 
Mann-Whitney test. CD69 expression on CD4, CD8 and  γδ  T  cells  from  TGCT  patients  at  
pre, 2wks and 3M post chemotherapy. Bars represent median. Error bars indicate upper 
quartile. Data analysed by Wilcoxon matched-pairs signed-rank test, *denotes p<0.05.  
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Table 16. Activation status of T cells from peripheral blood of healthy donors compared 
to that of TGCT patients. 
Data expressed as median (bold) with 25th and 75th quartile. Significant differences are 
highlighted in bold type. 
 
 
 
Table 17. T cell activation of peripheral blood T cells in TGCT patients pre and post 
chemotherapy.  
 Pre (n=10) 2wks (n=10) 3M (n=6)  
 
Median 25th 75th Median 25th 75th Median 25th 75th 
CD4+CD69+ 
 
0.26 0.12 0.50 0.26 0.15 0.32 0.58 0.40 0.74 
CD8+CD69+ 
        
0.78 0.39 0.94 0.98 0.60 1.60 0.58 0.47 0.75 
CD69+γδ                 0.60 0.59 1.76 0.98 0.55 2.73 0.86 0.61 1.55 
Data expressed as median (bold) with 25th and 75th quartile.  
 
 
 
Table 18. P values for T cell activation of peripheral blood T cells in TGCT patients 
before and at intervals following chemotherapy. 
 CD4+CD69+ CD8+CD69+ CD69+γδ 
Pre vs. 2wks 0.3570 0.0137 0.0273 
Pre vs. 3M 0.4375 0.3125 0.4375 
2wks vs. 3M 0.6875 0.1875 1.000 
Significant differences are highlighted in bold italic type. 
 
 
 
           Healthy (n=13)                 TGCT (n=15)  
p 
 Median 25th 75th n  Median 25th 75th n 
CD4+CD69+ 0.10 0.08 0.17 13  0.26 0.09 0.45 15 0.0538 
CD8+CD69+ 0.63 0.44 0.82 13  0.81 0.42 0.98 15 0.4070 
CD69+ γδ 0.59 0.28 1.48 13  0.60 0.36 1.75 15 0.4336 
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T Cells Isolated from TGCT Tissue Have a High Proliferative Capacity in vitro 
We have shown that T cells within TGCT lesions are predominantly recently activated TEM 
cells. Following activation, T cells enter the cell cycle and clonally expand in order to 
generate an effective immune response. Next, we determined the extent of T cell 
proliferation with and without in vitro stimulation. Cells were either unstimulated (IL-2 
only) or stimulated in vitro, for 5 days. TCR-mediated stimulation was achieved by 
stimulating with CD3/CD28 Dynabeads with IL-2. Prior to cell culture, cells were stained 
with a CelltraceTM proliferation dye, which is distributed equally between the daughter 
cells during each successive cell division thus cellular fluorescence intensity is halved. As a 
result, the proportion of cells that have undergone a particular number of cell divisions 
can be determined by flow cytometry. 
 
If T cells received the appropriate stimulus to proliferate within the tumour 
microenvironment, we would expect them to continue dividing in vitro without additional 
TCR stimulation. However, we showed that only a minority of CD4 (3.83% IQR 0.67-15.31) 
and CD8 (1.91% IQR 0.31-20.40) T cells were found to proliferate when cultured without in 
vitro stimulation (Figure 17a). This suggests that although T cells have been activated by 
cognate antigen very recently, the majority of T cells within the tumour are not 
proliferating. Next, we investigated the extent of proliferation following in vitro TCR-
dependant stimulation, to determine whether proliferation could be restored. Stimulation 
of these cells in vitro would determine whether they are proliferatively dysfunctional due 
to chronic stimulation (cell intrinsic) and whether being previously present in the tumour 
microenvironment influences their proliferative potential.   
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Following stimulation, the majority of CD4 (84.73% IQR 77.83-87.83) and CD8 (83.59% IQR 
75.99-92.91) T cells underwent at least one division (Figure 17b). In addition, we found 
there was no significant difference in the proliferative potential of CD4 T cells vs. CD8 T 
cells regardless of whether they were stimulated (p=1.000) or not (p=1.000). This suggests 
proliferation is suppressed in both T cell subtypes within the tumour microenvironment. 
However, the inability to proliferate is reversed by signalling through the TCR with 
appropriate costimulation.  
 
The extent of proliferation of CD4 and CD8 T cells was determined following TCR-
dependant stimulation. A small proportion of unstimulated cells showed proliferation, 
with the majority of these cells undergoing a single cycle of cell division (CD4: 2.48% out 
of 3.83%, CD8 1.74% out of 1.91%). This suggests cells directly isolated from the tumour 
have a very low proliferative potential. In contrast, the majority of in vitro stimulated CD4 
and CD8 T cells isolated from TGCTs underwent multiple rounds of cell division (Figure 
17). Combined, this suggests that T cells isolated from TGCTs are not incapable of 
proliferation, but are inhibited in doing so directly by the tumour and/or the milieu.  
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Figure 17. T cells isolated from TGCT tissues have a high proliferative capacity. 
Representative histograms (left) show the numbers of cell divisions of unstimulated (a) 
and stimulated (CD3/CD28 Dynabeads + IL-2) CD4 and CD8 T cells (b). Each peak (CD4, 
purple; CD8, blue) represents a cell division. Red peaks represent non-dividing cells. 
Percentages of total proliferating CD4 and CD8 T cells when unstimulated and stimulated 
are shown (middle). Box represents 25th and 75th percentile, line represents median, and 
whiskers represent 10-90 percentile. Percentages of T cells that have undergone 0 to 6+ 
divisions when unstimulated or stimulated were determined (right). Black bars represent 
CD4 T cells; white bars represent CD8 T cells. Bars represent median. Error bars indicate 
upper quartile. Data analysed by Wilcoxon matched-pairs signed-rank test.  
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Oligoclonal Populations of T Cells Develop within TGCT Lesions 
We hypothesise that T cells infiltrating TGCT are tumour specific. Consequently, we 
would expect oligoclonal populations of tumour specific cells to accumulate within the 
tumour  mass.   If   this  were   true   the   TCR  Vβ   usage   in   TIL  would   be   different   to   that   of  
PBMC. We compared the CD3+ TCR Vβ   repertoire   of   PBMC  with   that   of   TIL   by flow 
cytometry using a commercially available antibody kit. Figure 18 demonstrates the gating 
strategy  used  to  quantify  the  proportion  of  cells  expressing  a  particular  Vβ chain.  
 
We examined the clonality of T cells isolated from matched peripheral blood and TIL in 
NSGCTT (n=1), mGCT (n=1) and seminoma (n=3) patients. Figure 19a illustrates the 
proportion  of  each  Vβ  family  represented in PBMC and TIL expressed as a percentage of 
total T cells in a NSGCTT, mGCT and Seminoma patient. Clear differences were observed 
in the Vβ repertoire in all tumour types examined, and the data is summarised in the form 
of a discontinuous heat map (Figure 19b). Our   results   show   that   a   median   of   11   Vβ  
families (range: 6-12) are enriched in TIL when compared to matched peripheral blood, 
and that this can be an increase in excess of 200%. As expected, large increases in 
particular  Vβ  families  in  TIL  were reciprocated  with  large  reductions  in  other  Vβ  families.  
The greatest difference was observed in a NSGCTT patient who had an increase of 265% in 
Vβ13.1 T cells, which made up 11.6% of the total T cell infiltrate. Similar increases in this 
particular  Vβ   family  were  observed   in   4  out  of  5  patients.  Vβ   families   17   and  13.6  were  
increased in all patients examined,   while   Vβ18   was   always   at   lower   levels   in   TIL 
compared to PBMC. The results indicate that oligoclonal populations of T cells within 
TGCT do exist, suggestive of clonal expansion of tumour-specific T cells to multiple 
epitopes.  
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Figure 18.  Flow  cytometric  analysis  of  Vβ usage. 
Total CD3+ T  cells  were  analysed  (a).  Cells  were  stained  with  a  cocktail  of  Vβ  monoclonal  
antibodies, all conjugated to different fluorochromes. The dot plots depict the quantitative 
analysis  of  the  TCR  Vβ  repertoire  of  T  cells  from  PBMC  in  a  representative TGCT patient 
(b).  Quadrants  show  the  indicated  Vβ  families.   
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Figure 19. The clonality of tumour infiltrating T cells. 
The   proportion   of   each   Vβ   family   is   represented   as   a   percentage   of   total T cells. The 
representative  bar   charts   compare   the   frequency  of  each  Vβ   family   in  PBMC  (filled  bar)  
and TIL (open bar), for a NSGCTT (a), mGCT (b), and Seminoma (c) patient. Each graph 
represents a single patient. The discontinuous heat map demonstrates the degree of 
change in TIL  of  each  Vβ  family,  compared  to  PBMC  (d).  N, NSGCTT; S, Seminoma; M, 
mGCT. 
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TGCTs Contain Inflammatory Cytokine Secreting T Cells 
We have determined that CD4 and CD8 T cells infiltrating TGCTs are activated; antigen 
experienced and presumably clonally expanded cells. Next, we determined whether T 
cells   isolated  directly   from   the   tumour  were  producing   IFNγ  and  TNFα  by   intracellular  
cytokine staining.  Flow cytometric analysis revealed that inflammatory cytokines are not 
produced by T cells without in vitro stimulation (Figure 20a), suggesting cells are not 
producing inflammatory cytokine within the tumour mass. 
 
Stimulation with PMA/Ionomycin followed by intracellular staining for the cytokines 
IFNγ  and  TNFα was performed on CD4 and CD8 T cells from TIL, to verify that these cells 
are  able  to  produce  cytokine.  Both  CD4  and  CD8  TIL  release  IFNγ  and  TNFα  following  in 
vitro stimulation (Figure 20b), suggesting these cells are able to produce cytokine but their 
ability to do this in vivo is repressed. We used the same stimulation protocol to define and 
quantify inflammatory T cell effector subsets. Cytotoxic CD8 T cells and CD4 Th1 cells can 
be   classified   by   the   production   of   IFNγ   and  TNFα.  The cytokine profile of CD4 T cells 
(Figure 20c) and CD8 T cells (Figure 20d) from TIL was compared to that of autologous 
PBMC. We examined the proportion of dual cytokine secreting T cells (IFNγ+TNFα+) as 
well as single cytokine secretors   (IFNγ+TNFα- or   IFNγ-TNFα+), and non-secretors   (IFNγ-
TNFα-). There was no significant difference in the cytokine profile of T cells isolated from 
the tumour compared to those from peripheral blood (Table 19). Our results suggest the 
effector function of CD4 and CD8 TIL may be compromised within the tumour but, 
similarly to that observed with proliferative capacity of TIL, it can be rescued with 
additional stimulation in vitro. 
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Tumour Infiltrating T Cells Have Cytotoxic Capacity 
Our results indicate that T cells isolated from TGCT tissue are able to produce 
inflammatory cytokines upon stimulation. Next, we examined the cytotoxicity of T cells by 
measuring CD107a surface expression. CD107a is transiently mobilised to the surface of T 
cells as a prerequisite of degranulation in response to stimulus (Betts et al., 2003). CD107a 
was examined on the surface of CD4 and CD8 TIL and compared with that of autologous 
PBMC, following stimulation with PMA/Ionomycin (n=4) (Figure 21).  
 
There was a significant increase in the proportion of both CD107a expressing CD4 and 
CD8 T cells in TIL (CD4, 24.83 IQR: 22.80-51.67; CD8, 48.70 IQR: 40.67-71.99) compared to 
PBMC (CD4, 2.59 IQR: 1.30-2.97; CD8, 10.20 IQR: 8.78-15.89) (p=0.0286) with CD4 T cells 
isolated from PBMC having the least potential to degranulate. Stimulated CD8 T cells from 
TIL had a greater proportion of CD107a+ cells than CD4 T cells (Figure 21c) (p=0.0579); an 
observation which could be explained by the natural cytotoxicity of CD8 T cells. These 
results suggest cytotoxic activity of CD8 T cells isolated from TIL remains, and that CD4 T 
cells may acquire this activity within the tumour as illustrated by an increased ability to 
degranulate when compared to healthy PBMC controls.     
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Figure 20. Secretion of inflammatory cytokines by tumour infiltrating T cells following 
stimulation. 
IFNγ  and  TNFα  release is shown for unstimulated (a) and PMA/Ionomycin stimulated (b) 
CD4 and CD8 T cells from TIL and autologous PBMC. Bar graphs compare the percentage 
of total CD4 (c) and CD8 T cells (d)   from   PBMC   and   TIL   that   are   IFNγ+TNFα-, 
IFNγ+TNFα+,   IFNγ-TNFα- and   IFNγ-TNFα+ following PMA/Ionomycin stimulation. Bars 
show median. Error bars indicate upper quartile range. All data analysed by Wilcoxon 
matched-pairs signed-rank test. 
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Table 19. Single and dual cytokine secretion of tumour infiltrating T cells. 
 CD4 (n=4)  CD8 (n=4)  
 
PBMC TIL 
p 
PBMC TIL 
p 
 Median 25th 75th Median 25th 75th Median 25th 75th Median 25th 75th 
IFNγ+TNFα- 0.28 0.08 1.68 1.07 0.85 2.46 0.1250 2.08 1.04 8.25 19.54 13.42 29.61 0.1250 
IFNγ+TNFα+ 4.13 1.12 23.59 14.55 11.31 60.88 0.1250 19.51 5.40 52.17 27.53 23.82 61.15 0.2500 
IFNγ-TNFα- 64.72 46.99 79.67 49.95 20.99 63.53 0.1250 55.00 27.30 79.38 36.42 13.19 48.44 0.1250 
IFNγ-TNFα+ 25.39 18.65 34.14 25.69 11.30 37.43 0.8750 9.84 5.97 34.06 5.16 3.09 18.63 0.1250 
 Data expressed as median (bold) with 25th and 75th quartile. 
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Figure 21. Degranulation of tumour infiltrating T cells. 
CD107a expression was used as a marker of degranulation. Representative histograms 
show the expression levels of CD107a on CD4 and CD8 T cells from PBMC and TIL, with 
or without PMA/Ionomycin stimulation (a). Bar graphs compare median expression of 
CD107a on CD4 T cells and CD8 T cells (b) in PBMC and TIL. The proportion of CD107a+ 
TIL was compared between CD4 and CD8 T cells (c). Error bars indicate upper quartile. 
Data analysed by Wilcoxon matched-pairs signed-rank test.* denotes p<0.05.  
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T Cells Infiltrating TGCTs Express Inhibitory Receptors 
Negative regulatory receptors on the surface of T cells are upregulated following 
activation. If these receptors bind their respective ligands, T cell function becomes 
impaired (Barber et al., 2006, Freeman et al., 2000). Exhausted or dysfunctional T cells are 
regulated by multiple inhibitory receptors during an active immune response, which 
include the negative costimulatory receptors TIM-3 and PD-1. We examined the 
expression of these inhibitory receptors on CD4 and CD8 TIL and compared it to 
autologous PBMC (n=7) (Figure 22 and Table 20).  
 
Both CD4 and CD8 TIL have increased expression of TIM-3 (Figure 22b) and PD-1 (Figure 
22c), compared to autologous PBMC. In addition, the proportion of CD4 and CD8 T cells 
that were double positive for TIM-3 and PD-1 was significantly greater in TIL than PBMC 
(Figure 22d). In fact, double positive cells were practically absent in the peripheral blood 
of all patients examined. Moreover, the expression of both inhibitory receptors was more 
prominent on CD8 T cells (median: 18.01%) than CD4 T cells (median: 5.60%) in TIL.     
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Figure 22. Expression of negative regulatory receptors on T cells from PBMC and TIL. 
TIM-3 and PD-1 expression was determined on CD4 and CD8 T cells from PBMC (filled 
bar) and TIL (open bar) by flow cytometry (a). Proportions of CD4 and CD8 T cells that are 
TIM-3+, PD-1+ or TIM-3+PD-1+ are shown (b). Bars represent median. Error bars represent 
upper quartile range. Data analysed by Wilcoxon matched-pairs signed-rank test, *denotes 
p<0.05. 
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Table 20. Expression of negative regulatory receptors on T cells from PBMC and TIL. 
 
CD4 (n=7)  CD8 (n=7)  
 PBMC TIL 
p 
PBMC TIL 
p 
 Median 25th 75th Median 25th 75th Median 25th 75th Median 25th 75th 
TIM3+ 0.87 0.38 1.11 19.95 9.54 30.08 0.0156 1.37 0.65 1.75 25.74 14.00 36.14 0.0156 
PD-1+ 0.61 0.23 1.31 17.42 7.22 38.02 0.0156 0.91 0.30 1.77 35.14 2.62 48.00 0.0156 
TIM3+PD-1+ 0.04 0.03 0.05 5.60 4.39 9.14 0.0156 0.04 0.01 0.08 18.01 2.29 26.05 0.0156 
Data expressed as median (bold) with 25th and 75th quartile. Significant differences are highlighted in bold italic type.  
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TIM-3 Is Induced on CD8 T Cells Shortly After Chemotherapy 
There was no significant difference in the expression of TIM-3 or PD-1 on CD4 and CD8 T 
cells between PBMC of seminoma patients and healthy controls (Figure 23 and Table 21). T 
cells expressing both inhibitory receptors were virtually undetectable in PBMC from 
TGCT patients and healthy controls, however, shortly after chemotherapy (2wks) TIM-3 
was significantly upregulated on a proportion of CD8 T cells by up to 58% (Figure 24a, 
Table 22 and Table 23). Three months after chemotherapy, elevated levels of TIM-3 were 
not maintained and dropped to levels similar to those prior to chemotherapy. TIM-3 can 
be induced on T cells following activation (Canaday et al., 2013). Here we show a 
simultaneous increase in CD69 and TIM-3 expressing cells shortly after chemotherapy 
suggesting activation of cells may be induced by chemotherapy treatment. 
 
PD-1 Expressing CD8 T Cells Decline Following Tumour Removal 
A step wise decrease in PD-1 expression by CD8 T cells was observed over time post 
chemotherapy (Figure 24b), although statistical significance was not reached (Pre vs. 3M, 
p=0.0625). This is likely to be associated with the availability of tumour antigens following 
orchidectomy, and the decline in TEM cells that may express this ligand. In contrast, no 
differences were observed in the CD4 T cell compartment for either inhibitory receptor. 
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Figure 23. Expression of inhibitory receptors TIM-3 and PD-1 on peripheral blood CD4 
and CD8 T cells of healthy donors and TGCT patients. 
TIM-3 and PD-1 expression was determined on peripheral blood CD4 and CD8 T cells of 
healthy donors and TGCT patients. Proportions of CD4 and CD8 T cells that are TIM-3+ (a) 
and PD-1+ (b) are shown. Bars represent median. Error bars indicate upper quartile. Data 
analysed by Mann-Whitney test. 
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Table 21. Expression of inhibitory receptors TIM-3 and PD-1 on peripheral blood CD4 and CD8 T cells of healthy donors and TGCT 
patients. 
 CD4  CD8  
 Healthy (n=13) TGCT (n=15) 
p 
Healthy (n=13) TGCT (n=15) 
p 
 Median 25th 75th Median 25th 75th Median 25th 75th Median 25th 75th 
TIM3+  0.45 0.24 0.63 0.34 0.15 0.70 0.7125 0.22 0.15 0.28 0.38 0.17 0.67 0.0812 
PD-1+ 0.17 0.10 0.20 0.17 0.11 0.20 0.8178 0.45 0.36 0.72 0.71 0.38 0.80 0.3109 
Data expressed as median (bold) with 25th and 75th quartile. 
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Figure 24. Expression of inhibitory receptors TIM-3 and PD-1 on peripheral blood CD4 
and CD8 T cells following chemotherapy. 
TIM-3 and PD-1 expression was determined on peripheral blood CD4 and CD8 T cells at 
pre, 2wks and 3M post chemotherapy by flow cytometry. Proportions of CD4 and CD8 T 
cells that are TIM-3+ (a) and PD-1+ (b) are shown. Bars represent median. Error bars 
indicate upper quartile. Data analysed by Wilcoxon matched-pairs signed-rank test, 
*denotes p<0.05. 
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Table 22. Expression of inhibitory receptors TIM-3 and PD-1 on peripheral blood CD4 
and CD8 T cells following chemotherapy. 
Data expressed as median (bold) with 25th and 75th quartile.  
 
 
 
 
Table 23. p values for expression of inhibitory receptors TIM-3 and PD-1 on peripheral 
blood CD4 and CD8 T cells following chemotherapy. 
Significant differences are highlighted in bold italic type. 
 
 
 
 
 
 
 Pre (n=10) 2wks (n=10) 3M (n=6) 
 Median 25th 75th Median 25th 75th Median 25th 75th 
CD4+TIM-3+ 0.23 0.12 0.52 0.29 0.17 0.43 0.21 0.15 0.26 
CD8+TIM-3+ 0.29 0.16 0.60 0.46 0.24 0.90 0.26 0.15 0.30 
CD4+PD-1+ 0.17 0.11 0.23 0.19 0.17 0.29 0.11 0.06 0.13 
CD8+PD-1+ 0.75 0.38 0.96 0.57 0.26 0.97 0.40 0.30 0.58 
 CD4+TIM-3+ CD8+TIM-3+ CD4+PD-1+ CD8+PD-1+ 
Pre vs. 2wks 0.4316 0.0195 0.3750 0.5566 
Pre vs. 3M 0.4375 0.4325 0.0625 0.0625 
2wks vs. 3M 1.000 0.8438 0.0625 0.4375 
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PD-1 Ligands Are Expressed in TGCT Tissue 
A high proportion of tumour infiltrating CD4 and CD8 T cells express PD-1. Ligation of 
PD-1 by its ligands, PD-L1 or PD-L2, attenuates T cell function and induces cell cycle arrest 
(Bennett et al., 2003, Chemnitz et al., 2004, Latchman et al., 2001, Sharpe et al., 2007). Since 
we detect the expression of PD-1 on tumour infiltrating T cells, we investigated the 
expression of these corresponding ligands in a variety of primary TGCT tissues.  
The level of PD-1 ligand transcripts was determined in fresh TGCT specimens and healthy 
testis following orchidectomy, using qRT-PCR analysis. Expression levels in tumour tissue 
were compared to healthy testis tissue and were normalised to GAPDH, using the 2-ΔΔCt 
method. PD-L1 transcripts were found in all TGCTs examined, and were found at levels 
up to 2.5-fold higher than those in healthy testis (Figure 25a). In addition, all TGCT 
samples examined in this study exhibited increased PD-L2 expression when compared to 
normal testis (Figure 25b). The highest expression of both PD-1 ligands was generally 
found in seminoma tissues.  
 
Next, we determined the expression and abundance of the PD-1 ligand, PD-L2, in TGCTs 
by Western blot and densitometry, respectively (Figure 26). Western blot analysis revealed 
protein expression in normal healthy testis and TGCT tissue. In all cases, protein 
expression was greater in TGCT tissue than in healthy testis. Transcript levels correlate 
well with protein abundance in seminoma and mGCT, but correlation was less clear in 
NSGCTT samples. Here, we demonstrate for the first time that TGCTs express PD-1 
ligands, which may have a detrimental effect on anti-tumour T cell responses, thus 
contributing to tumour evasion mechanisms. 
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Figure 25. Expression of PD-1 ligands in primary TGCT tissue. 
The mRNA levels of PD-L1 (a), and PD-L2 (b) were determined by qRT-PCR. Each bars 
represent relative expression levels of individual patients.  “TESTIS”  represents the mean 
expression level in normal testis tissue of 3 patients. Expression is relative to testis and 
normalised to GAPDH. Each bar represents an individual patient. 
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Figure 26. Expression of PD-L2 protein in primary TGCT tissue. 
Western blot analysis was used for the detection of PD-L2 protein expression in TGCT 
tissue (a). GAPDH was used as a loading control and to determine relative protein 
abundance between patients. Relative abundance of PD-L2 was calculated by 
densitometry, relative to testis, and normalised to GAPDH (b). Each bar represents an 
individual patient.  
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Tumour Infiltrating NK Cells Are Predominantly CD56hiCD16- NK Cells 
We have demonstrated that T cells infiltrating TGCTs are antigen experienced, activated 
and are potentially capable of cytotoxic function under the appropriate stimulation. Since 
MHC expression on TGCTs may be low or absent (Hadrup et al., 2006), NK cells may play 
an important role in the recognition and subsequent cytolysis of tumour cells.  
 
Expression of CD56 and CD16 define two subsets of NK cells found in peripheral blood: 
CD56lowCD16+ and CD56hiCD16-. We have used flow cytometry to identify both NK cell 
subsets in PBMC and TIL (Figure 27). In the cohort of patients used in this study, we 
identify approximately 6.7 (IQR: 3.43-7.76) T cells for every NK cell in PBMC, compared to 
60.1 (IQR: 23.01-109.4) T cells for every NK cell in TIL (Figure 28a). This difference in T cell 
to NK cell ratio in PBMC and TIL is highly significant (p=0.0078). Moreover, the 
CD56lowCD16+ subset dominate in PBMC (95.43%, IQR: 88.93-97.26%), yet only a minority 
of this subtype are observed in TIL (36.78% IQR: 27.92-47.35%) (p=0.0078), therefore the 
NK cells infiltrating TGCTs are predominantly CD56hiCD16- (Figure 28b). Even though NK 
cells comprise only a small proportion of infiltrating lymphocytes, their ability to 
recognise and respond effectively to tumour cells makes them an important cell type 
within TGCTs. 
 
Next, we determined whether the increased proportions of CD56hiCD16- NK cells in TIL 
was also evident in the periphery. We determined the proportion of each NK cell subset in 
peripheral blood of TGCT patients and healthy controls. There was no difference in the 
proportion of peripheral blood NK cell subsets between TGCT patients and healthy 
controls (Figure 28c). 
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Figure 27. Gating strategy for identification of NK cell subsets. 
Doublets were excluded (a) and FSC-A and SSC-A properties were used to set the 
lymphocyte gate (b) Only live cells (PI negative) which lacked expression of CD3 were 
analysed (c). Expression of CD56 and CD16 define two subsets of NK cells in PBMC and 
TIL (d); CD56lowCD16+ (blue), CD56hiCD16- (red). 
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Figure 28. Comparison of NK cell subsets in PBMC and TIL. 
Comparison of the proportions of NK and CD3+T cells in PBMC and TIL expressed as the 
T cell:NK cell ratio (a). The proportion of CD56lowCD16+ and CD56hiCD16- NK cells in 
PBMC and TIL were compared and represented as a percentage of total NK cells (b). The 
proportion of CD56lowCD16+ and CD56hiCD16- NK cells in healthy donors and TGCT 
patients represented as a percentage of total NK cells (c). Each symbol represents an 
individual patient. Horizontal lines represent median. Horizontal line represents the 
median. Data analysed by Wilcoxon matched-pairs signed-rank test (a,b) or Mann-
Whitney test (c).  ** denotes p<0.01. 
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NKG2D is Downregulated on Tumour Infiltrating NK Cells 
NKG2D is an activating cell surface receptor which can mediate NK cell cytotoxicity 
against tumour cells which express its corresponding ligand(s). Tumour induced down-
regulation of NKG2D on NK cells has been shown to aid tumour immune evasion 
(Wiemann et al., 2005). Accordingly, we determined the density of NKG2D expression on 
the surface of NK cells, and compared this to peripheral blood NK cells. MFI was used to 
determine the density of NKG2D molecules on the surface of cells. 
 
NKG2D cell surface density was markedly reduced on the CD56lowCD16+ NK subset in TIL 
(MFI 832 IQR: 595-1239), compared to PBMC (MFI 2004 IQR: 1251-2196) (p=0.0313). The 
downregulation of NKG2D was even more pronounced in the CD56hiCD16- subset of TIL 
(MFI 779 IQR: 547-1077), compared to PBMC (MFI 2867 IQR: 2123-3247) (p=0.0022). There 
was no difference in NKG2D expression between either NK subset in TIL (Figure 29a,b), 
suggesting downregulation of NKG2D in both NK subsets to similarly low levels. 
 
We show a greater level of expression of NKG2D on CD56hiCD16- NK cells in PBMC from 
both TGCT patients and healthy donors (p=0.0313) (Figure 29c). This suggests NKG2D 
expression is universally higher on peripheral blood derived CD56hiCD16- NK cells, and is 
therefore not likely to be a direct consequence of testicular tumour development.  
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We analysed the proportions of both NK cell subsets in peripheral blood of TGCT patients 
before chemotherapy, 2wks and 3 months post treatment. There was no statistical 
difference in the proportion of either NK cell subset between these time points (Figure 
30a), suggesting neither the loss of tumour antigens nor chemotherapy alter NK cell subset 
ratios.  
 
Furthermore, we determined NKG2D expression on NK cells at the same intervals pre and 
post chemotherapy. Interestingly, we detected a stepwise increase in NKG2D expression 
on CD56hiCD16- NK cells, which was statistically significant between pre and 3 months 
post chemotherapy (p=0.0313) (Figure 30b). This may indicate that NK cells within the 
tumour, which have significantly reduced NKG2D expression, may re-enter circulation 
during tumour development subsequently lowering NKG2D MFI. Following tumour 
removal, these cells are not subjected to NKG2D downregulation, leading to a gradual 
increase of NKG2D density on NK cells over time. 
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Figure 29. NKG2D expression on NK cell subsets from PBMC and TIL. 
Differential expression of NKG2D is shown for both NK subsets (a). Comparison of 
NKG2D MFI on CD56lowCD16+ and CD56hiCD16- cells within PBMC and TIL is shown (b). 
Comparison between NKG2D MFI on CD56lowCD16+ and CD56hiCD16- NK cells in healthy 
donors and TGCT patients (c). Box represents 25th and 75th percentile, line represents 
median, and whiskers represent 10-90 percentile. Data analysed by Wilcoxon matched-
pairs signed-rank test (b) or Mann-Whitney test (c). *denotes p<0.05, ** denotes p<0.01. 
 
 
 
 
a
CO
UN
T
NKG2D
CD56hiCD16- CD56lowCD16+
0
1000
2000
3000
4000 *
PBMC TIL
**
*
CD56lowCD16+
CD56hiCD16-
NK
G2
D 
M
FI
b
PBMC
TIL
Healthy
CD56lowCD16+ CD56hiCD16-
0
500
1000
1500
2000
2500
3000 *
NK
G2
D 
M
FI
Healthy TGCT
CD56lowCD16+ CD56hiCD16-
0
500
1000
1500
2000
2500 **
NK
G2
D 
M
FI
TGCTc
0
1000
2000
3000
4000 *
PBMC TIL
**
*
CD56lowCD16+
CD56hiCD16-
NK
G2
D 
M
FI
130 
 
 
 
 
Figure 30. Changes in the proportion of NK cell subsets and NKG2D expression 
following chemotherapy. 
The proportion of CD56lowCD16+ and CD56hiCD16- NK cells at pre, 2wks and 3M post 
chemotherapy (a). Each symbol represents an individual patient. Horizontal lines 
represent median. Comparison of NKG2D MFI on CD56lowCD16+ and CD56hiCD16- NK 
cells at pre, 2wks and 3M post chemotherapy is shown (b). Box represents 25th and 75th 
percentile, line represents median, and whiskers represent 10-90 percentile. Data analysed 
by Wilcoxon matched-pairs signed-rank test, *denotes p<0.05. 
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Tumour Infiltrating NK Cells are Functional 
Next, we examined the functionality of NK cells isolated from TGCTs using an in vitro co-
culture method with an MHC-deficient tumour cell line (K562), and measured cytokine 
production and cytotoxic capacity (degranulation). Degranulation was determined by the 
mobilisation of CD107a to the surface of NK cells, as assessed by flow cytometry. 
Noticeably, CD56 expression on the CD16+ subset of NK cells was increased following 
tumour cell co-culture presumably due to in vitro culture conditions. 
 
IFNγ and TNFα production was detected only in the CD56hiCD16- subset of NK cells 
(Figure 31a). Both NK subsets degranulated in response to K562 co-culture (Figure 31b). T 
cells were used as a negative control and as expected, did not secrete cytokine (data not 
shown) or degranulate in response to K562 co-culture (Figure 31c). Unexpectedly, the 
proportion of NK cells which mobilise CD107a upon stimulation was significantly higher 
in the CD56hiCD16- (61.60% IQR: 48.38-64.44%) subset than in the CD56lowCD16+ (20.78% 
IQR: 17.03-25.62) subset (p=0.0079) (Figure 32a). Generally, peripheral blood derived 
CD56lowCD16+ NK cells are naturally cytotoxic, whereas the CD56hiCD16- subset has low 
natural cytotoxicity, the opposite to what we observe in NK cells isolated from TGCTs. 
 
In a smaller cohort of patients (n=3), we determined whether the difference in cytotoxic 
potential of both NK cell subsets was consistent at different Effector:Target ratios (Figure 
32b). At all NK:K562 ratios examined the CD56hiCD16- subset had increased expression of 
CD107a in comparison to its CD16+ counterpart. Degranulation was greatest at an E:T ratio 
of 1:5 for both NK subsets. Two-way ANOVA statistical analysis revealed that NK cell 
phenotype accounts for 48.66% of total variance (p<0.0001) and E:T ratio accounts for 
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26.81% of total variance (p=0.0032). A Bonferroni post hoc analysis indicated that 
differences were significantly different for ratios of 1:1, 1:5, and 1:10. Although statistical 
significance was not reached for ratios of 5:1 and 10:1, there was a clear trend towards 
greater cytotoxicity in the CD56hiCD16- subset. This data suggests that NK cells within 
TGCT lesions have the potential to lyse tumour cells under the appropriate stimulus, and 
the CD56hiCD16- subset shows the greatest cytotoxic potential. 
 
The co-culture method used involved resting NK cells in media supplemented with IL-2. 
High dose IL-2 induces lymphokine-activated killer (LAK) activity in NK cells enabling 
them to effectively kill Daudi cells, which are otherwise resistant to NK cell lytic activity. 
The generation of LAK cells has been demonstrated in vitro, but their development in vivo 
is highly speculative. To confirm cytotoxicity was specifically induced by the NK cell 
subsets described and not due to the development of LAK cells, we co-cultured rested NK 
cells with the Daudi cell line at a ratio of 1:1, and assessed the extent of degranulation.  
 
All tumour infiltrating NK cells had greatly diminished cytotoxic responses towards the 
Daudi cell line compared to the K562 cell line (Figure 33). CD107a upregulation was 
virtually absent on the CD56lowCD16+ subset following stimulation with Daudi cells (mean 
1.63%; SEM 1.21). Surface expression was marginally higher on the CD56hiCD16- subset 
following Daudi cell co-culture (mean 6.68%; SEM 2.25). Nevertheless, the difference in 
expression of CD107a between the Daudi and K562 cell lines was highly significant for the 
CD56lowCD16+ (p=0.0052) and the CD56hiCD16- (p=0.001) subset. In conclusion, NK cells do 
not degranulate in response to Daudi cell stimulation, suggesting tumour infiltrating NK 
cells do not acquire LAK activity following short term culture or within the tumour. 
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Figure 31. Gating strategy and representative flow cytometric analysis for functional 
studies of tumour infiltrating NK cells. 
Production  of  IFNγ  and  TNFα  by  tumour  infiltrating  NK  cell  subsets  following  K562  co-
culture is shown (a). CD56hiCD16- (purple) and CD56lowCD16+ (blue) NK cells were gated 
and analysed for their expression of CD107a without stimulation (unstimulated), and 
following co-culture with either K562 or Daudi cell lines (b). Representative histograms are 
shown. T cells (green) were also analysed for CD107a expression without stimulation, and 
following co-culture with K562 and Daudi cell lines (c).  
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Figure 32. Functional analysis of tumour infiltrating NK cells. 
NK cells were co-cultured with K562 tumour cell line at a ratio of 1:1. The expression of 
CD107a on each NK subset was determined and expressed as a proportion of total NK 
cells within that subset (a). Box represents 25th and 75th percentile, line represents median, 
and whiskers represent 10-90 percentile. Data analysed by Mann-Whitney, **denotes 
p<0.01. The expression of CD107a on CD16+ (open bars) and CD16- (filled bars) NK subsets 
at E:T ratios of 10:1, 5:1, 1:1, 1:5 and 1:10 is shown (b). Bars represent median, error bars 
indicate upper quartile. Data analysed by a two-way ANOVA with Bonferroni post-test,  
*denotes p<0.05. 
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Figure 33. Degranulation of tumour infiltrating NK cell subsets against an NK-resistant 
tumour cell line. 
The ability of both NK cell subsets to degranulate in response to an NK sensitive tumour 
cell line was determined. NK cells were co-cultured with K562 (filled bar) and Daudi 
(open bar) tumour cell line at a ratio of 1:1. The expression of CD107a on each NK subset 
was determined and expressed as a proportion of total NK cells within that subset. Bars 
represent mean, error bars indicate SEM. Data analysed by paired t test, having passed 
D’Agostino & Pearson omnibus normality test. **denotes p<0.01 *** denotes p<0.001. 
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TGCTs Express NKG2D-Activating Ligands  
NK cells express many different cell surface receptors that deliver either activating or 
inhibitory signals. It is the relative balance of these signals that regulates NK cell activity. 
If activating stimulation exceeds that of inhibitory, NK cells respond by producing 
inflammatory cytokines and releasing cytolytic granzymes. Engagement of NKG2D by 
tumour-expressing ligands can trigger NK cell cytolytic activity. A number of NKG2D 
ligands (MICA, ULBP1, 2, and 3) were determined in TGCT tissue by qRT-PCR (Figure 
34). Transcript levels of all ligands were compared directly to healthy testis. MICA 
transcripts were found in all TGCTs examined, but were present at less than half the level 
found in healthy testis. Expression of ULBP1 and 3 was virtually absent in TGCT tissue, 
regardless of tumour type, whereas ULBP2 transcripts were detectable in TGCTs at levels 
lower than healthy testis. Protein expression of MICA and ULBP2 was confirmed in all 
TGCT samples using Western blot analysis (Figure 35a). Densitometry revealed MICA 
protein was present in TGCT tissue at levels comparable to healthy testis (Figure 35b). 
ULBP2 protein expression was greater in TGCT tissue than in healthy testis, in a 
proportion of tumour samples. Expression levels of ULBP2 were independent of tumour 
type (Figure 35c). This data reveals the expression of NKG2D ligands in TGCT tissue 
which may contribute to NK cell activation and subsequent tumour cell lysis.  
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Figure 34. Expression of NKG2D activating ligands in primary TGCT tissue. 
The mRNA levels of MICA (a), ULBP1 (b), ULBP2 (c) and ULBP3 (d) is shown. Black bars 
represent relative expression levels of individual patients and grey bars represent the 
mean expression level in normal testis tissue of 3 patients. Expression is relative to testis 
and normalised to GAPDH. 
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Figure 35. Protein expression of NKG2D ligands, MICA and ULBP2, in primary TGCT 
tissue. 
Western blot analysis of MICA and ULBP-2 to determine protein expression in TGCT 
tissue (a). GAPDH was used as a loading control and to determine relative protein 
abundance between patients. Relative protein abundance was calculated by densitometry, 
relative to testis, and normalised to GAPDH. Each filled bar represents an individual 
patient. 
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Expression of NK Cell-Associated Markers on Tumour Infiltrating CD4 and CD8 T 
Cells 
T cells are the predominant lymphocyte subset infiltrating TGCT lesions. However, 
cytotoxic NK cells are also present but at lower frequencies. It has been shown previously 
that the expression of NK-associated markers may regulate T cell effector function in 
cancer patients (Speiser et al., 1999), thus we investigated the expression of the NK cell 
markers, CD161 and CD56, on tumour infiltrating T cells. The proportion of T cells which 
express NK cell-associated markers in TIL was compared to those in autologous PBMC, 
using flow cytometry. Figure 36 represents the gating strategy used for the numeration of 
each T cell subset. Table 24 summarises the expression levels of each NK marker on T cell 
subsets, with corresponding statistical significance.  
 
CD4+CD161+ T Cells are elevated in TGCT Tissue 
CD161 expressing CD4 and CD8 T cells are a minor population of cells found in peripheral 
blood, which are described as containing all IL-17 producing cells. In the context of CD8 T 
cells, CD161 expression is correlated with diminished proliferative and cytotoxic capacity 
(Takahashi et al., 2006). We show the proportion of CD161+CD8 T cells was significantly 
lower in TIL (1.29 IQR: 0.44-3.46) compared to autologous PBMC (5.51 IQR: 2.49-12.89) 
(p=0.0059). Conversely, the proportion of CD161+CD4 T cells was significantly higher in 
TIL compared to matched PBMC (p=0.0039) (Figure 37a). Interestingly, the proportion of 
CD161+CD4 T cells in peripheral blood decreases over time to a significantly lower 
proportion at 3 months post chemotherapy (8.71 IQR: 6.38-10.09), compared to pre- 
treatment (12.11 IQR: 10.24-14.02) (p=0.0313) (Figure 37b).  
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CD8+CD56+ T Cells are rarely found in TGCT Tissue 
CD56+ T cells have been described as a subset which demonstrates enhanced MHC-
unrestricted cytotoxicity (Kelly-Rogers et al., 2006). Consequently we examined the 
presence of these cells within TGCT tissue. We determined the frequency of CD56+CD8 T 
cells in TIL and peripheral blood, and found this subset was at significantly lower levels in 
TIL compared to autologous PBMC (p=0.0059) (Figure 37c). It has been suggested that CD8 
T cell effector function correlates with CD56 surface expression, whereby greater CD56 
expression relates to increased cytokine production and cytotoxic capacity (Ohkawa et al., 
2001).  
 
NKG2D Is Downregulated on CD8 T Cells Infiltrating TGCTs 
We have previously shown a reduction of NKG2D surface expression on tumour 
infiltrating NK cells, hence we determined the proportion of CD8 NKG2D+ T cells in TIL 
and peripheral blood (Figure 38a). We found a significant reduction in the proportion of 
CD8 T cells expressing NKG2D in TIL, compared to PBMC (Figure 38b). This suggests 
NKG2D is globally down-regulated by the tumour microenvironment, and is not specific 
to NK cells alone. 
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Figure 36. Gating strategy for NK-associated markers on T cells. 
Cells were first gated to remove doublet cells before gating on lymphocytes based on FSC-
A and SSC-A properties. Dead cells were subsequently removed by gating on propidium 
iodide (PI) negative cells along with CD3. CD4 (green) and CD8 (red) T cells were 
subsequently gated from the CD3+PI- population (a). Representative histograms show 
expression of CD161 (b) on CD4 and CD8 T cells, and CD56 (c) expression on CD8 T cells.  
 
b
c
CD161
CO
UN
T
CD56
CD
8
CD4
PI
CD3
FS
C-
H
FSC-A
SS
C-
A
FSC-A
a
CO
UN
T
CD8+ T cells
CD8+ T cells
CD4+ T cells
142 
 
 
 
Figure 37.  Identification of tumour infiltrating T cell subsets expressing NK-associated 
markers. 
CD161 expression was determined on CD4 and CD8 T cells from PBMC and TIL (a).  
Comparison of CD161 expression on CD4 T cells at pre, 2wks and 3M post chemotherapy 
is shown (b). Each symbol represents an individual patient. Horizontal line represents the 
median. Data analysed by Wilcoxon matched-pairs signed-rank test. * denotes p<0.05,  
** denotes p<0.01. Expression of CD56 on CD8 T cells was determined and represented as 
a proportion of total CD8 T cells (c). Bars represent median. Error bars represent the upper 
quartile. Data analysed by Wilcoxon matched-pairs signed-rank test. ** denotes p<0.01.  
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Figure 38. Expression of NKG2D on CD8 T cells from PBMC and TIL. 
Representative histogram showing NKG2D expression on CD8 T cells in PBMC and TIL 
(a). Expression of NKG2D on CD8 T cells is significantly reduced in TIL compared to 
PBMC (b). Bars represent median. Error bars indicate upper quartile. Data analysed by 
Wilcoxon matched-pairs signed-rank test, *denotes p<0.05. 
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Table 24. Identification of tumour infiltrating T cell subsets expressing NK-associated 
markers.  
   PBMC  TIL 
p  Median 25th 75th  Median 25th 75th 
CD4+CD161+  
     (n=10) 
8.61 3.32 12.86  22.07 15.74 29.79 0.0039 
CD8+CD161+  
     (n=10) 
5.51 2.49 12.89  1.29 0.44 3.46 0.0059 
CD8+CD56+ 
     (n=9) 
5.92 1.13 7.07 
 
0.68 0.49 1.48 0.0059 
CD8+NKG2D+ 
      (n=6) 
82.83 80.67 85.23 
 
31.96 19.51 42.96 0.0313 
Data expressed as median (bold) with 25th and 75th quartile. Significant differences are 
highlighted in bold italic type.  
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          Table 25. Summary of differences observed between T cells isolated from       
          peripheral blood and TIL 
Description/Characteristic Difference in TIL compared to PBMC($) 
CD4:CD8 ratio Ð 
 
T cell memory phenotype  
      Naive Ð 
      TEM Ï 
 
Activation markers 
 
      CD69 expression  Ï 
      CD38 density  Ï 
 
TCR diversity 
 
Ð 
 
Degranulation potential of T cells in vitro 

Ï 
 
Negative regulatory molecule expression 
 
      TIM-3 Ï 
      PD-1 Ï 
         ($) Arrows represent properties that are increased or decreased in TIL compared  
             to PBMC. 
 
            Table 26. Summary of differences observed between NK cells and NK-like  
            cells isolated from peripheral blood and TIL 
Description/Characteristic Difference in TIL compared to PBMC($) 
T:NK cell ratio Ï 
  
Proportion of NK cell subset  
      CD56hiCD16- Ï 
      CD56lowCD16+ Ð 
NKG2D expression 
      NK cells Ð
      CD8 T cells Ð
Proportion of CD161 expressing cells  
      CD4 T cells Ï
      CD8 T cells Ð
 
Proportion of CD8+CD56+ T cells Ð
                  ($) Arrows represent properties that are increased or decreased in TIL compared 
              to PBMC. 
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Discussion 
This chapter described the phenotype and function of lymphocytes that infiltrate TGCTs. 
The differences in phenotype and cell proportions of T cells (Table 25) and NK cells (Table 
26) observed between PBMC and TIL are summarised. In addition, changes in circulating 
lymphocytes were monitored following tumour removal and the onset of chemotherapy.  
 
Phenotype and frequency of peripheral and tumour infiltrating lymphocytes in TGCT 
patients 
Although large frequencies of lymphocytic infiltrates are found in many TGCTs, 
spontaneous regression is extremely rare (Balzer and Ulbright, 2006, Sarid et al., 2002), 
suggesting tumour immune escape mechanisms are at play. The phenotype and function 
of immune infiltrates have been examined in multiple tumour types. However, the 
significance of this infiltrate has been subject to conflicting reports. Tumour-infiltrating T 
cells have demonstrated effective anti-tumour activity in some malignancies (Clark et al., 
1989, Clemente et al., 1996, Pages et al., 2010) but support tumour growth and development 
in others (Curiel et al., 2004). In the majority of cases, the presence and proportion of 
cytotoxic vs. regulatory cell subsets has been correlated with disease progression and 
prognosis (Chin et al., 1992, Shah et al., 2011, Wakabayashi et al., 2003).    
 
Studies using IHC techniques have identified T cells, B cells and macrophages 
surrounding TGCT tissue (Torres et al., 1997, Grobholz et al., 2000). One such study 
showed increased numbers of T cells and macrophages per unit area in seminoma 
compared to NSGCTTs. Interestingly, in this study the frequency of B cells was the same. 
Another study using IHC revealed equal proportions of CD4 T cells, CD8 T cells, and B 
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cells within seminoma lesions (Bols et al., 2000). Conversely, CD4:CD8 T cell ratios greater 
than one were reported in some seminoma lesions, suggesting CD4 T cells were the 
dominant T cell subset (Grobholz et al., 2000). In the present study, we show a 
predominance of αβ  T  cells  within TGCTs. In agreement with (Bols et al., 2000), we found 
near equal proportions of CD4 and CD8 T cells within these tumour lesions. This suggests 
both T cell subsets are migrating into TGCT lesions with similar efficiency.  
 
Naive T cells circulate the peripheral blood and lymphatics, and enter secondary 
lymphoid organs where they are antigen-primed and clonally expand before entering 
inflamed tissue (Mackay, 1993). We hypothesise that priming of tumour-specific T cells in 
TGCT patients occurs in tumour draining lymph nodes where T cells subsequently expand 
and infiltrate the tumour at similar frequencies. Alternatively, T cells may enter the 
tumour at the CD4:CD8 T cell ratio found in peripheral blood (approximately 2:1), but 
once inside the tumour mass CD8 T cells preferentially activate in response to cognate 
antigen and proliferate in situ, thereby lowering CD4:CD8 towards a 1:1 ratio. If TGCT 
cells express MHC class I, or expression is induced on tumour cells by the inflammatory 
environment, it would allow presentation of antigen directly to CD8 T cells at the tumour 
site. Conversely, most tumours lack MHC class II expression and therefore CD4 T cells 
cannot be activated through these TCR dependant mechanisms within the tumour without 
the presence of APCs. In turn, this may allow greater CD8 T cell activation and subsequent 
inflation of the CD8 T cell pool in TGCT tissue. It would be interesting to consider the 
possibility that CD8 T cells are able to directly target tumour cells that express MHC class 
I, and that CD4 T cells are present to help the cytotoxic response, and aid the development 
of long-lived memory cells (Bevan, 2004).  
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If tumour infiltrating T cells have limited specificity i.e. are tumour antigen restricted, it is 
likely that the  TCRVβ  repertoire  observed would be less diverse than that of peripheral 
blood, and the subsequent enrichment of specific Vβ  chains  may be observed. Examination 
of   the  TCRVβ  repertoire  of  T  cells  by   flow  cytometry,   revealed an enrichment of certain 
TCRVβ  in  all  TGCTs  examined,  irrespective of tumour type, confirming a restriction of the 
repertoire. Importantly, this was not confined  to  a  single  TCRVβ  family  suggesting  there  is  
no single dominant epitope responsible for the lymphocytic infiltrate, but instead suggests 
the generation of oligoclonal T cell populations which are specific to multiple tumour 
antigens. In support of this, a previous study demonstrated that most seminomatous 
tumours comprise numerous clonally expanded T cells (Hadrup et al., 2006). An additional 
study revealed a polyclonal population of T cells (Grobholz et al., 2000), again indicative of 
multiple T cell populations specific to numerous tumour targets. We did observe, 
however, an increase in Vβ13.1 in all patients examined suggesting tumours may share the 
expression of certain antigens that provoke a response through this family. Further 
analysis including deep sequencing of the CDR3 region of these Vβ13.1 T cells is required 
to determine whether the specificity of these cells in the same between patients. 
 
Overall, our data suggests clonally expanded T cells are present within tumour lesions as a 
result of either a) recognition of cognate antigen presented directly by the tumour or by 
APCs co-inhabiting tumour lesions, or b) preferential migration of these cells into the 
tumour following expansion in secondary lymphoid organs. A recent publication 
describes the selective recruitment of naive T cells into the tumour mass, where 
subsequent activation and effector differentiation of CD8 T cells occurs (Thompson et al., 
2010). In this paper, they demonstrated antigen presentation directly by the tumour or 
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through cross-presentation by APCs to initiate CD8 T cell activation. This would support 
the notion of clonal expansion within the tumour. The methods used in our study did not 
allow location of T cell expansion to be determined, nor did it allow the discrimination of 
CD4 and CD8 T cells. Our experimental setup compared the  TCRVβ  repertoire  of  TIL  with 
autologous PBMC, and as a result may underestimate the degree of oligoclonality as 
tumour-specific T cells may enter circulation,   thereby  increasing  the  same  TCRVβ  subset  
in peripheral blood. We speculate that an abundance of tumour-specific T cells with 
multiple antigen specificities reside within TGCT lesions. The location of activation and 
clonal expansion of these T cells remains unclear. 
 
Antigen experienced T cells downregulate CD45RA expression, and upregulate CD45RO 
expression, and subsequently differentiate into central or effector memory T 
cells. Differentiation between central and effector memory populations and naive and 
effector populations is achieved by the addition of the chemokine receptor CCR7, or the 
costimulatory molecule, CD28. Loss of CCR7 expression allows the migration of T cells 
from secondary lymphoid tissue to inflamed peripheral tissues i.e. to the tumour site. To 
determine whether TIL was categorically antigen-experienced we examined the expression 
of CCR7 and CD45RA on tumour infiltrating T cells. The majority of T cells found within 
TGCT lesions had lost expression of both CCR7 and CD45RA. This was observed in both 
the CD4 and CD8 T cell compartments, whereby up to 90% of cells were negative for both 
molecules, indicative of TEM cells. This suggests the majority of T cells within TGCT lesions 
have experienced cognate antigen. In comparison, PBMC from TGCT patients had a much 
lower proportion of TEM cells than that observed in TIL; the majority of peripheral blood T 
cells were naive. In agreement with our findings, a previous study demonstrated the 
150 
 
expression of CD45RO on the majority of tumour infiltrating T cells in TGCT patients 
(Grobholz et al., 2000). Another study looked at the expression of both CD45RO and CD28 
to define memory phenotypes, and observed an expression profile indicative of TEM cells 
(Hadrup et al., 2006). The increased effector memory T cell pool we and others have 
observed in TIL of TGCT patients is not a unique feature to this tumour type, and has been 
used as a prognostic factor in a wide range of tumours (Rauser et al., 2010, Koulis et al., 
1997, Attig et al., 2009). In this context, elevated proportions of antigen experienced T cells 
generally indicate improved prognosis.  
 
Furthermore, we observed a striking increase in the proportion of peripheral blood TEM 
cells in TGCT patients compared to gender and age matched healthy individuals. This 
increase in TEM cells was directly reciprocated with a statistically significant decrease in the 
proportion of naive T cells. We speculate that the rise in TEM cells in peripheral blood 
during active disease can occur by one of two mechanisms. Firstly, tumour infiltrating T 
cells, presumably tumour-specific, re-enter the systemic circulation from the tumour by an 
unknown mechanism. Secondly, and more likely, APCs such as DCs residing in tumour 
lesions sample the environment and become activated following tumour antigen uptake. 
Following maturation, DCs migrate into tumour draining lymph nodes, where they 
present processed tumour antigens to T cells. Recently activated tumour-specific T cells 
could potentially enter peripheral blood before migrating into tumour tissue, thereby 
elevating the frequency of TEM cells in PBMC.  
 
To substantiate our claim of tumour-specific T cells entering systemic circulation, we 
monitored the proportion of memory subsets over time following tumour removal. 
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Longitudinal analysis demonstrated a reduction in the peripheral blood TEM cell pool 
following the removal of tumour burden, in agreement with the kinetics of a cell-mediated 
immune response. Based on the short life-span of TEM cells in the absence of cognate 
antigen, we hypothesise that removal of the tumour restricts the supply of antigen, 
resulting in the death of the majority of antigen-specific cells. We assume long-lived 
tumour-specific T cells are generated following the primary immune response, which 
reside within the effector and central memory pools, to enable a rapid secondary response 
following subsequent antigen encounter. Unfortunately, blood samples prior to disease 
onset where unobtainable in this study so we were unable to determine the extent of 
change in the memory T cell pool during tumour development.  
 
Blood samples for longitudinal analysis were taken at time points that coincided with the 
onset of adjuvant chemotherapy. All patients within this cohort received the same 
adjuvant chemotherapy regimen (single dose carboplatin) and samples were acquired at 
the same time points pre- and post- chemotherapy. The mode of action of platinum-based 
chemotherapeutics is mediated by its interaction with DNA to form intrastrand DNA 
adducts (Siddik, 2003). It is not cell specific and can potentially mediate cytotoxic effects 
towards immune cells, which ultimately triggers apoptosis in cycling cells. Tumour-
specific T cells, predominantly TEM cells, are likely to be proliferating in response to 
tumour antigens, and as a result they could be more sensitive to the cytotoxic effects of 
carboplatin than naive T cells. This would also lead to diminishing levels of TEM cells 
following chemotherapy, increasing the proportion of the naive cell pool, as we have 
observed in this study. 
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Both chemotherapy and immune response kinetics may contribute to a reduction of TEM 
cells in peripheral blood over time. We cannot categorically determine the extent of which  
these two mechanisms are involved as we are unable to distinguish between the effects of 
chemotherapy and the reduction of tumour antigen load. Future work would ideally 
include in vitro studies to determine whether particular T cell subsets are more prone to 
the effects of chemotherapy drugs, and correlate this with full blood counts to determine 
the extent of T cell depletion in vivo. In addition, longitudinal analysis of T cell memory 
phenotype in patients with testicular cancer who did not receive chemotherapy 
(surveillance) would allow us to accurately determine the effect of reduced tumour 
antigen load alone.  
 
The TEM phenotype infiltrating TGCTs demonstrates they have previously encountered 
cognate antigen but gives no indication as to when this recognition event occurred. 
Moreover, the memory phenotype does not indicate the extent of tumour-specific versus 
“irrelevant”  bystander  T-cell recruitment into the tumour. To date, the activation status of 
TIL from TGCTs is unknown therefore we investigated this on freshly isolated tumour 
residing T cells. We examined the surface expression of CD69 and CD38, and found a 
substantial proportion of both CD4 and CD8 T cells expressing these molecules. CD69 is 
induced within an hour of activation and its expression is only transient (Demaria et al., 
1994). The rapid upregulation and transient nature of CD69 expression following 
activation suggests T cells are activated within the tumour, independent of locality of 
initial antigen encounter. T cell activation was confirmed using CD38, a marker which is 
upregulated on the surface of activated leukocytes (Malavasi et al., 2006).  
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CD69 is known to trigger proinflammatory responses by inducing T cell proliferation 
(Cebrian et al., 1988) and cytokine secretion (Santis et al., 1992) in CD8 T cells; directly 
contributing to the inflammatory response. However, the functional consequences of CD69 
expression on CD4 T cells is less clear. Recently, populations of CD69+ CD4 T cells with 
specific regulatory functions have been described. (Han et al., 2009) described a tumour-
induced   CD69+CD4+CD25−   T   cell   subset,   which   increased during tumour progression, 
and was capable of suppressing CD4 T cell proliferation by expression of surface-bound 
TGF-β.  Another  paper  described  the  ability  of  CD69+ T cells to induce the expression of 
IDO in tumour residing macrophages (Zhao et al., 2012). IDO inhibits the proliferation 
(Uyttenhove et al., 2003, Frumento et al., 2002) and cytotoxic capability (Gajewski et al., 
2006) of antigen-specific T cells, and enhances the suppressive activity of Tregs (Zou, 
2006). We speculate that activated CD4 T cells present within TGCT lesions, may contain 
populations of potentially regulatory cell subsets, contributing to tumour immune escape 
mechanisms, however, further investigation is needed to confirm this.  
 
Following removal of the tumour mass by radical orchidectomy, chemotherapy is given to 
reduce the high rates of relapse (20%) observed in testicular cancers, even in the absence of 
secondary metastasis. Interestingly, in this study we observe a significant increase in CD69 
expression on CD8 T cells shortly after chemotherapy in a number of TGCT patients. This 
suggests that a high frequency of residual tumour cells may be circulating in these 
patients, and that chemotherapy induces lysis of these residual tumour cells allowing the 
release of numerous tumour antigens. Released antigens could be captured, processed and 
cross-presented to CD8 T cells by DCs, leading CD8 T cell activation and hence 
upregulation of CD69. As the primary tumour has already been removed through surgery, 
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these activated T cells may then accumulate in the peripheral blood. It would be 
interesting to determine the specificity of these cells, as this may aid the development of 
immunotherapeutics to treat residual disease in instances where adjuvant chemotherapy is 
not appropriate, and minimise side effects of standard chemotherapy regimens. However, 
we should also consider the direct effects of chemotherapeutic drugs on T cell activation. 
The effect of platinum-based chemotherapy on the activation of T cells is unknown, 
however, one publication demonstrated that other types of chemotherapy drugs can 
induce atypical CD69 surface expression on peripheral blood T cells in the absence of 
costimulation (Morgan and Holguin, 2002).  
 
Functional analysis of peripheral and tumour infiltrating lymphocytes in TGCT patients 
Activation following stimulation through the TCR and costimulatory molecules, 
ultimately leads to clonal expansion, a requirement for effective immune responses. We 
found that T cells isolated directly from TGCTs did not proliferate in the presence of IL-2 
alone. However, stimulation of T cells through the TCR with appropriate costimulation 
resulted in multiple cell divisions over a 5 day period. Combined, these results suggest T 
cells are not clonally expanding within the tumour but regain proliferative capability 
when stimulated outside the tumour environment. We speculate that various regulatory 
mechanisms are at play, which suppress the proliferation of T cells, and induce a state of 
reversible anergy mediated directly by the tumour or its milieu. This temporary state has 
been described previously where T cell exhaustion was efficiently reversed with addition 
of exogenous IL-2 (Beverly et al., 1992). Reduced proliferative potential of T cells within the 
tumour could be mediated by the lack of costimulation. MHC class I expressing tumours 
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are able to present antigens, but the lack of costimulatory molecules on tumour cells 
promotes anergy and tolerance, thus exerting detrimental effects.  
 
With these in mind, we hypothesise that T cells proliferate within secondary lymphoid 
organs and subsequently migrate to the tumour, as opposed to proliferating in situ. 
Alternatively, chronic antigenic stimulation within the tumour may have generated a cell 
phenotype typically associated with exhaustion, whereby T cells are rendered 
proliferatively incompetent. Ki-67 is a nuclear protein associated with proliferation and is 
used as a marker to differentiate between clonally expanding cells and the resting 
population. During progression through the cell cycle, Ki-67 can be detected within the 
nucleus by intracellular staining techniques. In future studies, we would use this marker 
to assess the proliferation of T cells ex vivo.  
 
The absence of costimulation and/or high co-inhibition is sufficient to induce cell cycle 
arrest and inhibit cytokine production in antigen-specific T cells. In the inflammatory 
environment of the tumour we may expect high levels of proliferation. However, we have 
illustrated a potentially detrimental effect of the tumour microenvironment on T cell 
proliferation within the tumour mass. We therefore also investigated the ability of these 
cells to secrete inflammatory cytokines and undergo degranulation following in vitro 
stimulation. We show that ex vivo production  of  IFNγ  and  TNFα  is  practically  absent  in  T  
cells directly isolated from TGCTs. Activated cytotoxic CD8 T cells and CD4 Th1 cells 
should secrete these cytokines as part of the inflammatory response towards the tumour. 
This was not observed, further substantiating our claim that T cell effector function is 
actively inhibited by the tumour microenvironment, inducing T cell dysfunction. 
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Following stimulation by a TCR independent mechanism using PMA/Ionomycin, a high 
proportion of CD4 and CD8 T cells secrete both these cytokines, suggestive of defects in 
proximal signal transduction, in addition to inhibitory signalling. We postulate that 
cytokine production in response to TCR stimulation may be defective in tumour residing T 
cells. This stimulation method is universally used to determine the effector subtype of T 
cells. The   secretion   of   IFNγ   and  TNFα  by  CD4 T cells suggests a proportion of tumour 
infiltrating CD4 T cells are Th1 cells. Th1 effector cells stimulate an inflammatory response 
by recruiting APCs into the tumour mass, which would further increase tumour antigen 
presentation to infiltrating T cells. In addition, Th1 cells can aid a cytotoxic T cell response 
by stimulating dendritic cells to produce more costimulatory molecules. Furthermore, 
IFNγ  secretion increases the efficiency of antigen processing and presentation to cytotoxic 
CD8 T cells, and induces MHC class I expression on tumour cells. These qualities make 
Th1 cells an important cell type in the generation of an inflammatory response against the 
tumour. 
 
We show populations of CD4 Th1 cells and CD8 T cells within TGCTs, which could be 
explained by the increased migration of these particular cell subtypes to tumour tissue. 
CXCR3 is expressed primarily on activated cytotoxic CD8 T cells and CD4 Th1 cells, but 
not on Th2 cells (Qin et al., 1998, Loetscher et al., 1996). Importantly, it is also expressed on 
T cells infiltrating TGCTs (Schweyer et al., 2002). Its chemokine ligand, IP-10, is 
consistently expressed on seminoma-associated endothelial cells (Schweyer et al., 2002), 
enhancing the recruitment of lymph node-activated CD8 T cells and CD4 Th1 cells. It was 
also shown that IFNγ   is   produced   directly   by   the   tumour.   We   speculate   that   IFNγ  
produced by both the tumour and the functional T cell repertoire, could augment the 
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expression of IP-10, further contributing to the recruitment and polarization of effector T 
cells. This could also help explain the vast numbers of lymphocytes observed in seminoma 
compared to NSGCTTs. 
 
It is important to note that other CD4 T cell subsets could be present within TIL. This 
includes the Th2 subset which secretes IL-4, IL-5 and IL-13. These cytokines mediate a 
regulatory and anti-inflammatory effect on other immune cells, which may actively 
contribute to tumour immune evasion. In addition, Tregs, which are important in 
regulating an immune response, may be present in TGCTs. In the context of tumour 
immunology,  secretion  of  TGFβ  and  IL-10 by Tregs has been implicated in the inhibition of 
anti-tumour immune responses, thereby preventing tumour clearance. Increased 
frequencies of Tregs is associated with poor prognosis in many tumour types including 
breast and colorectal cancers (Dranoff, 2005). Future studies would establish the presence 
of Tregs in TGCTs, and would involve in vitro assays to determine their ability to inhibit 
antigen-specific T cell effector function, and to decipher the exact inhibitory mechanisms 
involved. 
 
Interestingly, we also observed an increase in the proportion of CD4+CD161+ T cells 
within TIL, compared to PBMC. All IL-17 secreting T cells are contained within this cell 
population (Cosmi et al., 2008), suggesting an elevated presence of Th17 cells within these 
tumours. Th17 cells also produce IFNγ  (Annunziato et al., 2007) and recruit granulocytes 
into inflamed tissues. We therefore speculate that Th17 cells contribute to the generation of 
an inflammatory environment within TGCT lesions. We also observe a decrease in the 
proportion of CD161+CD4 T cells in circulation following tumour removal, suggesting 
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these cells are increased in numbers during tumour development and fall to baseline levels 
upon tumour removal. Combined, it suggests these cells may play a potentially important 
role in tumour immunity and further studies are warranted to elucidate their function. 
 
Next, we investigated the cytotoxic potential of T cells isolated from the tumour, and 
compared it to T cells from autologous PBMC. We found that tumour residing CD8 T cells 
had a greater capacity to degranulate in response to in vitro stimulus compared to their 
peripheral blood counterparts. In agreement with our results, a previous publication 
showed that CD8 T cells expressed markers of cytotoxic potential, and were in direct 
contact with apoptotic TGCT cells (Yakirevich et al., 2002). Combined, this suggests 
tumour cell death in tumour lesions may be mediated by cytotoxic granule release by CD8 
T cells. Another study examined the cytotoxicity of tumour infiltrating CD8 T cells by 
examining ex vivo CD107a surface expression and in situ granzyme B expression (Hadrup 
et al., 2006). They reported increased frequencies of CD107a+ cells in TIL, as well as 
increased intracellular cytotoxic granzyme in tumour immune cells. We found cytolytic 
activity in PBMC was restricted to CD8 T cells; however we observed a surprisingly high 
percentage of CD4 T cells isolated from TGCT tissue that degranulated upon stimulation.  
 
Comparable results were reported in CD4 T cells isolated from renal cell carcinomas (Attig 
et al., 2009). Many articles describe the ability of CD4 T cells to direct cytotoxicity towards 
viral and bacterial antigens (Appay, 2004, van de Berg et al., 2008, Brown, 2010). A recent 
publication showed that antigen-specific CD4 T cells can exert significant MHC class II-
restricted cytotoxicity (Hildemann et al., 2013). This paper shows that mobilization of 
CD107a to the cell surface, and the ability to secrete cytotoxic granules was comparable in 
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magnitude to CD8 T cells. Others have shown CD4 T cell populations with increased 
levels of intracellular perforin (Appay et al., 2002) and cytotoxic granzymes (Zaunders et 
al., 2004). Although the majority of studies have focused predominantly on virus-specific 
cytotoxic CD4 T cells, it would be interesting to investigate whether CD4 T cells isolated 
from TGCT tissue could potentially contribute to the direct killing of tumour cells, should 
the tumour environment allow. The physiological relevance of this to TGCTs is not fully 
clear due to the low or absent MHC class II expression on TGCTs. Future studies would 
extend this work to analyse cytotoxic granule release and autologous tumour lysis by both 
CD4 and CD8 T cells isolated from TIL. In addition, the generation of tumour-specific 
cytotoxic CD4 T cell clones from tumour residing T cells may be an attractive approach in 
targeting tumour cells where MHC class II is induced or constitutively expressed. 
 
Regulation of T cell function in TGCTs 
Anti-tumour T cells may become compromised following entry into the tumour milieu. T 
cells require both TCR signalling and costimulation to mount an effective immune 
response.  However, if antigen-specific T cells were activated in lymphoid organs prior to 
tumour infiltration, there would be no requirement for costimulation within the tumour 
microenvironment for subsequent activation. Therefore, negative regulatory mechanisms, 
other than the availability of costimulatory molecules, may be regulating effector T cell 
function. Here we postulate various modes of regulation, which could suppress or restrict 
an efficient anti-tumour response.  
 
Previous studies have revealed the lack of Fas-L expression on TGCTs, which would 
potentially suppress a cytotoxic immune response on cells expressing its receptor, Fas 
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(Bols et al., 2000). Consequently, immune suppressive mechanisms in addition to Fas-L 
may be present. Here we examined the expression of the inhibitory receptors TIM-3 and 
PD-1 on tumour infiltrating T cells. To our knowledge, we are the first to describe the 
expression of these molecules on T cells infiltrating TGCTs. We show a significant 
proportion of T cells expressed one or both of these receptors. This was particularly 
apparent for cytotoxic CD8 T cells, where expression of both receptors was observed on a 
high proportion of cells.  
 
TIM-3 expression on   IFNγ-secreting CD4 Th1 cells has also been shown to regulate Th1 
immunity and tolerance in vivo (Hastings et al., 2009, Monney et al., 2002). Interaction of 
TIM-3 with its putative ligand galectin-9 (Gal-9) triggers apoptosis of TIM-3+ T cells. 
Recent studies have shown that TIM-3 is upregulated on exhausted CD8 T cells (Jones et 
al., 2008). TIM-3+ T cells are dysfunctional as they cannot produce cytokine or proliferate 
in response to stimuli. It is important to note that not all dysfunctional T cells express TIM-
3, nor are all dysfunctional T cells rescued by blockade of the TIM-3-galectin 9 interaction. 
Further studies have demonstrated that exhausted T cells are characterised by sustained 
expression of the PD-1 (Barber et al., 2006). In agreement with our observations, PD-1 
expression on tumour infiltrating T cells has been well documented in other solid tumours 
(Blank et al., 2006, Ahmadzadeh et al., 2009). Interference with PD-1 signalling restores 
functional T cell responses and improves clinical outcome in multiple tumour types 
(Zhang et al., 2009, Yamamoto et al., 2008), but this alone is not guaranteed to reverse T cell 
exhaustion (Blackburn et al., 2008). During a normal T cell response, recently activated T 
cells also upregulate surface PD-1 expression, therefore PD-1 may solely reflect an 
activated cell phenotype (Fourcade et al., 2009). Overall, the our data and previous 
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literature suggests both TIM-3 and PD-1 can function as negative regulators of T cell 
responses, and we speculate that signalling through both receptors may synergistically 
mediate T cell dysfunction in TGCTs. 
 
Co-expression of TIM-3 and PD-1 is strongly correlated with immune dysfunction in 
patients with cancer (Fourcade et al., 2010, Sakuishi et al., 2010). This has important 
consequences in our study, whereby TIL that co-express TIM-3 and PD-1 were often 
observed among CD8 TIL. In addition, CD8 T cells expressing TIM-3 and PD-1 have been 
shown to produce IL-10, further limiting the magnitude of CD4 (Said et al., 2010) and CD8 
(Jin et al., 2010) T cell responses. Simultaneous targeting of the both pathways may prove 
most effective in reversing T cell exhaustion. We speculate that T cells may acquire 
multiple inhibitory surface molecules during tumour progression, which effectively 
prevents efficient T cell activation.  
 
We have also demonstrated for the first time the expression of PD-1 ligands, PD-L1 and 
PD-L2, in a variety of TGCT tissues. Interaction with these ligands can lead to cell cycle 
arrest and apoptosis of T cells expressing PD-1. Unfortunately, our methodology did not 
allow us to distinguish the cell type(s) that express these ligands, and we envisage 
determining this in situ by IHC. Expression of PD-L1 has been demonstrated on mouse 
Sertoli cells of the testis as part of normal testicular immune privilege (Dal Secco et al., 
2008). If this is the case in human testis, we could be underestimating the level of PD-L1 
expression in tumour tissue as we normalised PD-L1 levels to healthy testis. Expression of 
PD-L1 by Sertoli cells could in fact inadvertently contribute to T cell dysfunction and 
ultimately aid tumour immune evasion. In all cases, PD-L1 expression was greater in 
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seminoma tissue than any other testicular tumour type. This could be due to higher 
expression levels of PD-L1 on seminoma cells than non-seminoma cells. Many tumours 
express PD-L1 on their surface including renal cell carcinoma (Thompson et al., 2006), 
oesophageal cancers (Ohigashi et al., 2005) and breast cancer (Ghebeh et al., 2006), where it 
is associated with suppression of T cell function and poor prognosis. Alternatively, 
elevated numbers of APCs within the microenvironment of seminoma lesions and 
increased frequencies of activated T cells, both of which express this ligand, would also 
explain the higher expression level of PD-L1 we observed in seminoma. The contribution 
of each PD-L1-expressing subset to induce T cell dysfunction is unclear but here we 
outline a number of ways in which the tumour microenvironment may be regulating T 
cells. 
 
We also demonstrated elevated expression of PD-L2 in all TGCTs examined. Generally, 
tumour cells express very low levels of PD-L2 or show focal expression (reviewed in 
(Rozali et al., 2012)). Interestingly, PD-L2 is expressed by tumour-associated fibroblasts 
(Nazareth et al., 2007), APCs (Latchman et al., 2001) and activated T cells (Messal et al., 
2011). Together, this suggests immune cells and stromal cells of the tumour may express 
PD-L2, rather than the tumour cells themselves. We speculate that PD-1 ligands are 
expressed by multiple cell types that are present within the testicular tumour mass. We 
would hypothesise that the immune infiltrate may contribute to its own demise whereby 
tumour antigen-induced activation of the immune system leads to expression of inhibitory 
molecules on APCs and their receptors on activated T cells. This process could be 
exaggerated in tumour masses, leading to T cell anergy and an exhausted T cell 
phenotype. 
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In addition to PD-1 ligands, APCs and T cells are known to express Gal-9, the ligand for 
TIM-3 (Zhu et al., 2005). Gal-9-induced TIM-3 signalling mediates T cell dysfunction in the 
cancer setting (Li et al., 2012). We show TIM-3 expression is restricted to activated 
cytotoxic CD8 T cells and CD4 Th1 cells, leading to inhibition of T cell subsets specifically 
involved in anti-tumour immunity. Expression analysis of Gal-9 by qRT-PCR would not 
discriminate between internal and surface expression of Gal-9. Only surface expression of 
Gal-9 is able to interact with TIM-3 and subsequently induce T cell dysfunction. In the 
future, Gal-9 expression would be determined by digestion of TGCT tissue and 
subsequent surface staining with an anti-Gal-9 antibody.  
 
The methodology used in this study does not allow a clear distinction of inhibitory ligand 
expression between tumour cell, immune cell and tumour stroma. Induction of T cell 
dysfunction through inhibitory receptors seems to be an important tumour immune 
escape mechanism in TGCT patients. Therefore, the expression of other inhibitory 
receptors, including Lag-3 and BTLA, would be investigated, and the correlation between 
cellular function and inhibitory receptor expression would be determined. Signalling 
through multiple inhibitory receptors may have an additive or synergistic effect on T cell 
dysfunction, and determining the contribution of each would enable the development of 
more effective cancer immunotherapies.  
 
The role of NK cells in TGCTs 
It has been shown that the generation of tumour-specific CD8 T cells is enhanced by 
activated NK cells, which promote the maturation of DCs and provide them with antigenic  
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material following tumour cell lysis (Kalinski et al., 2005). In addition, NK cells can directly 
kill target cells that lack MHC class I expression without prior sensitisation, as well as 
those displaying stress-induced molecules, including MICA/B and ULBPs. MHC class I 
expression on TGCTs is either low, focal or absent (Nouri et al., 1993, Bols et al., 2000, 
Hadrup et al., 2006). Together, this would suggest that TGCT-residing NK cells may play a 
fundamental role in the initial recognition and subsequent lysis of tumour cells. We and 
others (Grobholz et al., 2000, Hadrup et al., 2006), have shown few NK cells in TGCTs 
compared to T cell frequency, yet the phenotype and function of these NK cells has not 
been previously investigated.  
 
We show the predominant NK cell subset within TGCTs is the CD56hiCD16- population. 
We and others have shown that this subset represents only a minority subset in peripheral 
blood, ranging from approximately 5-10% of total NK cells (Sinkovics and Horvath, 2005), 
in contrast to sites of peripheral inflammation where CD56hiCD16- NK cells represent 40–
60% of total NK cells (Dalbeth et al., 2004). We speculate that the preferential accumulation 
of CD56hiCD16- NK cells in TGCTs is in part due to increased CXCR3 surface expression 
(Campbell et al., 2001) and its corresponding chemokine, IP-10, being secreted by 
seminoma stroma. However, the migratory potential alone may not explain the increase of 
CD56hiCD16- cells into TGCT tissues in all instances. Increased proliferation of these NK 
cells within the tumour would elevate the levels of CD56hiCD16- cells. The interaction of 
the CD56hiCD16- NK population with DCs induces proliferation in this subtype but not in 
the CD56lowCD16+ population (Moretta et al., 2004). Therefore, local interaction with 
tumour residing DCs may result in elevated frequencies of CD56hiCD16- NK cells. 
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Within peripheral blood, the CD56hiCD16- subset of NK cells are predominantly cytokine 
secreting cells, with lower cytotoxic potential than their CD56lowCD16+ counterparts 
(Cooper et al., 2001). Surprisingly, we observed enhanced cytokine secretion and cytotoxic 
capacity of tumour infiltrating CD56hiCD16- NK cells following stimulation. It has been 
suggested that CD56hi NK cells are an activated form of CD56low cells (Cooper et al., 2001), 
which may indicate an activated phenotype of NK cells in TGCTs, a prerequisite for 
cytotoxic activity. This may also explain the increased CD56 expression on CD16+ cells 
following in vitro stimulation in this study. Alternatively, IL-2 supplementation during in 
vitro stimulation, or its secretion by activated T cells within the tumour microenvironment, 
could lead to increased cytotoxicity of CD56hiCD16- NK cells (Robertson et al., 1992). 
Overall, we consider NK cells to play an important role in anti-tumour immunity, yet the 
high frequency of infiltrating T cells, as well as tumour induced suppression mechanisms, 
may hinder their ability to effectively interact and lyse tumour cells. 
 
In the present study, we demonstrate effective tumour killing by tumour residing NK cells 
in vitro, however, lysis in this system (using K562 cells) was mediated by the lack of MHC 
class I on the tumour cell line, and not through activation of NKG2D. NK cells expressing 
NKG2D specifically lyse tumours expressing NKG2D ligands including MICA/B and 
ULBPs (Arina et al., 2007), and blockade of NKG2D results in an impaired ability to kill 
transformed targets (Strid et al., 2008). We demonstrate expression of NKG2D activating 
ligands, MICA and ULBP2, on a number of tumour samples, but not ULBP1 or 3. Tumour 
cells may evade NKG2D-mediated immune surveillance by specifically shedding MICA 
and ULBP2 via metalloproteinases (Bauer et al., 1999, Waldhauer and Steinle, 2006), 
reducing the ability of NK cells to recognise the tumour. Soluble MICA and ULBP2 have 
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been show to promote the internalization and subsequent degradation of NKG2D in NK 
cells (Groh et al., 2002), rendering them less efficient at tumour cell lysis. This may help 
explain our observation of decreased NKG2D expression on both NK cell subsets that 
infiltrate TGCTs, and may render these cells unable to receive activating signals through 
NKG2D. These observations suggest a prominent role for MICA and ULBP2 in TGCT 
immune surveillance. By promoting the reduction of NKG2D ligands on the cell surface, 
tumour cells may efficiently escape innate immune recognition (Diefenbach and Raulet, 
2002). Future studies would aim to determine the effect of NKG2D downregulation on the 
functionality of NK cells, through the use of tumour cells lines which provoke NK cell-
mediated cytotoxicity through activating NKG2D. 
 
Furthermore, we found that NKG2D expression on tumour-infiltrating CD8 T cells was 
extensively downregulated. NKG2D costimulates and augments TCR-mediated activation 
of CD8 T cells (Bauer et al., 1999, Roberts et al., 2001), but chronic stimulation with NKG2D 
ligands can lead to its internalisation (Cerboni et al., 2009), leading to functional 
impairment (Groh et al., 2002). In summary, NKG2D is downregulated on both NK cells 
and CD8 T cells, which is presumably mediated by the tumour. The negative regulation of 
NKG2D may be an important mechanism of tumour-induced immune suppression of both 
the innate and adaptive immune response in TGCT patients. Furthermore,  TGFβ secreted 
by tumour stroma or Tregs may also downregulate NKG2D expression. Several 
publications have described TGFβ-induced downregulation of NKG2D on tumour 
residing NK cells and CD8 T cells, rendering them less efficient at tumour cell killing 
(Crane et al., 2010, Friese et al., 2004). Our results also show a reduction in NKG2D density 
on CD56hiCD16- NK cells in peripheral blood. The expression of NKG2D over time was 
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significantly increased following tumour removal; suggesting NK cells with decreased 
NKG2D expression may be entering systemic circulation. 
 
To determine the extent of NKG2D ligand shedding from the tumour surface and the 
potential role of TGFβ in mediating immune evasion in TGCT patients, levels of these 
molecules in patient sera during tumour development would need to be determined. We 
would expect higher levels of these molecules in TGCT patients with active disease than in 
post-operative patients or healthy donors. We show for the first time that NKG2D 
expression is downregulated on both the innate and adaptive immune cells that infiltrate 
TGCTs.  
 
Finally, we demonstrated the presence of   activated   γδ   T   cells   in   TGCTs. In contrast to 
(Zhao et al., 1995), who observed a high percentage of γδ T cells in TIL, we observed 
proportions similar to those found in peripheral blood, and (Bols et al., 2000) 
demonstrated   only   focal   staining   of   γδ T cells by IHC. Importantly, MICA and ULBP-
expressing  tumours  are  recognised  and  killed  by  γδ  T  cells (Bauer et al., 1999, Maeurer et 
al., 1996), mediated not only through their TCR but also by activation of the NKG2D 
signalling pathway (Rincon-Orozco et al., 2005). This   suggests  γδ  T   cells  may  be  able   to  
directly target TGCTs, although we assume that surface expression of NKG2D is also 
reduced  on  γδ  T  cells, and dysfunction extends to this cell type. 
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Conclusion 
In conclusion, TGCTs are infiltrated by a variety of immune cells with putative anti-
tumour activity. Of particular importance are the CD4 and CD8 T cell subsets, which 
predominate in TIL. Cell surface expression analysis suggests these T cells are antigen 
experienced, recently activated, oligoclonal populations; many of which have cytotoxic 
capacity. Our findings suggest T cells from TGCTs have high proliferative potential upon 
TCR stimulation in vitro, yet clonal expansion within the tumour masses may be restricted.  
The upregulation of inhibitory receptors on T cells and the down regulation of NKG2D on 
T cells and NK cells suggest multiple immune suppressive mechanisms exist within the 
tumour microenvironment; some of which span both the innate and adaptive arms of the 
immune system. The role of this immune infiltrate in controlling tumour growth, and the 
antigen specificity of T cells infiltrating these tumours is presently unknown.  
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CHAPTER 4: CANCER TESTIS ANTIGEN 
RESPONSES IN TGCT PATIENTS  
 
Introduction 
Tumour-specific antigens (TSAs) are expressed in a high proportion of tumours of various 
histopathological types, but are absent in healthy somatic tissue, with the exception of the 
CTAg family proteins (e.g. Melanoma-associated antigen - MAGE), which are expressed in 
testicular germ cells. These antigens are not presented to the developing immune system 
in the thymus hence central tolerance is not generated against them. In addition, the 
blood-testis barrier (BTB) prevents the presentation of CTAgs in the periphery. The 
tumour restricted expression of TSAs makes them excellent targets for anti-tumour 
immune responses mediated by cytotoxic CD8 T cells. MAGE antigens have been studied 
in great detail, and many T cell epitopes have been described (Traversari et al., 1992, 
Ottaviani et al., 2005, Zhang et al., 2002, Luiten and van der Bruggen, 2000). Elevated levels 
of MAGE-specific T cells in peripheral blood have been described in patients with various 
cancers (Zerbini et al., 2004, Goodyear et al., 2005) but are absent or at very low frequency 
in healthy donors. The importance of MAGE-specific T cells in anti-tumour immunity 
have been demonstrated by their ability to induce tumour regression in vaccine trials 
(Godelaine et al., 2003, Coulie et al., 2002, Karanikas et al., 2003). 
 
In this chapter we examined the frequency and kinetics of MAGE-specific T cell responses 
in TGCT patients and in cancer-free healthy individuals. The functional characteristics of 
MAGE-specific T cells were also investigated. 
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Cancer Testis Antigens are Expressed in TGCTs 
There is conflicting evidence regarding the expression profile of CTAgs in TGCTs, 
including MAGE family antigens (Grobholz et al., 2000, Chen et al., 2013, Hara et al., 1999). 
Therefore, we examined the transcript levels of various MAGE antigens and, where 
appropriate, the protein abundance in TGCT tissue and healthy testis. 
 
Firstly, CTAg expression was determined in each tissue by qRT-PCR represented relative 
to healthy testis, and normalised to GAPDH. Gene transcripts for all CTAgs examined 
were abundant in healthy testis. MAGEA1 transcripts were detected in 50% of seminoma 
patients (2 out of 4), but were present at levels lower than that of healthy testis. MAGEA1 
expression was not observed in NSGCTT (0 out of 2) or mGCT tissue (0 out of 1) (Figure 
39a). MAGEA3 was expressed in 25% of seminoma tissues, with levels 1.58-fold greater 
than healthy testis, but was practically absent in all other tissue specimens (Figure 39b). 
Similarly, MAGEA4 was expressed in 25% of seminoma samples, but was undetectable in 
other TGCT specimens (Figure 39c). NY-ESO-1 was expressed at low levels in one 
seminoma specimen (Figure 39d). MAGEB1 expression was detected in healthy testis, but 
not in any TGCT tissues (Figure 39e). 
 
Noticeably, patients with low, but detectable expression of MAGEA1 also had high 
expression of either MAGEA3 (patient 68CL) or MAGEA4 (patient 75NS). This suggests 
multiple MAGE antigens are expressed in a proportion of seminoma tumours. 
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Figure 39. Expression of CTAg transcripts in primary TGCT tissue. 
The mRNA levels of MAGEA1 (a), MAGEA3 (b), MAGEA4 (c), NY-ESO-1 (d), and 
MAGEB1 (e) is shown. Each bars represent relative expression levels of individual 
patients.  “TESTIS”  represents  the  mean  expression  level  in  normal  testis  tissue  of  3  
patients. Expression is relative to testis and normalised to GAPDH.  
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To verify whether transcript levels correlate with protein expression, we performed 
western blot analysis with specific MAGEA antibodies on healthy testis and TGCT 
samples (Figure 40a). Protein abundance was determined by densitometry. MAGEA1, A3 
and A4 protein expression levels correlated well with transcript levels (Figure 40b,c,d). 
 
We show differential expression of MAGEA antigens in TGCTs at both the mRNA and 
protein level. Expression of these antigens was only detectable in seminoma specimens. 
We also show a proportion of TGCTs that expressed more than one MAGEA family 
antigen. NY-ESO-1 and MAGEB1 are not expressed in TGCTs. 
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Figure 40. Expression of CTAg protein in primary TGCT tissue. 
Western blot analysis of MAGEA1, MAGEA3 and MAGEA4 to determine protein 
expression in TGCT tissue (a). GAPDH was used as a loading control and to determine 
relative protein abundance between patients. Relative protein abundance was calculated 
by densitometry, for MAGEA1 (b), MAGEA3 (c) and MAGEA4 (d), relative to testis, 
normalised to GAPDH.  
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MAGE-specific CD8 T Cells are Detectable in TGCT Patients 
A proportion of TGCTs express MAGEA family antigens and the vast majority of these 
tumours have an immune infiltrate. We therefore investigated whether cell mediated 
immune responses are generated against these antigens. If spontaneous MAGE-specific T 
cell responses are generated towards the tumour, we would expect to detect these cells in 
peripheral blood of TGCT patients. 
 
We examined the frequency of MAGEA1, MAGEA3 and MAGEA4-specific T cells from 
PBMC of TGCT patients (n=22) by MHC-dextramer analysis, following ten day T cell line 
peptide culture (TCL). Peptide lines were set up with freshly isolated PBMCs, without 
prior enrichment of CD8 T cells. Figure 41 illustrates the experimental procedure used for 
dextramer staining, including an example of positive dextramer staining and subsequent 
purification. Table 27 details the peptides used in the TCL stimulation assay and those 
present in the MHC-peptide-dextramer complexes. Flow cytometry analysis was used to 
visualise dextramer positive (MAGE-specific) T cells. 
 
Representative density plots show the presence of MAGE-specific CD8 T cells in 
peripheral blood of TGCT patients, following TCL culture (Figure 42). The specificity of 
dextramer staining was illustrated by the absence of staining of CD8-negative T cells 
(presumably CD4 T cells and NK cells) and low background staining with the negative 
dextramer (irrelevant peptide). A positive response was defined as a frequency of MAGE-
specific cells greater than an arbitrary value of 0.05% of the total CD8 T cell pool. The 
percentage of cells binding to the negative control dextramer was deducted.  
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Figure 41. Schematic demonstrating the procedure for identification and purification of 
MAGE-specific T cells. 
PBMCs were stimulated with immunogenic peptides corresponding to various MAGE 
antigens, in the presence of IL2, IL7 and IL15, for 10 days. MAGE-specific cells were 
detected using MHC-dextramer   staining  and  analysed  by   flow  cytometry.  The   ‘Pre  Sort’  
density plot (right) is representative of a patient with a positive response directly 
following TCL culture. ‘Post  sort’  density plot (left) is the same sample following magnetic 
selection of dextramer positive cells. Where appropriate, cells were set up for limiting 
dilution cloning for functional analysis. 
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 Table 27. Detailed list of peptides used in T Cell Line assays and Dextramer complex. 
Gene 
product 
HLA 
restriction 
HLA 
frequency (%) 
Peptide*                     
(aa Sequence) 
Position 
  NY-ESO-1 A2 42.6 MLMAQEALAFL 1-11 
  MAGEA1 A2 42.6 KVLEYVIKV 278-286 
 
B7 21.4 RVRFFFPSL 289-298 
    MAGEA2 A2 42.6 YLQLVFGIEV 157-166 
  MAGEA3 A1 29.1 EVDPIGHLY 168-176 
 A2 42.6 KVAELVHFL 112-120 
    MAGEA4 A2 42.6 GVYDGREHTV 230-239 
        
      * each letter represents an amino acid. Letters in bold are shorthand as referred to in  
        the text 
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Figure 42. Detection of MAGE-specific T cells by peptide-MHC dextramer. 
Flow cytometry contour plots illustrate the detection of MAGE- specific CD8 T cells in 
TGCT patients prior to chemotherapy, using MHC-peptide Dextramers. Representative 
plots show KVAE (a), EVDP (b) and RVRF (c) –specific T cells detected in TGCT patients, 
following 10 day peptide TCL expansion. The left column demonstrates cells stained 
positive for MAGE- specific dextramer and the right column with the non-specific 
dextramer (negative control). Dextramer positive cells are highlighted in blue. 
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The magnitude of a MAGE-specific response was calculated, and expressed as a 
proportion of total CD8 T cells (Figure 43a). MAGEA1 (RVRF) -specific T cells were 
detected in 9% of TGCT patients at frequencies of 0.06% to 0.58% of total CD8 T cells. 
Approximately a third (31%) of TGCT patients assessed had a MAGEA3 (combined EVDP 
and KVAE) response. Patients with an EVDP response had EVDP-specific cells at 
frequencies of 0.13% to 1.14% of total CD8 T cells. The frequency of KVAE-specific T cells 
in patients with a KVAE response was lower than that of EVDP, ranging from only 0.06% 
to 0.33% of total CD8 T cells. Interestingly, one seminoma patient had both a MAGEA1 
(RVRF) and a MAGEA3 (EVDP) response. Another patient had responses to two MAGEA3 
peptides (EVDP and KVAE) presented through different HLA molecules. In this patient 
cohort, no NY-ESO-1 (MLMA), MAGE-A2 (YLQL) or MAGEA4 (GVYD) –specific T cell 
responses were detected. Overall, MAGE-specific responses were detected in 36% (8 out of 
22) of patients, one of whom developed responses to multiple MAGEA antigens. The 
HLA-type of patients with a positive response was subsequently determined to verify the 
validity of the response. In all cases, the observed responses to a particular HLA-restricted 
peptide were consistent with the HLA-type of the patient. 
 
Next, we categorised responding TGCT patients according to tumour type - seminoma 
and NSGCTT (Figure 43b). All MAGEA1 (RVRF) responses were from seminoma patients, 
whereas MAGEA3 responses (combined KVAE and EVDP) were detected in both 
seminoma and NSGCTT patients. Our results reveal that MAGE-specific T cells are 
present in the peripheral blood of TGCT patients, presumably generated towards MAGEA 
family-expressing tumours.  
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Figure 43. The rate of detection of MAGE-specific T cells from PBMC of TGCT patients. 
In TGCT patients in whom a MAGE-specific T cell response was detected the frequency of 
MAGE specific T cells is shown as a percentage of total CD8 T cells, following 10 day 
peptide TCL culture (a). The dotted line represents the threshold for a positive response. 
The threshold was set at an arbitrary value of 0.05% of total CD8 T cells, and is indicated 
by a dotted line. The frequency of cells stained positive with the non-specific dextramer 
was deducted for the MAGE-specific dextramer frequency. Positive responses were 
detected against EVDP, RVRF and KVAE peptides, and were categorised by tumour type 
(b). # represents points from the same patient with a MAGEA1 and MAGEA3 response.  
$ represents points from the same patient with a MAGEA3 response to 2 peptides 
presented through different HLA serotypes. 
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MAGEA3-specific T Cells Secrete Inflammatory Cytokines 
Next we addressed the function of MAGE-specific T cells through the use an EVDP-
specific T cell clone generated from a seminoma patient prior to adjuvant chemotherapy. 
The generation of a MAGEA3 T cell clone (TCC) involved pulsing PBMC with EVDP 
peptide followed by short term in vitro culture, followed by enrichment using the EVDP-
dextramer and MACS technology. Subsequent cloning of single cells was achieved by a 
limiting dilution cloning method. The procedure and representative enrichment from a 
short term culture is shown in Figure 41. Developing clones were visualised and tested for 
dextramer specificity between 14 days and 28 days following setup. 
 
The enrichment of dextramer positive cells by MACS gave a purity of between 75% and 
98% in the patients tested. Unfortunately, cloning efficiency was surprisingly low, and 
only a single T cell clone was generated. To our knowledge, this is the first MAGEA3-
specific T cell clone generated from a patient with testicular cancer.  
 
Next we determined the functional capabilities of these cells following peptide stimulation 
in vitro. The MAGEA3-specific  clone  was  assessed  for  its  ability  to  release  IFNγ  and  TNFα,  
following co-culture with HLA-A1-positive EVDP-pulsed target cells (LCL). We 
determined the production of inflammatory cytokines by intracellular cytokine staining. 
The TCC produced both  IFNγ  and  TNFα  following  co-culture with EDVP peptide pulsed 
LCLs at low E:T ratios (Figure 44). Interestingly, a higher proportion of cells released 
TNFα  compared   to   IFNγ   following   stimulation  at   1:10   (45.97  vs.   7.17)   and  1:1   (15.48  vs.  
2.06) E:T ratios. No cytokine release was observed following co-culture with LCL pulsed  
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with irrelevant peptide (KVAE), or with IL-2 alone. Representative dot plots show that the 
majority of MAGE-specific cells were producing TNFα only. All IFNγ secreting cells 
simultaneously produced TNFα and no IFNγ single-secreting cells were observed 
following stimulation with peptide-pulsed LCL (Figure 44a). 
 
MAGEA3-specific T Cells Recognise Endogenously Processed Antigen 
Next, we determined whether the MAGEA3-specific T cell clone was able to recognise 
endogenously processed and presented MAGEA3 antigen. This was achieved by co-
culturing the TCC with an HLA-A1+ MAGEA3+ tumour cell line, HT-29, and examining 
the production of IFNγ  and  TNFα. This revealed a high proportion of cells which secrete 
TNFα  but  very  few  which  secrete  IFNγ  (Figure 45), similar to that observed following co-
culture with peptide pulsed LCL. HT-29 cells pulsed with peptide showed similar results 
to those not pulsed with peptide, suggesting HT-29 cells are effectively presenting 
MAGEA3. Incubation of HT-29 cells with an irrelevant CD8 T cell clone (virus-specific) 
does not induce cytokine production in these cells (Figure 45b). This confirms that the 
MAGEA3-specific TCC is recognising and responding to endogenously processed 
MAGEA3, and the HT-29 cell line is not inducing cytokine production independent of 
TCR engagement. 
 
MAGEA3-Specific T Cells Have High Cytolytic Potential 
The cytotoxic potential of cells cannot be solely predicted based on the cytokines they 
secrete. We used the mobilisation of CD107a on the cell surface as an indicator of 
degranulation, a prerequisite for cytotoxic granzyme release. The TCC was stimulated 
with LCL pulsed with either EVDP or an irrelevant peptide (KVAE), or with a HT-29 cell  
182 
 
line (Figure 46). We found that CD107a surface expression was induced on EVDP-specific 
CD8 T cells following co-culture with EVDP-pulsed LCL (Figure 46a,b) and HT-29 cell line 
(Figure 46c). We also show that increasing the proportion of target cells from 1:1 to 1:10 
induces degranulation in a greater proportion of T cells, presumably due to an increase in 
the number of MHC molecules presenting EVDP peptide. 
 
In addition, we examined the proportion of CD107a expressing cells according to their 
cytokine profile (Figure 47). We show that the majority of cells simultaneously secreting 
TNFα and IFNγ, or TNFα alone were strongly associated with CD107a expression. This 
suggests cytokine secretion is a good indicator of cytotoxic potential. Interestingly, HT-29 
cells induced degranulation of a high proportion of T cells without inducing cytokine 
production (1:10 ratio, 42.60%). This was also observed following stimulation with EVDP-
pulsed LCLs, but to a lesser extent (1:10 ratio, 8.56%). This suggests that a proportion of 
MAGE-specific T cells can mediate cytolytic activity without secreting inflammatory 
cytokines. In summary, we have observed that all EVDP-specific cytokine secreting cells 
are cytotoxic; however, we have identified a population of cytotoxic cells that fail to 
secrete inflammatory cytokines.  
 
Finally, a peptide titration assay was used to determine the avidity of the EVDP-specific T 
cell clone. Cells were stimulated with 10-fold dilutions of peptide ranging from 10-5 to 10-11 
M, and IFNγ levels in cell culture supernatant were determined by ELISA. A reduction in 
IFNγ secretion was demonstrated with diminishing concentrations of peptide (Figure 48a). 
This clone had fairly low avidity for peptide with 50% maximal IFNγ release at a peptide  
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concentration between 10-6 and 10-7 (Figure 48b). This is comparable however with MAGE-
specific T cell clones generated from PBMC of multiple myeloma patients (Goodyear et al., 
2005), but is considerably lower than viral specific clones generated in our laboratory (data 
not shown).  
 
Overall, our results suggest that MAGEA3-specific T cells isolated from peripheral blood 
of TGCT patients have high cytotoxic potential, although the avidity of the TCR:pMHC 
interaction may be low. Moreover, this HLA-A1-restricted MAGEA3-specific T cell clone, 
but not an HLA-A1-restricted irrelevant (virus-specific) T cell clone, has the capacity to 
degranulate in response to tumour cells that have the capacity to present MAGEA3 
through HLA-A1. 
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Figure 44. Inflammatory cytokine secretion of an EVDP–specific TCC generated from 
PBMC of a seminoma patient, following stimulation with LCL pulsed with EVDP 
peptide. 
Cell were stimulated with LCL pulsed with irrelevant peptide (LCL+KVAE) and with test 
peptide  (LCL+EVDP).  Flow  cytometry  dot  plots  illustrate  the  secretion  of  IFNγ  and  TNFα  
with irrelevant and test peptide (a). EVDP-specific T cells were stimulated with peptide 
loaded LCL at E:T ratios of 1:10 and 1:1 with test peptide EVDP (filled bars). Control 
experiments (open bars) were cells treated with irrelevant peptide KVAE at a 1:10 ratio, 
and T cells alone.  The  secretion  of  IFNγ  (b)  and  TNFα  (c) was quantified and represented 
as a percentage of total dextramer positive cells. 
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Figure 45. Inflammatory cytokine secretion of an EVDP –specific TCC stimulated with 
endogenously presented MAGEA3 antigen. 
EVDP-specific T cells (a) and an irrelevant T cell clone (b) were stimulated with HT-29 
tumour cell line at E:T ratios of 1:10 and 1:1. Negative control (open bar) was T cells alone. 
Positive control was HT-29   cells   pulsed  with  EVDP  peptide.   The   secretion   of   IFNγ   and  
TNFα  was  quantified  and  represented  as  a  percentage  of  total  dextramer  positive  cells. 
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Figure 46. Cytotoxic potential of an EVDP-specific TCC. 
CD107a was used as a marker of degranulation. Histograms illustrating the proportion of 
cells expressing CD107a following stimulation with test peptide is shown (a). The 
induction of surface CD107a expression of an EVDP –specific T cell clone stimulated with 
EVDP pulsed LCL (b) and HT-29 cell line (c), at E:T ratios of 1:10 and 1:1, is shown. 
CD107a expression was expressed as the percentage of total EDVP-specific cells. Negative 
control (open bar) was LCL pulsed with KVAE peptide and T cells alone in (b), and T cells 
alone in (c). Positive control in (c) was HT-29 cell line pulsed with EVDP peptide. 
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Figure 47. Cytotoxic capacity of an EVDP-specific T cell clone in relation to cytokine 
secretion. 
The proportion of cells that are CD107a positive following stimulation was determined for 
each cytokine group. Histograms illustrating the proportion of cells expressing CD107a 
following  stimulation  with  test  peptide,  within  the  IFNγ+TNFα+ (blue), IFNγ-TNFα- (red), 
and  IFNγ-TNFα+ (green) quadrants is shown (a). The proportion of CD107a positive cells 
following stimulation with EVDP peptide pulsed LCL (b) and HT-29 (c) was represented 
as a percentage of cells within that cytokine group.  
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Figure 48. Titration of EVDP peptide concentration to establish avidity of EVDP-
specific TCC. 
EVDP-specific T cells were co-cultured with EVDP loaded LCLs or MAGEA3 expressing 
HT-29   cell   line,   and   response   was   measured   using   IFNγ   production   (a). For peptide 
titration, LCLs were pulsed with 10-fold diminishing concentrations of peptide from 10-5M 
to 10-11M. Spontaneous IFNγ   production   (open   bars)  was   tested   by   co-culture of clones 
with LCL pulsed with irrelevant peptide (KVAE), T cells alone, LCL alone, or HT-29 alone. 
A standard curve of the logarithmic relationship between concentration and absorbance 
was used to calculate  the  IFNγ  concentration  in  cell  culture  supernatants.  The maximum 
and  minimum  IFNγ  release  was  calculated  and  used  to  determine  the  half  maximal  IFNγ  
release (EC50) of the clone (b). The dotted line represents the EC50 for the clone, which was 
between 10-6M to 10-7M. 
0 50 100 150 200 250 300
HT-29 only
T cells+HT-29
LCLs ONLY
M)-5T cells+LCLs+KVAE (10
T cells only
M)-11T cells+LCL+EVDP (10
M)-10T cells+LCL+EVDP (10
M)-9T cells+LCL+EVDP (10
M)-8T cells+LCL+EVDP (10
M)-7T cells+LCL+EVDP (10
M)-6T cells+LCL+EVDP (10
M)-5T cells+LCL+EVDP (10
IFNJ (pg/ml)
a
b
10- 1 110- 1 010- 910- 810- 710- 610- 5
0
10
20
30
40
50
60
70
80
90
100
Peptide (M)
%
 m
ax
im
al 
IF
N J
 re
le
as
e
r2=0.9891
EC50=4.58 x 10-7
190 
 
Quantitation of CTAg Responses in TGCT Patients  
We have identified, isolated and analysed MAGE-specific CD8 T cells in peripheral blood 
of TGCT patients. Using dextramers we have shown the expression of MAGE antigens 
within testicular tumours. Dextramer analysis has its limitations as it requires prior 
knowledge of immunogenic epitopes and the HLA type of patients. In addition, dextramer 
analysis may underestimate the number of patients with a MAGE-specific response as 
only one or two epitopes are being examined. Dextramer analysis is further complicated 
by the need to expand antigen-specific cells in vitro to enable efficient detection. It is 
important to note that this experimental system only detects CD8 T cells and therefore 
does not provide information regarding MAGE-specific CD4 T cells, which are 
fundamental for an effective cell-mediated immune response.  
 
We therefore quantitated CTAg responses in a large cohort of patients (n=45) using a 
combination of MAGE overlapping peptides, which span the entire length of the protein, 
and a highly sensitive IFNγ ELISPOT assay. The robustness of this assay is proven and 
permits its use in a clinical trial setting, such as those conducted in our institute. This assay 
allows the simultaneous detection of CD4 and CD8 T cell responses, which are HLA 
unrestrictive and fully quantitative. In addition, presentation of peptides is done so by 
autologous PBMCs, removing the use of artificial target cells, which may provoke non-
specific  IFNγ  production. 
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MAGEA-specific T Cells are elevated in TGCT Patients 
We determined the frequency of CTAg-specific cells in healthy donors. Cells were 
stimulated with overlapping peptides (or appropriate controls) in the ELISPOT assay for 
16-18 hours. A single IFNγ secreting cell is represented as a single spot. In the peripheral 
blood of healthy donors absent or very low frequencies of CTAg-specific cells were 
present (Figure 49). The highest frequency of   IFNγ   secreting  CTAg  specific  T   cells  were  
against the NY-ESO-1 antigen, with 41 cells per million PBMC detected (0.0041%). For 
MAGEA antigens the frequency of cells ranged from 0 to 40 cells. MAGEB1 specific cells 
were practically absent in healthy donors with a maximum of 9 cells per million PBMC. 
We set a positive response threshold at double the highest CTAg-specific cell frequency 
found in healthy donors (82 cells per million PBMC).  
 
Next, we investigated the frequency of CTAg-specific cells in NSGCTT (n= 10), mGCT (n= 
6), and seminoma (n= 29) patients. Clinically, mGCTs are classified as part of the NSGCTT 
subtype. This classification is used because the management of mGCT is the same as 
NSGCTT. However, in this study we have placed mGCT into its own category since these 
tumours contain elements of both seminoma and non-seminoma. Figure 50 is a 
representative ELISPOT readout, demonstrating the presence of MAGEA1, A3, and A4-
specific T cells in the peripheral blood of a seminoma patient. Spots in the unstimulated 
well represent cells  releasing  IFNγ  non-specifically, which were detectable at low levels in 
this patient. Patients with high background were excluded from analysis. NY-ESO-1 and 
MAGEB1-specific cells were undetectable in this patient. CEFT (positive control) induced a 
high frequency of spots demonstrating cells are responsive to antigenic peptide 
stimulation. 
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Figure 49. CTAg-specific responses determined by ELISPOT from PBMC of Healthy 
donors. 
Representative ELISPOT spots from a healthy donor demonstrating an absence of specific 
cells to all CTAgs examined (a). Between 250,000 and 350,000 PBMC were stimulated with 
overlapping peptides spanning the full length of a CTAg protein. Each spot represents a 
single antigen-specific  IFNγ  secreting  cell. The negative control was cells stimulated with 
vehicle  only   (DMSO,  unstimulated).   Spots   in   these  wells  were   cells   releasing   IFNγ  non-
specifically, and were subsequently deducted from CTAg peptide stimulated values. 
Positive control was stimulation with CEFT peptide library, containing known antigenic 
peptides for CMV, EBV, Flu and Tetanus. Computational analysis was used to count the 
spots in each well. Values were converted to represent the frequency of IFNγ   secreting  
cells per 106 PBMC for each CTAg (n=17) (b). Black dotted line represents the maximum 
number of CTA-specific cells found in healthy donors. Grey dashed line represents the 
threshold for a positive CTAg response.  
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Figure 50. CTAg-specific responses from PBMC of a seminoma patient, determined by 
ELISPOT. 
Representative ELISPOT spots from a TGCT patient with a MAGEA1, MAGEA3 and 
MAGEA4 response. Between 250,000 and 350,000 PBMC were stimulated with 
overlapping peptides spanning the full length of a CTAg protein. Each spot represents a 
single antigen-specific  IFNγ  secreting  cell. The negative control was cells stimulated with 
vehicle only (DMSO, unstimulated). Spots in these wells were cells releasing   IFNγ  non-
specifically, and were subsequently deducted from CTAg peptide stimulated values. 
Positive control was stimulation with CEFT peptide library, containing known antigenic 
peptides for CMV, EBV, Flu and Tetanus. Computational analysis was used to count the 
spots in each well. Values  were   converted   to   frequency   of   IFNγ   secreting   cells   per   106 
PBMC. Patients with a high frequency of spots in the unstimulated wells were excluded 
from further analysis. 
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The frequency of cells specific to MAGEA1 (Figure 51), MAGEA3 (Figure 52), MAGEA4 
(Figure 53), NY-ESO-1 (Figure 54), and MAGEB1 (Figure 55) in healthy donors and 
patients with various TGCTs, are shown. Table 28 summarises the frequency of each CTAg 
response according to tumour type. 
 
A direct comparison of the frequency of cells in healthy donors and TGCT patients was 
depicted according to the CTAg they were stimulated with (Figure 56). We observed 
positive MAGEA1 responses in 17% of mGCT patients and 31% of seminoma patients. 
MAGEA1-specific responses were absent in all NSGCTT patients analysed (Figure 56a). 
Furthermore, the magnitude of positive MAGEA1 responses was far greater in seminoma 
patients (up to 0.149% of PBMC) compared to mGCT patients (0.0248% of PBMC). The 
median frequency of MAGEA1-specific cells was statistically higher in seminoma patients 
than in healthy donors (p=0.0009) and NSGCTT patients (p=0.0307). No significant 
differences were observed between other tumour types. MAGEA3 responses were 
detected in patients across all testicular tumour types (Figure 56b), and we show that 31% 
of seminoma, 50% of mGCT and 30% of NSGCTT patients developed a spontaneous 
immune response to this antigen. The magnitude of responses was similar across all TGCT 
types, with up to 0.07% of total PBMC being specific to MAGEA3. The median frequency 
of MAGEA3-specific cells was significantly greater in both seminoma (p= 0.0072) and 
NSGCTT (p=0.0292) patients, compared to that of healthy donors. MAGEA4 responses 
were detected in 33% of mGCT and 28% of seminoma patients, with median frequencies 
significantly greater in the seminoma than in healthy donors (p=0.0226). Conversely, no 
positive responses were identified in NSGCTT patients. 
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NY-ESO-1 and MAGEB1-Specific Cells are Undetectable in TGCT Patients 
We show expression of MAGEA family proteins in TGCTs and spontaneous cell mediated 
immune responses towards these antigens. We showed that NY-ESO-1 and MAGEB1 
transcripts were undetectable in the majority of TGCTs, and would therefore not expect T 
cell responses to be generated against these antigens. For that reason it was important to 
determine the frequency of NY-ESO-1 and MAGEB1-specific cells in TGCT patients 
compared to healthy donors. Our data suggests immune responses are not generated to 
either of these antigens, as levels of CTAg-specific cells were similar in TGCT patients and 
healthy individuals, irrespective of tumour type.  
 
In summary, both dextramer analysis and ELISPOT analysis revealed that MAGEA1 and 
MAGEA3 –specific T cell responses are generated in TGCT patients, whereas NY-ESO-1 
responses are absent. ELISPOT analysis also demonstrated the presence of MAGEA4-
specific cells in seminoma patients, which were overlooked using dextramer methodology. 
We extended analysis to examine the frequency of MAGEB1-specific cells by ELISPOT, but 
no positive responses were detected in healthy controls or TGCT patients. In this study, 
ELISPOT analysis suggests NSGCTTs only provoke an immune response against 
MAGEA3, a finding which correlates well with our dextramer analysis. 
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Figure 51. Frequency of MAGEA1-specific T cells in healthy donors and TGCT patients. 
The frequency of MAGEA1 specific T cells in healthy donors (a), NSGCTT (b), mGCT (c), 
and seminoma (d) patients was determined by IFNγ secretion in an ELISPOT assay. Cells 
were stimulated with overlapping peptides spanning the entire length of MAGEA1 
protein. CEFT peptide pool was used as a positive control; DMSO was used as a negative 
control. Values were represented as frequency of MAGEA1 specific T cells per 106 PBMC. 
Each bar represents an individual patient. Dotted line represents the threshold for a 
positive response. 
 
 
 
           MAGEA1
HD
-N
C
HD
-M
C
HD
-A
D
HD
-G
P
HD
-E
M
HD
-R
P
HD
-M
B
HD
-J
W
HD
-J
T
HD
-G
R
HD
-F
M
HD
-A
S
HD
-B
A
HD
-A
S
HD
-B
1
HD
-B
2
HD
-D
L
0
50
100
150
200
250
300
600
900
1200
1500
CT
Ag
-sp
ec
ifi
c 
IF
N J
 s
ec
re
tin
g 
ce
lls
 p
er
 1
06
PB
M
C
           MAGEA1
08
JP
09
DW
20
KB
31
GS
50
RN
62
M
L
0
50
100
150
200
250
300
600
900
1200
1500
CT
Ag
-sp
ec
ifi
c 
IF
N J
 s
ec
re
tin
g 
ce
lls
 p
er
 1
06
PB
M
C
           MAGEA1
03
RD
10
CP
17
YH
18
M
P
21
LW
23
DW
38
M
T
49
NC 66
M
I
74
SW
0
50
100
150
200
250
300
600
900
1200
1500
CT
Ag
-sp
ec
ifi
c 
IF
N J
 s
ec
re
tin
g 
ce
lls
 p
er
 1
06
PB
M
C
           MAGEA1
01
DB
02
PM
04
SD
05
TB 07
IB
11
DO
12
AW
13
SC
14
AM
15
SK
16
PR
22
DG
25
PM
27
M
C
34
SR
37
SR
40
DC
41
ZY
43
SJ
44
SA
45
PR
47
M
H
52
RA
57
M
V
82
M
C
87
AB
89
KJ
90
LS
91
PN
0
50
100
150
200
250
300
600
900
1200
1500
CT
Ag
-sp
ec
ifi
c 
IF
N J
 s
ec
re
tin
g 
ce
lls
 p
er
 1
06
PB
M
C
a b
c d
Patient Patient
Patient Patient
Healthy NSGCTT
mGCT Seminoma
198 
 
 
 
 
Figure 52. Frequency of MAGEA3-specific T cells in healthy donors and TGCT patients. 
The frequency of MAGEA3 specific T cells in healthy donors (a), NSGCTT (b), mGCT (c), 
and seminoma  (d)  patients  was  determined  by  IFNγ  secretion  in  an  ELISPOT  assay.  Cells  
were stimulated with overlapping peptides spanning the entire length of MAGEA3 
protein. CEFT peptide pool was used as a positive control; DMSO was used as a negative 
control. Values were represented as frequency of MAGEA3 specific T cells per 106 PBMC. 
Each bar represents an individual patient. Dotted line represents the threshold for a 
positive response. 
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Figure 53. Frequency of MAGEA4-specific T cells in healthy donors and TGCT patients. 
The frequency of MAGEA4 specific T cells in healthy donors (a), NSGCTT (b), mGCT (c), 
and seminoma  (d)  patients  was  determined  by  IFNγ  secretion  in  an  ELISPOT  assay.  Cells  
were stimulated with overlapping peptides spanning the entire length of MAGEA4 
protein. CEFT peptide pool was used as a positive control; DMSO was used as a negative 
control. Values were represented as frequency of MAGEA4 specific T cells per 106 PBMC. 
Each bar represents an individual patient. Dotted line represents the threshold for a 
positive response.  
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Figure 54. Frequency of NY-ESO-1-specific T cells in healthy donors and TGCT 
patients. 
The frequency of NY-ESO-1 specific T cells in healthy donors (a), NSGCTT (b), mGCT (c), 
and seminoma  (d)  patients  was  determined  by  IFNγ  secretion  in  an  ELISPOT  assay.  Cells  
were stimulated with overlapping peptides spanning the entire length of NY-ESO-1 
protein. CEFT peptide pool was used as a positive control; DMSO was used as a negative 
control. Values were represented as frequency of NY-ESO-1-specific T cells per 106 PBMC. 
Each bar represents an individual patient. Dotted line represents the threshold for a 
positive response. 
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Figure 55. Frequency of MAGEB1-specific T cells in healthy donors and TGCT patients. 
The frequency of MAGEB1 specific T cells in healthy donors (a), NSGCTT (b), mGCT (c), 
and seminoma  (d)  patients  was  determined  by  IFNγ  secretion  in  an  ELISPOT  assay.  Cells  
were stimulated with overlapping peptides spanning the entire length of MAGEB1 
protein. CEFT peptide pool was used as a positive control; DMSO was used as a negative 
control. Values were represented as frequency of MAGEB1-specific T cells per 106 PBMC. 
Each bar represents an individual patient. Dotted line represents the threshold for a 
positive response. 
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Figure 56. Overall frequency of CTAg-specific T cells in healthy donors and TGCT 
patients. 
The frequency of MAGEA1 (a), MAGEA3 (b), MAGEA4 (c), NY-ESO-1 (d), and MAGEB1 
(e) -specific T cells in healthy donors (n=17), NSGCTT (n= 10), mGCT (n= 6) and seminoma 
(n= 29) patients was determined. Values are represented as the frequency of CTAg-specific 
T cells per 106 PBMC. Each point represents an individual patient. Dotted line shows the 
threshold for positive response, defined as double the highest response determined in 
healthy donors. Solid horizontal line represents the median. Data analysed by Mann-
Whitney test. * denotes p<0.05, ** denotes p<0.01, *** denotes p<0.001. 
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       Table 28. Overall frequency of CTAg-specific T cells in healthy donors and TGCT patients. 
 Healthy  NSGCTT  mGCT  Seminoma 
Median 25th 75th  Median 25th 75th  Median 25th 75th  Median 25th 75th 
MAGEA1 0.0 0.0 12.83  5.00 0.0 23.33  17.5 0.0 90.00  21.67 6.67 101.7 
MAGEA3 0.0 0.0 2.92  10.00 0.0 243.30  121.70 0.0 396.7  36.0 0.0 124.2 
MAGEA4 0.0 0.0 11.63  0.0 0.0 9.17  24.17 0.0 311.3  8.33 0 220.40 
NY-ESO-1 0.0 0.0 4.17  0.0 0.0 12.50  16.67 0.0 33.75  0.0 0.0 18.33 
MAGEB1 0.0 0.0 2.92  0.0 0.0 0.0  0.0 0.0 3.30  0.0 0.0 3.75 
        Data expressed as median (bold) with 25th and 75th quartile.  
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The Ability to Generate a MAGE-specific Response is Independent of Age 
An aging immune system may be less efficient at generating a primary response to newly 
encountered antigens due to a reduced naive T cell compartment. This is primarily caused 
by the accumulation of highly differentiated T cell subsets generated during persistent 
viral infection (Wherry and Ahmed, 2004). We therefore investigated the effect of age on 
the ability of seminoma patients to mount a CTAg specific response. NSGCTT and mGCT 
patients were excluded from this analysis due to small sample size. Seminoma patients 
were classified into   “responders”   and   “non-responders”,   depending   on   whether a 
response was detected above the positive threshold. We found the ability to generate a 
MAGEA1, A3 or A4-specific immune response was totally independent of patient age 
(Figure 57).  
 
The Magnitude of a MAGEA4-Specific T cell Response is Age-Dependent 
Next, we determined the correlation between the frequency of MAGE-specific T cells and 
the age of responding patients (Figure 58). There was no significant correlation between 
patient age and the frequency of MAGEA1 or MAGEA3-specific cells. Interestingly, strong 
negative correlation was observed between patient age and the frequency of MAGEA4-
specific cells (p=0.0458). Our data suggests increasing age has a detrimental effect on the 
magnitude of a MAGEA4-specific immune response, but has no effect on the frequency of 
MAGEA1 or A3-specific cells in seminoma patients. 
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Figure 57. The effect of age on the possibility of generating a T cell response to MAGE 
antigens. 
The age of seminoma patients with a positive response (grey) and a negative response 
(white) to MAGEA1 (a), MAGEA3 (b) and MAGEA4 (c) is shown. Box represents 25th and 
75th percentile, line represents median, and whiskers represent 10-90 percentile. Data 
analysed by Mann-Whitney test.  
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Figure 58. Correlation between frequency of CTAg-specific  IFNγ  secreting  cells  and  age 
of seminoma patients. 
Correlation between numbers of CTAg-specific   IFNγ   secreting   cells   from   PBMC   of  
seminoma patients and age for MAGEA1 (n=9) (a), MAGEA3 (n=9) (b) and MAGEA4 (n=8) 
(c). Spearman's rank correlation coefficient (r) and significance (p) were determined. 
Significant p values are highlighted in bold type. Each symbol represents an individual 
patient.  
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Patient Age of Disease Onset Differs Between Tumour Types 
We observed different ages of disease onset between different testicular tumour types 
(Figure 59). Specifically, the age of disease onset in seminoma patients (mean age: 41) was 
significantly higher than NSGCTT patients (mean age: 26) (p=0.0007). Similarly, the mean 
age of mGCT patients in this cohort was 39, compared with a median age of 26 for 
NSGCTT (p=0.001). Seminoma patients have increased MAGE responses compared to 
NSGCTT patients, even though the average age is significantly higher. This suggests 
tumour type has a greater effect than age in the generation of MAGE-specific responses. 
 
 
Metastatic Potential of the Tumour is Associated with Elevated Levels of MAGEA3-
specific T Cells in NSGCTT Patients 
Clinical grading of TGCTs depends on the subtype of disease. Generally, tumours are 
categorised using a combination of factors including tumour size, vascular invasion and 
metastasis, and the levels of specific tumour markers. In this study, mGCT patients had 
localised disease with undetectable lymph node metastasis. Consequently, these patients 
could not be effectively categorised and were subsequently omitted from further analysis.   
 
We categorised NSGCTT patients based on the presence of tumour tissue solely in the 
testis (localised), or which had evident lymphovascular invasion or retroperitoneal lymph 
node metastasis (metastatic). We found that all NSGCTT patients with a MAGEA3-
response had secondary tumour masses in the retroperitoneal lymph nodes. All patients in 
this group demonstrated elevated levels of MAGEA3-specific T cells in peripheral blood, 
compared to patients with localised disease (p=0.0396) (Figure 60a). Based on these results, 
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we hypothesise that disease progression and metastasis of NSGCTTs is associated with the 
development of a MAGEA3-specific T cell response. 
 
Generation of a MAGE-Specific Response is not determined by Tumour Stage in 
Seminoma Patients  
We categorised seminoma patients into two groups depending on the stage of disease. The 
majority of patients with seminomatous tumours are presented with clinical stage I disease 
(Stage I). To generate groups large enough for effective comparison, we grouped together 
all patients with clinical stage II and above (Stage II-IV). We detected no significant 
association between tumour stage and the presence or magnitude of an immune response 
to any MAGE antigen assessed (Figure 60b). MAGE responses were detected in 
approximately 30% of patients with stage I disease and 30% of patients with stage II-IV 
disease.  
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Figure 59. Age of TGCT patients used in ELISPOT assay, categorised by tumour type. 
Age of patients with NSGCTT (n=10), mGCT (n=6) or seminoma (n=29) used in the 
ELISPOT assay. Horizontal line represents the mean. Data analysed by student T test. 
 *** denotes p<0.001. 
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Figure 60. Effect of tumour stage on the frequency of CTAg-specific  IFNγ  secreting  cells  
in TGCT patients. 
Numbers of CTAg-specific   IFNγ   secreting   cells   per   106 PBMC were determined in 
NSGCTT (a), and seminoma (b) patients grouped by tumour form (localised or metastasis, 
NSGCTT) or tumour stage (I or II-IV, seminoma). Each symbol represents an individual 
patient, and horizontal line represents median. Data analysed by Mann-Whitney test. 
 * denotes p<0.05. 
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Multiple MAGE Responses are Generated in TGCT Patients 
Several studies show the expression of multiple MAGE antigens in tumours of various 
histopathological types (Mashino et al., 2001). In this study, we have demonstrated the 
expression of multiple MAGEA family antigens in TGCT tissue. Assessment of MAGE 
responses by dextramer analysis revealed a patient who had both a MAGEA1 and a 
MAGEA3-specific CD8 T cell response. These observations led us to investigate the 
incidence of multiple MAGE responses in a cohort of TGCT patients where a MAGE 
response was detected,  as  defined  by  a  positive  IFNγ  ELISPOT  result (n=21). 
 
Figure 61 outlines the frequency of MAGEA1, A3 and A4-specific cells for individual 
patients in this cohort. As previously shown, NSGCTT patients only generate MAGEA3 
responses thus multiple MAGE responses were not generated (Figure 61a). In contrast, the 
majority of mGCT patients (2 out of 3) and nearly half the seminoma patients (7 out of 15), 
responded to at least two of the MAGEA-family antigens assessed (Figure 62). Moreover, 
four seminoma patients exhibited responses to all three MAGE antigens. We did not 
observe any association between the number of MAGEA family responses and tumour 
stage or patient age in seminoma patients (data not shown).  
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Figure 61. TGCT patients with single and multiple MAGEA family responses. 
Numbers of CTAg-specific  IFNγ  secreting  cells  in  PBMC  for  each  patient in NSGCTT (a), 
mGCT (b) and seminoma (c). Dotted line shows the threshold for positive response, 
defined as double the highest response present in healthy donors. Responses to MAGEA1 
(green circle), MAGEA3 (blue square), and MAGEA4 (red triangle) are shown. 
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Figure 62. Frequency of responses to multiple MAGE antigens according to tumour 
type. 
The number of patients which respond to MAGEA1, MAGEA3, MAGEA4 or a 
combination of these antigens is shown. Responding patients are divided according to 
tumour type. NSGCTT n=3, mGCT n=3, seminoma n=15. 
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MAGE-specific T cell Frequency Diminishes Over Time 
The majority of TGCT patients were treated by radical orchidectomy to remove the 
primary tumour, thus reducing tumour antigen load. Highly elevated levels of MAGE-
specific T cells detected in a significant proportion of TGCT patients imply repeated 
antigenic stimulation of these cells, and subsequent clonal expansion. We therefore 
investigated whether the removal of tumour antigens affected the magnitude of MAGE-
specific responses in TGCT patients. Specifically, we compared the levels of MAGE-
specific T cells in patients shortly after tumour removal but before chemotherapy, and at 
various intervals following treatment. Figure 63 shows the representative kinetics of a 
MAGEA3 and MAGEA4-specific response in a patient with and a patient without a 
response prior to chemotherapy.  
 
We further demonstrate the dynamics of MAGE-specific responses in individual patients, 
pre and post adjuvant chemotherapy. A clear reduction in the frequency of MAGE-specific 
cells over time was observed in all patients assessed (Figure 64). We observed a significant 
reduction in MAGE-specific T cells as soon as two weeks after treatment, in patients with a 
known response before treatment. The diminishing frequency of MAGE-specific T cells 
was even more apparent at later time points post chemotherapy. Next we compared the 
frequency of MAGE-specific T cells before treatment with the frequency of MAGE-specific 
T cells at the latest time point at which a blood sample was obtained for a particular 
patient (between 3 and 18 months after treatment). We show that the frequency of MAGE-
specific T cells was significantly lower at the later time point for all MAGE antigens 
(p=0.0156), in all patients assessed (Figure 65a). We then determined the extent of the 
reduction in MAGE-specific T cells over time by calculating the percentage decrease in cell 
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numbers relative to the frequency of MAGE-specific cells before treatment (0%). The 
median decrease was shown from all available time points and grouped into 2 categories. 
We observed a stepwise decrease in the frequency of MAGE-specific cells over time, for all 
MAGE antigens (Figure 65b). Specifically, MAGEA1 responses were reduced by a median 
of 93.1% over the course of observation. Similarly, MAGEA3-specific cells were 
diminished by 87.4% and MAGEA4 by 94.8%. It is important to note that these responses 
were greatly reduced but low frequencies of cells were still detectable in the majority of 
patients. 
 
To compliment these results, we ascertained whether patients with dextramer responses 
prior to treatment experienced a reduction in the proportion of MAGE-specific T cells 
following treatment. We investigated the frequency of MAGE-specific T cells in three 
patients, each with a response to a different peptide, before, and at two intervals after 
chemotherapy. Representative examples show the detection levels of MAGE-specific CD8 
T cells pre and post chemotherapy (Figure 66a). We observed a general reduction in the 
proportion of MAGE-specific T cells over time. In all cases, frequencies had diminished to 
levels below the positive response threshold nine months post chemotherapy (Figure 66b). 
These observations are in agreement with our ELISPOT results where we demonstrate a 
decline in MAGE-specific T cells over time following treatment. 
 
We also investigated the frequency of MAGE-specific T cells at various time points after 
treatment in patients who did not have a detectable response prior to treatment. Patients 
where a response was not detected before chemotherapy showed no significant change in 
the frequency of MAGE-specific T cells at intervals post treatment (Figure 67). 
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Figure 63. Kinetics of MAGE-specific responses determined using ELISPOT assay. 
Representative ELISPOT spots from a TGCT patient with (a) and without (b) a MAGEA3 
and MAGEA4 response prior to chemotherapy (pre). Each spot represents a single 
antigen-specific  IFNγ  secreting  cell.  The presence of MAGE-specific cells at pre, 3 months 
and 12 months post chemotherapy are shown. A reduction in the frequency of spots 
indicates a reduction in the proportion of CTAg specific cells in PBMC of TGCT patients.   
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Figure 64. Kinetics of MAGE-specific responses in TGCT patients with a positive 
response prior to chemotherapy. 
Numbers of CTAg-specific   IFNγ   secreting   cells  were  determined  prior   to   chemotherapy  
treatment (0 months), and then at specific time-points following the onset of treatment 
(0.5,3,6,9,12,15,18 months). Each graph shows one patient. Dashed horizontal line shows 
the threshold for positive response, defined as double the highest response determined in 
healthy donors.  
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Figure 65. The reduction of MAGE-specific T cells following chemotherapy. 
The frequency of MAGEA1, MAGEA3, and MAGEA4 -specific T cells at pre and post 
chemotherapy (a). Post chemotherapy is defined as the latest time point available in this 
patient cohort, and is between 3 and 18 months post treatment. The overall reduction of 
MAGEA1, MAGEA3, and MAGEA4 -specific T cells at various time points post 
chemotherapy, of all TGCT patients with a positive response prior to chemotherapy (b). 
Chemotherapy onset defined as 0 months. Each point represents the median value. 
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Figure 66. Dynamics of a single epitope MAGE-specific CD8 T cell response following 
chemotherapy. 
Flow cytometry contour plots illustrate the detection of KVAE, EVDP and RVRF-specific T 
cells pre (left column) and post (right column) chemotherapy (a). Dextramer positive cells 
are highlighted in blue. The frequency of MAGE responses were determined at 2 intervals 
post chemotherapy and represented as percentage of total CD8 T cells (b). The dotted line 
represents the 0.05% threshold for a positive response. 
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Figure 67. Kinetics of MAGE-specific responses in TGCT patients without a response 
prior to chemotherapy. 
Numbers of CTAg-specific   IFNγ   secreting   cells  were  determined  prior   to   chemotherapy  
treatment (0 months), and then at specific time-points following the onset of treatment 
(0.5,3,6,12,15,18 months). Each graph shows one patient. Dashed horizontal line shows the 
threshold for positive response, defined as double the highest response determined in 
healthy donors.  
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MAGE-specific Cells are Predominantly Cytotoxic CD8 T Cells 
In a smaller cohort of patients (n=10) where a positive MAGE-specific response was 
detected, we defined the subtype and functionality of cytokine secreting T cells. PBMC 
from TGCT patients were stimulated with appropriate overlapping MAGE peptides, and 
IFNγ and TNFα production was assessed. The majority of cells secreting inflammatory 
cytokines in response to MAGE peptide stimulation were found to be CD8 T cells (Figure 
68a,b). However, cytokine secreting MAGE-specific CD4 T cells were present at lower 
frequencies in the majority of patients, and correlated positively with the frequency of 
MAGE-specific CD8 T cells (p=0.0156) (Figure 68c). Interestingly, CD8 T cells were 
predominantly TNFα   only secreting cells (IFNγ-TNFα+), whereas CD4 T cells comprise 
equal proportions of TNFα   only and dual secreting (IFNγ+TNFα+) cells. MAGE-specific 
IFNγ only  secreting  cells   (IFNγ+TNFα-) were at particularly low levels in the majority of 
patients. Noticeably,   IFNγ   only secreting cells were readily detectable when stimulated 
with CEFT peptides, whereas TNFα only secreting cell were very rare. The results suggest 
tumour-specific T cells, specifically MAGE-specific CD8 T cells, have a unique cytokine 
profile. 
 
Next we determined the cytotoxic capacity of CD8 T cells in relation to the cytokines they 
secrete, by assessing CD107a surface expression (Figure 69). A median of 99.89% of the 
IFNγ+TNFα+ cells expressed CD107a on their surface, and 88.51%   of   the   IFNγ-TNFα+ 
subset. Surprisingly,  only  21.67%  of   IFNγ+TNFα- cells had detectable cytotoxic potential. 
The cytokine and cytotoxicity profile of these cells is similar to that described earlier with 
the MAGEA3-specific T cell clone. 
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Figure 68. The secretion of inflammatory cytokines,   IFNγ   and   TNFα,   from  CD4 and 
CD8 T cells following MAGE peptide stimulation. 
Patients with MAGE-specific T cell responses were determined by IFNγ  ELISPOT.  PBMC  
from a number of these patients (n=10) were stimulated with the appropriate MAGE 
overlapping peptides to determine the T cell subset(s) (CD4 and/or CD8) that are releasing 
inflammatory cytokines. The  proportion  of   IFNγ+TNFα-,   IFNγ-TNFα+ and IFNγ+TNFα+ T 
cells following stimulation was determined for each patient (a) and the average of all ten 
patients (b), and represented as a percentage of total CD4 or CD8 T cells. Error bars 
represent SEM. Correlation between the proportion of cytokine secreting CD4 T cells and 
CD8 T cells was determined (c). Spearman's rank correlation coefficient (r) and 
significance (p) were determined. Significant p values are highlighted in bold type. Each 
symbol represents an individual patient.  
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Figure 69. The magnitude of degranulation of CD8 T cells that secrete single or multiple 
cytokines. 
CD8 T cells were identified by the positive expression of CD3 and CD8. They were 
analysed   for   expression   of   IFNγ and TNFα following stimulation with the appropriate 
MAGE overlapping peptides. Unstimulated cells were used as a negative control, CEFT 
peptides were used as a positive control (a). Representative histograms of CD107a surface 
expression   on   IFNγ+TNFα-,   IFNγ+TNFα+,   and   IFNγ-TNFα+ subsets following MAGE 
peptide stimulation is shown (b). The proportion of CD107a expressing cells within each 
cytokine subset is shown (c). Bars represent mean. Error bars indicate SEM. Data analysed 
by Kruskal-Wallis   with   Dunn’s   multiple comparison test. * denotes p<0.05, *** denotes 
p<0.001. 
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Figure 70. Summary of MAGE-specific T cell immunity in TGCT patients 
Diagrammatic representation of the presence of MAGE-specific T cells in patients 
according to disease type and stage (a).  The frequency of MAGE-specific T cells is low or 
absent in healthy donors and NSGCTT patients with localised disease. Multiple MAGE 
responses are frequently detected in seminoma patients regardless of tumour stage. 
MAGEA3 responses, but not MAGEA1 or A4, are detectable in NSGCTT patients with 
metastatic disease.  The frequency of peripheral blood-derived MAGE-specific T cells 
declines by up to 95% following treatment (b). 
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Discussion 
The main finding in this chapter is the frequent development of spontaneous T cell 
immunity in TGCT patients to multiple tumour-specific antigens, namely MAGEA1, A3 
and A4. We show a decline in MAGE-specific T cells overtime, which is likely to be 
associated with reduced tumour-antigen load. In addition, CD8 T cell responses dominate 
the MAGE-specific T cell pool.  The key points are summarised in Figure 70. 
 
Dextramer analysis reveals MAGE-specific CD8 T cells in TGCT patients 
CTAg expression has been observed in a wide range of tumours and can induce a cellular 
immune response towards the tumour, which could play an important role in controlling 
disease progression (Boon and van der Bruggen, 1996). Many classical seminomas have 
been shown to express MAGEA1, MAGEA3 (Cheville and Roche, 1999) or MAGEA4 
(Aubry et al., 2001), yet NSGCTT have been negative in the majority of cases (Grobholz et 
al., 2000, Chen et al., 2013). Another study demonstrated greater levels of MAGEA1, A3, 
and A4 mRNA transcripts in seminoma patients compared to NSGCTT patients, although 
transcripts were detectable in both tumour types (Hara et al., 1999). We examined CTAg 
expression in TGCTs at both the gene and protein level. Most importantly, we show that 
concomitant expression of different MAGE proteins in the same specimen. Other studies 
have shown NY-ESO-1 expression in carcinoma in situ (CIS) cells, which are the pre-
cancerous lesions from which all germ cell tumours arise, although the later tumours cease 
to express this antigen (Satie et al., 2002). In this present study, we found a single 
seminoma patient with NY-ESO-1 expression, which suggests this tissue contained 
elements of immature cancer precursors and is rarely expressed in fully differentiated 
disease. MAGEB1 expression has previously been shown in all seminomatous tumours 
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(Yuasa et al., 2001). Conversely, we demonstrate a lack of expression of this antigen in all 
seminoma tissues, although expression in healthy testis was detected. The vast 
lymphocytic infiltrate observed in seminoma may underestimate the level of CTAg 
expression, as our method determined the expression of antigens in whole tumour tissue 
and could not discriminate against immune cells. In addition, focal antigen expression 
may be missed in a single small biopsy, and may not be representative of the entire 
tumour mass. 
 
An interesting question is whether spontaneous CD8 T cell responses are generated to 
MAGE antigens in TGCT patients. The detection of such responses would suggest the 
priming of naive antigen specific CD8 T cells directly by the tumour or through cross-
presentation by APCs. The resulting expansion of such cells following recognition of 
cognate antigen, if they do indeed exist, should be detectable in peripheral blood of TGCT 
patients. We initially performed a comprehensive examination of peripheral blood-derived 
CD8 T cell responses to CTAgs in patients with testicular cancer, using dextramer 
complexes. The only previously documented CD8 T cell response to CTAg proteins in 
TGCT patients was detected using in situ tetramer staining, where they demonstrated the 
presence of MAGEA3-specific T cells in primary TGCT tissue (Hadrup et al., 2006). 
 
In the present study, dextramer analysis revealed that MAGEA1 and MAGEA3 -specific 
CD8 T cells are detectable in peripheral blood of TGCT patients. Detectable levels of 
MAGE specific CD8 T cells were demonstrated in 8/22 patients following short-term 
epitope specific expansion. MAGEA1 and MAGEA3 responses were detected in seminoma 
patients, which correspond with the expression profile of these antigens in this tumour 
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subtype. Interestingly, one seminoma patient in this cohort generated both a MAGEA1 
and MAGEA3 response, and another patient generated a MAGEA3 response against two 
peptides which are presented through different HLA molecules. Combined, the findings 
from both patients demonstrate the broad immunogenicity of seminomatous tumours, and 
the efficient presentation of these antigens to CD8 T cells.  
 
In this assay, it is possible that a significant proportion of the MAGE- specific CD8 T cells 
we have observed may be attributable to in vitro expansion. Therefore we are unable to 
unequivocally determine whether MAGE-specific T cells in patients were in fact 
spontaneous tumour-specific responses, or inflation of naive MAGE-specific T cells in 
vitro. Due to the small volume of blood received from patients, T cells had to be expanded 
in vitro, which did not allow us to accurately surface  phenotype these cells and therefore 
determine if they were derived from the naive or memory T cell pool. We assume that a 
single round of short term antigenic stimulation would not expand antigen specific naive 
T cells to a detectable level. In support of this assumption, a previous study using PBMCs 
from healthy donors, showed that five rounds of peptide loaded autologous DC 
stimulation was required to elevate antigen specific effector T cells to detectable levels (Li 
et al., 2004). Spontaneous and readily detectable MAGE-specific responses may be 
underestimated as some patients may have mounted a response below the detection limit 
of this assay. Overall, we speculate that MAGE-specific effector memory T cells are 
preferentially expanded following short-term culture with epitope specific peptides, which 
were originally derived from in vivo primed T cells.  
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In this set of experiments, we did not observe a single CD8 T cell response to MAGEA4. As 
previously discussed, MAGEA4 is expressed in seminoma tissues and therefore a 
MAGEA4-specific T cell response could potentially be mounted in these patients. It is 
important to note that the present methodology only covered a single MAGEA4 epitope 
thus we cannot be certain that a MAGEA4 response is not generated in these patients. The 
fact that more than 50 CTAg genes have been described with many immunogenic 
epitopes, of which we are only covering a few of these antigens suggests we are 
considerably underestimating the frequency and spectrum of the CTAg-specific response 
in TGCT patients using dextramer analysis. 
 
The development of multiple MAGEA family specific T cell responses is dependent on 
tumour type 
Next, we determined the actual frequency of CTAg-specific T cells in healthy donors and 
TGCT   patients   using   an   IFNγ   ELISPOT   method,   in   combination   with full protein-
spanning overlapping 15mer peptides. This method allowed the simultaneous detection of 
functional CTAg-specific CD8 T cells and CD4 Th1 cells, covering all known and unknown 
epitopes for a particular antigen. This methodology relies on the presentation of peptides 
to T cells by APCs and by T cells themselves (Burrows et al., 1992).  
 
As expected, all CTAg-specific T cells were absent or at low frequencies in all 17 healthy 
donor where specific cells were at frequencies between 0 and 0.0041% of total PBMC for 
each antigen. It is not surprising that these cells are detectable in healthy donors, where 
they presumably reside in the naive T cell repertoire, ready for primary encounter of 
cognate antigen. In agreement with this, it has been estimated that in the naive CD8 T cell 
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pool a frequency of approximately 1/105 T cells are specific for a given pMHC complex 
(Arstila et al., 1999). Undetectable levels in tumour-free individuals could be explained by 
levels present below the detectable threshold of this assay, or the fact that naive T cells 
predominantly circulate in lymphoid tissue and therefore are undetectable in peripheral 
blood. 
 
MAGEA-specific responses were found in 21/49 TGCT patients, many of which had 
responses to 2 or more MAGEA antigens with up to 0.149% of cells being specific to a 
particular MAGE antigen. In agreement with our dextramer assay, NSGCTT patients only 
generated a response towards MAGEA3. Interestingly, mGCT patients also demonstrate 
multiple MAGE responses suggesting it is the seminoma elements in these tumours that 
are provoking the responses. We speculate that the generation of a MAGEA3 response in 
the absence of primary MAGEA3 expression in NSGCTT tissue, could be explained in two 
ways. Firstly by immunoediting of the antigenic phenotype of the tumours by specific 
cytotoxic immune responses (Dunn et al., 2004a). Here, particular MAGE antigens would 
have been expressed in some tumour cells at some point in time, but have now been 
eradicated by the immune system, so protein expression is no longer detectable. Secondly, 
distant metastases may develop that express MAGEA3 and the immune response may be 
generated toward this secondary tumour tissue. In support of the latter, tumour diagnosis 
indicated that patients with a MAGEA3 response in this NSGCTT cohort did indeed 
exhibit metastatic disease. We therefore wonder whether the expression of MAGEA3 is 
required by tumour cells to aid the migration from the primary tumour, and the presence 
of MAGEA3-specific cells may act as a useful indicator of disease progression and 
metastatic potential of NSGCTTs. In support of this, previous studies have associated 
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MAGEA family antigen expression with lymph node metastasis and lymphatic vessel 
invasion (Kavalar et al., 2001, Katano et al., 1997). MAGEA3 has been shown to be a 
mediator of extracellular matrix protein function, which promotes tumour cell migration 
and enhances invasive cancer cell growth (Liu et al., 2008). We speculate that tumour 
metastases derived from primary NSGCTTs express MAGEA3 to enable effective 
migration. In doing so, MAGEA3 expression increases the immunogenicity of the tumour, 
subsequently provoking an anti-MAGEA3 response, which is detectable in affected 
patients. Interestingly, we show that the stage of disease in seminoma patients does not 
affect the probability of generating an immune response towards MAGE antigens, nor 
does it correlate with the magnitude or multitude of the detectable responses.  
 
Concerning the relationship between MAGE expression and the presence of detectable 
MAGE-specific T cell responses, one responding patient (91PN) in whom we detected 
multiple MAGE responses showed very low or absent MAGE protein expression in 
tumour tissue. As mentioned previously, this may simply reflect the incomplete covering 
of antigen expression due to the small biopsy size which therefore may not be 
representative of the entire tumour mass. The only other patient (47MH) in which we have 
CTAg expression data, showed very low or absent levels of MAGE proteins in tumour 
tissue and accordingly elevated levels of MAGE-specific T cells were not detected. 
 
Patients with testicular tumours containing seminomatous elements commonly exhibited 
responses to a combination of MAGEA1, A3 and A4 antigens. MAGEA family antigens are  
co-expressed in various tumours, which suggest their regulation is part of a coordinated 
gene expression programme. The inclination towards genome-wide demethylation of CpG 
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islands in cancer (De Smet C, 1996), may largely explain the existence of multiple CTAg 
expression in seminoma tissue, and the multiple MAGE-specific responses we found in 
these patients. Sequence homology between all three MAGE antigens examined in this 
study is around 80% (Lurquin et al., 1997). Consequently, overlapping peptides spanning 
the length of one particular MAGE antigen could potentially present a proportion of very 
similar peptides, stimulating the same T cells even though a different set of peptides were 
used. Interestingly, if this were the case then elucidating the exact peptide would be of 
particular interest, in the context of future treatments, to develop immunotherapies which 
target multiple MAGE-antigens with a single TCR specificity. Unfortunately, we could not 
determine the exact peptides in which responding T cells were specific given that single 
peptides from the overlapping peptide pools were unavailable. 
 
In this study it was noted that MAGEA4 responses were highly prevalent in TGCT 
patients as demonstrated using the ELISPOT and overlapping peptide method. This 
suggests the dextramer assay may hugely underestimate the rate of a CTAg response. 
Importantly, it also suggests many immunogenic epitopes exist that are currently 
undefined and future works requires the elucidation of such epitopes.  
 
NY-ESO-1 and MAGEB1 –specific T cell responses are not generated in TGCT patients 
As previously discussed, both tumour development and chemotherapy may inadvertently 
breakdown the blood-testis-barrier (BTB). We and others show that MAGEA family, NY-
ESO-1 and MAGEB1 antigens are highly expressed in healthy testicular tissue. If 
breakdown of the BTB occurs, spermatogenic cells expressing many highly immunogenic 
proteins, including these CTAgs, may be compromised and released antigens could be 
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subsequently presented to T cells. If this were the case, we would expect to detect elevated 
responses to these antigens, especially towards NY-ESO-1, which has been described as 
one of the most immunogenic CTAgs. We clearly demonstrated that responses are not 
generated against NY-ESO-1 or MAGEB1 in patients with testicular cancer. This suggests 
MAGE responses observed in TGCT patients are provoked by tumours expressing these 
antigens and not indirectly by disruption of healthy testicular architecture during tumour 
progression. Further work is required to examine T cell responses to other CTAgs, 
particularly MAGEC1, which has recently been shown to be expressed in seminoma (Chen 
et al., 2011), although very few T cell epitopes of MAGEC1 have been described to date. 
Using our ELISPOT method and overlapping peptides to MAGEC1 would enable the 
discovery of new T cell epitopes. 
 
The effects of age on MAGE-specific T cell responses in TGCT patients 
Next, we investigated the effect of age on the development of an immune response to 
MAGE antigens and correlated this with the magnitude of the response. We showed that 
the likelihood of generating a response to a MAGE antigen is not dependent on age, 
although the magnitude of a MAGEA4 response does decline with age. The mechanism 
whereby the frequency of MAGEA4-specific cells is affected by ageing whilst the other 
antigens are not is unclear. We show that the majority of MAGEA4 responses (88%) are 
accompanied by other MAGE responses. It could be that MAGEA4 is less immunogenic 
than other MAGE antigens and the subsequent proliferation of MAGEA4-specific cells is 
lower, which may be further exacerbated in older patients. An aging immune system may 
be less efficient at generating a primary response to newly encountered antigens due to a 
reduced naive T cell compartment. Here, an unexplained preferential reduction of naive T 
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cells specific to MAGEA4 epitopes may occur with increased age. We demonstrated that 
the age of disease onset in seminoma patients was significantly higher than NSGCTT 
patients. Since MAGE responses are more common in seminoma patients, even though the 
mean age of disease onset was 15 years greater than NSGCTT patients, we speculate that 
tumour type has a far greater effect on the generation of MAGE responses than age.  
 
MAGE-specific T cell responses diminish over time 
The treatment schedule for patients with testicular cancer involves radical orchidectomy to 
remove the primary tumour, followed by adjuvant chemotherapy to eradicate residual 
disease. Combined, this treatment schedule reduces tumour burden and tumour antigen 
load, as proven clinically by the simultaneous reduction in peripheral blood tumour 
markers. Elevated levels of MAGE-specific T cells, which we have observed in patients 
shortly after tumour removal (but before chemotherapy), diminish considerably following 
treatment. Patient 09DW had elevated frequencies of both MAGEA3 and MAGEA4 -
specific T cells, however, within 3 months these levels had dropped considerably. 
Interestingly, this patient did not receive chemotherapy treatment following 
orchidectomy, suggesting it may be the loss of tumour antigens following tumour removal 
and not the cytotoxic effects of chemotherapy that leads to the decline of MAGE-specific T 
cells over time. 
 
We followed a cohort of patients for several months post treatment and found that during 
this time the majority of MAGE-specific cells were lost; although detectable levels were 
still observed in most patients up to 18 months later. We also demonstrated this in an 
epitope-specific manner by dextramer analysis, and found a marked decrease in T cells 
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specific to single MAGEA1 and MAGEA3 epitopes in all patients analysed. We speculate 
that the decline in MAGE-specific response over time mimics the kinetics of adaptive 
immunity following acute infection. Here, we assume the presentation of tumour antigens 
to naive T cells activates the primary immune response leading to elevated levels of 
MAGE-specific T cells, which we have described. Many of these cells are likely to enter the 
inflamed tumour environment, hence the large lymphocytic infiltrate observed in TGCTs. 
We have demonstrated the presence of large frequencies of MAGE-specific T cells in 
circulation of many TGCT patients, which were lost following tumour removal. Usually, 
an infection is cleared by the adaptive immune response, but in our case the tumour is not 
cleared by the immune system, but is done so by treatment. Nevertheless, the dose of 
tumour antigen falls below the response threshold and we assume this leads to the death 
of the majority (85 to 95%) of activated MAGE-specific effector T cells by apoptosis, similar 
to that observed following clearance of viral and bacterial infections (Badovinac et al., 2002, 
Kaech et al., 2002b). Following this contraction phase, a small fraction of the effector pool 
differentiate further to form the memory pool, which is maintained in the absence of 
antigen for long periods of time (Lau et al., 1994).  
 
We postulate that the remaining MAGE-specific T cells which we observed in some 
patients many months after tumour antigen removal, are in fact these long-lived memory 
pool. Previous studies have shown that this long-lived memory pool retains the potential 
to   rapidly   produce   IFNγ   and   TNFα   and   to   quickly   reacquire   cytotoxic   activity   when  
exposed to antigen (Barber et al., 2003, Kaech et al., 2002a). It would be interesting to 
speculate that these long-lived memory T cells in TGCT patients may protect them from 
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subsequent tumour development. Protection could be generated not only against TGCTs 
but also against other cancers that express MAGEA-family antigens.  
 
Interestingly, many but not all patients we examined had detectable levels of MAGEA-
specific T cells following tumour removal, suggesting a substantial memory pool may not 
have been generated in some patients. Many experimental models have demonstrated that 
effective CD8 T cell immunity requires CD4 T cells for initiating and maintaining 
antitumor immune responses, and also to enable the generation of sustainable memory 
cells (Klebanoff et al., 2006). We have definitively shown that MAGE-specific CD4 T cells 
do exist alongside MAGE-specific CD8 T cells in the majority of TGCT patients, but are at 
significantly lower frequency than the CD8 T cell counterparts. Although the frequency of 
MAGE-specific CD4 T cells correlates positively with the MAGE-specific CD8 T cell 
repertoire, this low frequency may not be adequate to induce the generation of long-lived 
memory T cells. In addition, CD8 T cells that do populate the memory pool without CD4 T 
cell help have been shown to respond poorly to re-stimulation with antigen (Wherry and 
Ahmed, 2004). 
 
 The complete loss of MAGE-specific T cells over time, which was demonstrated in some 
TGCT patients in the present study, may be due to the lack of MAGE-specific CD4 T cells. 
We cannot rule out however the possibility that overlapping MAGE peptide pools made of 
15-mer peptides more efficiently stimulated CD8 T cells than CD4 T cells. However, the 
majority of known MAGE immunogenic peptides expressed through MHC class II are 
between 13 and 22 amino acids long, suggesting CD4 T cell responses should be induced 
as efficiently as CD8 T cell responses.  
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The consequences of MAGE-specific responses in clinical outcome of TGCT patients are 
not definitively clear. In this context, it would be useful to conduct follow-up studies to 
determine whether TGCT patients with recurrent disease generated a MAGE response in 
the first instance. Low relapse rates in these patients would hinder this analysis, however 
the fact that relapse usually occurs within the first two years following treatment, would 
suggest it may be quickly achieved with a large enough patient cohort. We performed a 
follow-up survey in a small cohort of TGCT patients where MAGE-specific T cell 
responses had been assessed. In this cohort, only one patient (HP07) experienced tumour 
recurrence and he lacked responses for all MAGE antigens. Whether relapse was due to 
the absence of natural T cell immunity towards the tumour could not be determined.  
 
Next, we determined whether a MAGEA response could be generated in seminoma and 
mGCT patients following chemotherapy. A response was not detected in these patients 
prior to chemotherapy, nor was one generated following chemotherapy. This could imply 
that chemotherapy-induced lysis of residual tumour cells does not provoke a T cell 
response, or that residual tumour cells are simply not present in these patients. 
Alternatively, a T cell response is being generated but not towards MAGE antigens, 
possibly due to the lack of expression of MAGE antigens in these cells.  
 
The functionality of MAGE-specific T cells from TGCT patients 
Next, we determined the functionality of CTAg-specific CD8 T cells isolated from 
peripheral blood of TGCT patients. MAGE-specific CD8 T cell responses were detected in 
a number of patients using dextramers, yet the frequency was too low to effectively 
analyse their functionality. Instead we generated a T cell clone from a seminoma patient, 
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which was specific for MAGEA3168-176 peptide (EVDP), where expression was restricted 
through HLA-A1. The EVDP-specific clone demonstrated cytokine production and 
cytolytic activity towards peptide-loaded targets. More importantly, cytotoxicity was 
directed towards an HLA-A1-expressing tumour cell line (HT-29) presenting 
endogenously processed MAGEA3 antigen. Interestingly, HT-29 cells induced cytotoxicity 
(degranulation) in up to 40% of MAGEA3-specific cells without inducing cytokine 
production; a phenomenon that was practically absent when cells were stimulated with 
peptide loaded targets. We assume this is due to the nature of stimulation, which may be 
more physiological than transformed B cells (LCLs) to present antigen. HT-29 cells are 
known to express MICA on their surface (Salih et al., 2002), and it could be the interaction 
with NKG2D on the T cell surface that induced this greater cytotoxic capacity we 
observed.  
 
We show that MAGE-specific CD8 T cell responses are generated in TGCT patients 
although the cytokine profile of these cells following stimulation was unexpected. The 
majority  of   cytokine   secreting  cells   secreted  TNFα  alone;  a   smaller  proportion  produced  
both  TNFα  and  IFNγ, and very few produced IFNγ alone. We confirmed this observation 
by stimulating PBMC, from patients with a known response, with overlapping MAGE 
peptides and examined subsequent cytokine production. Similarly, we found the majority 
of MAGE-specific CD8 T cells that produced cytokine, only  secreted  TNFα.  This  was  also  
apparent in CD4 T cells but to a lesser extent. Only a very small percentage of cytokine 
secreting  cells  secreted  IFNγ  alone,  but  the  ones  that  did  showed  a  diminished  ability  to  
degranulate. In agreement with our observations, a recent study investigating TAA-
specific CD8 T cells in hepatocellular carcinoma demonstrated their impaired ability to 
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produce  IFNγ  (Flecken et al., 2013).  Others  have  shown  impaired  IFNγ  secreting  capacity  
of HCMV-specific CD8 T cells among kidney transplant recipients (Yang et al., 2008). This 
suggests that the efficacy of MAGE-specific CD8 T cell response is functionally limited, 
presumably due to an exhausted or anergic phenotype induced within the suppressive 
tumour environment.  
 
High-avidity recognition of tumour antigens has been shown to be essential for effective in 
vivo anti-tumour responses (Zeh et al., 1999). We therefore determined the avidity of the 
MAGEA3-specific T cell clone for its cognate antigen, EVDPIGHLY. The avidity of this T 
cell clone was defined by the concentration of peptide required to elicit a T cell response 
after loading onto target cells (LCLs). We showed that its avidity was similar to MAGE-
specific clones previously generated in our laboratory from AML and myeloma patients. 
In this assay, a high avidity T cell was classified as requiring < 1 nM peptide loaded on 
target cells for activation and subsequent cytokine release. Our clone required between 100 
and 1000 nM peptide to induce a half maximal response (EC50), suggesting our clone has a 
low avidity for cognate antigen (Snyder et al., 2003). Among the many immunosuppressive 
mechanisms mediated by the tumour microenvironment, impaired T cell activation and 
clonal expansion and diminished effector function would fit with the generation of low 
avidity MAGE-specific CD8 T cells, as detected in this present study. 
 
However, we have shown that these low avidity MAGE-specific T cells are able to 
sufficiently recognise and induce cytotoxicity towards presented antigen even though the 
avidity for cognate antigen may be low. From this data we could speculate that MAGE-
specific T cells were anergised or exhausted in vivo and may regain full functional 
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competence, including cytokine secretion, upon repeated in vitro peptide stimulation with 
IL-2. The IFNγ   ELISPOT   method   used   to   quantify   the   magnitude   of   specific   MAGE  
responses may underestimate the frequency of MAGE-specific cells, since multiple 
cytokine profiles exist. Populations of both MAGE-specific CD4 T cells and CD8 T cells 
show differential secretion of inflammatory cytokines,  whereby  many  did  not  secrete  IFNγ  
but  were  still  cytotoxic.  Future  studies  would  perhaps  utilise  TNFα  as  a  means  to  quantify  
MAGE-specific cells in an ELISPOT assay,   as   TNFα   only   secreting   cells   demonstrate  
cytotoxic potential. In addition, granzyme B and perforin would also be measured to 
quantify more specifically the cytotoxicity of MAGE-specific T cells. 
 
Due to the rare availability of TIL, we have only explored the specificity of tumour-specific 
T cells in peripheral blood. At this stage, we can only assume that MAGE-specific T cells 
found in the peripheral blood of TGCT patients also exist within the tumour mass. 
Whether the functionality of these cells mimics what we have demonstrated in vitro is 
unclear. We speculate that immunosuppressive mechanisms are at play within the 
tumour, which may have a detrimental effect on the anti-MAGE response. 
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Conclusion 
In conclusion, we show that pMHC dextramer complexes are valuable in the detection and 
isolation of epitope-specific CTAg responses from peripheral blood of TGCT patients. 
However, the poor detection threshold, the requirement for in vitro expansion and the 
incomplete picture of the spectrum and magnitude of responses, meant a more 
comprehensive and quantitative approach had to be undertaken. By combining MAGE 
overlapping peptides with a highly sensitive  IFNγ  ELISPOT  assay,  we  show for the first 
time that multiple MAGEA family-specific T cells are elevated in seminoma and mGCT 
patients. Interestingly, NSGCTT patients only developed responses towards MAGEA3 and 
were shown to be associated with disease progression. MAGE-specific T cells were 
cytotoxic in vitro, but  many  had  an   impaired  ability   to  produce   IFNγ   following  peptide  
stimulation. The physiological relevance of MAGE responses in limiting tumour growth 
and metastasis in vivo remains to be determined.  
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CHAPTER 5: GENERAL DISCUSSION 
 
The importance of the immune system in protecting against cancer was originally 
proposed in   Burnet’s theory of cancer immunosurveillance. This model states that the 
immune system recognises transformed cells as they arise and together, the innate and 
adaptive arms of the immune system eradicate these cells. Supporting this model is the 
fact that immunocompromised patients are more susceptible to tumour development 
(reviewed in (Dunn et al., 2004b, Zitvogel et al., 2006)). In addition, the generation of 
endogenous immunity to tumour antigens, as demonstrated in this study, provides 
compelling evidence in support of natural immunosurveillance. Expression of stress 
ligands such as MICA/B and ULBPs, or the presentation of tumour-antigens, such as the 
MAGEA family, on the surface of tumour cells targets them for destruction. Despite the 
diverse range of immune mechanisms that target transformed cells, the high prevalence of 
cancer would indicate that the immune response is unable to effectively control its growth 
and spread (Dranoff, 2009). One mechanism of tumour immune escape is the promotion of 
immune cell dysfunction or exhaustion.  
 
In the present study, we have frequently detected multiple MAGEA family-specific T cells 
in peripheral blood of patients with tumours containing seminomatous elements. In 
contrast, MAGE-specific cells were only present at very low levels in healthy individuals 
and are only elevated in NSGCTT patients with metastatic disease. We presume the low 
levels we detect in healthy individuals are antigen inexperienced and are therefore 
contained within the naive T cell pool. We show that the majority of T cells within TGCT 
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lesion are TEM cells. We believe the significant increase in peripheral blood TEM cells in 
TGCT patients correlates with the elevated incidence of tumour-specific T cells, some of 
which are antigen-experienced MAGE-specific T cells. We observed considerable 
enrichment   of   the   TCRVβ   repertoire   of   TIL,   however   we   failed   to   find   evidence   of  
restricted  TCRVβ  usage  between  patients.  This  suggests  that  there  is  likely  to  be  extensive  
TCR diversity among tumour reactive T cells, along with multiple MAGE antigen 
specificities and TCR affinities.  
 
Intracellular cytokine staining following MAGE overlapping peptide stimulation revealed 
the presence of both MAGE-specific CD4 and CD8 T cells in peripheral blood of TGCT 
patients. Pro-inflammatory MAGE-specific CD8 T cells were more prevalent than their 
MAGE-specific CD4 T cell counterparts. We did notice however a significant proportion of 
T cells within the tumour that did not secrete inflammatory cytokine following in vitro 
stimulation. We speculate that these T cells are irreversibly dysfunctional or are releasing 
immunoregulatory cytokines. Although CD8 T cells are predominately associated with the 
production of inflammatory cytokines, there is evidence suggesting they secrete 
immunoregulatory cytokines including IL-4 and IL-10 (Schuler et al., 2001). Moreover, CD4 
T cell subsets including Th2 and Tregs are associated with the release of 
immunosuppressive cytokines including IL-4, IL-10  and  TGFβ.  In  addition,  we  detected  a  
significant increase in CD161-expressing CD4 T cells in the tumour indicative of IL-17-
secreting Th17 cells. Further studies are required to determine the extent of pro-tumour 
and anti-tumour activity of these T cell subsets in TGCTs. We may however be 
underestimating the extent of MAGE-specific responses, especially in the case of CD4 T 
cells. There could potentially be a greater proportion of MAGE-specific CD4 T cells that 
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secrete pro-tumour associated cytokines, which were not investigated in this study. The 
secretion of immunoregulatory cytokines by MAGE-specific cells may favour an 
immunoregulatory response, contributing to tumour immune escape and consequently 
tumour progression. Understanding the potential roles of Th1, Th2, Th17 and Treg subsets 
in a MAGE-specific response may help develop improved therapeutic strategies for 
boosting an anti-tumour response. 
 
The locality of initial tumour antigen recognition is currently unclear but our findings 
suggest that MAGE-expressing tumours do provoke a T cell response to such antigens. 
Unfortunately, we were unable to clarify whether T cells infiltrating the tumour were 
CTAg-specific due to the rare availability of tumour tissue, and the potentially 
unresponsiveness of TIL to TCR stimulation with native antigen. Nevertheless, the fact 
that they are detectable in peripheral blood would suggest that TIL are likely to contain a 
vast number of T cells with MAGE specificity. With this in mind, the lack of T cell 
proliferation and cytokine production by cells isolated from tumour tissue without in vitro 
stimulation, suggests initial antigen presentation occurs prior to tumour infiltration and 
clonal expansion commences here. In addition, LN-activated CD8 T cells may proliferate 
further within the tumour microenvironment, as described previously in brain tumours 
(Masson et al., 2007). Generally, cross-presentation of tumour antigens by DCs in the 
tumour-draining LN is considered the primary mode of naive tumour-specific CD8 T cell 
activation (Nelson et al., 2001, Hargadon et al., 2006). We hypothesise that T cell priming 
occurs via this mechanism and subsequent activation presumably occurs within the 
tumour mass, as signified by the expression of recent activation marker CD69 on tumour-
residing T cells. The exact mechanism of T cell activation within the tumour remains to be 
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determined. However, we speculate that this may occur by either direct interaction with 
the tumour or through antigen presentation by tumour-residing professional APCs. 
Various studies have demonstrated low or absent expression of MHC class I on TGCT 
tissue (Nouri et al., 1993, Bols et al., 2000, Hadrup et al., 2006), suggesting the latter may be 
the most likely mechanism of tumour antigen recognition and activation within the 
tumour mass.  
 
The mechanisms operating in the capture, processing and presentation of released tumour 
antigens to T cells in TGCTs in vivo is unknown. Rapid proliferation of tumour cells during 
normal tumour growth and development is associated with a degree of tumour cell 
apoptosis and necrosis, subsequently releasing tumour antigens in the process. In 
addition, we have observed the presence of NK cells within tumour lesions and 
demonstrated the cytotoxicity of these NK cells against MHC class I deficient target cells. 
This implies that this cell type could contribute to the release of MAGE antigens by direct 
lysis of TGCT cells. This would suggest that TGCT-residing NK cells may play a 
fundamental role in the initial recognition and subsequent lysis of tumour cells. DCs are 
present in TGCT lesion (Bols et al., 2000), and we propose these cells are important in the 
capture of released tumour antigens and subsequent processing and presentation to T 
cells. 
 
A striking feature of the current study is that although NK cells are effective killers of 
tumour cell lines, they do not effectively eliminate tumours in TGCT patients. Moreover, 
multiple MAGEA family-specific T cell responses were detected in TGCT patients. 
However, there was no indication of these cells limiting tumour growth, which suggests 
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that expanded MAGE-specific immunity has limited value in controlling tumour growth 
in vivo despite the potent effector function of MAGE-specific T cells in vitro. It is difficult to 
determine the efficacy of a tumour-specific response that is observed in TGCT patients, as 
mortality is low and recurrence is very rare, even in patients with metastatic disease. We 
can therefore assume that MAGE-specific T cells are deficient in their ability of tumour 
clearance, although they may slow tumour growth and progression. The indolent course 
that seminoma follows may be due to the presence of a vast lymphocytic infiltrate, unlike 
primary NSGCTTs, which are more aggressive, exhibit a lesser immune infiltrate and fail 
to provoke a MAGE-specific response.  
 
Aside from tumours reducing immunogenicity, additional mechanisms must be at play to 
enable them to evade immune destruction. Here, we propose possible routes of 
immunoregulation within TGCTs that could potentially lead to T cell hyporesponsiveness. 
These include the upregulation of inhibitory receptors TIM-3 and PD-1, and the 
downregulation of activating receptor NKG2D on tumour infiltrating T cells. We 
determined that TGCT tissue, especially seminoma, expressed PD-1 ligands. It is unknown 
whether this expression is by the tumour per se or by the immune infiltrate. Nonetheless, T 
cell activation in an environment with inadequate costimulation, or in the elevated 
presence of co-inhibitory molecules (PD-L1 and PD-L2), could lead to the induction of T 
cell anergy. In addition, prolonged antigen stimulation within the tumour 
microenvironment can lead to an exhausted T cell phenotype, which is associated with the 
high expression of multiple inhibitory receptors including TIM-3 and PD-1. This can 
further contribute to T cell dysfunction, as signalling through these receptors can lead to 
cell cycle arrest and disruption of cytotoxic potential.  
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We propose that anergy and exhaustion may both contribute towards T cell dysfunction in  
TGCTs. T cell anergy may be induced at the time of first antigen stimulation whereas 
exhaustion is a progressive, hierarchical process where dysfunction worsens, and 
correlates with the acquisition of multiple inhibitory receptors over time (Wherry et al., 
2007). We observed both single and dual staining of PD-1 and TIM-3 on CD8 T cells, and 
we speculate that dual inhibitory receptor-expressing T cells are more dysfunctional than 
single inhibitory receptor-expressing T cells.  It has been reported that dual expressing 
NY-ESO-1–specific CD8 T cells are highly dysfunctional compared to single-expressing or 
non- expressing  −  NY-ESO-1–specific CD8 T cells (Fourcade et al., 2010). In the future, we 
would assess the expression of additional inhibitory receptors on the surface of MAGE-
specific T cells and correlate this with the extent of T cell dysfunction. 
 
MAGE-specific T cells are only likely to have a direct effect on testicular tumour growth if 
they are able to enter the tumour microenvironment. We readily detected these cells in the 
peripheral blood of TGCT patients prior to adjuvant chemotherapy. We were intrigued to 
find that the vast majority of MAGE-specific cells had diminished a few months later, 
although low frequencies were still detectable in some patients up to 18 months later. In 
the future, we would investigate the memory phenotype of these cells ex vivo, to 
definitively confirm whether or not MAGE-specific T cells are antigen experienced and to 
determine the phenotype of the low frequency persistent population. We speculate that 
the elevated MAGE-specific populations we detect are TEM cells, as we have observed 
elevated levels of TEM in TGCT patients. In addition, the decline in MAGE-specific T cells 
over time correlates with the reduced proportion of TEM cells in peripheral blood of TGCT 
patients. Furthermore, it is likely that the remaining MAGE-specific T cells contribute to 
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immunological memory and confer long-term protection. MAGE-specific immunological 
memory is not present in the peripheral blood all patients, which is probably due to 
biological factors such as the homing and tissue distribution of these T cells. In conclusion, 
we show a decline in MAGE-specific immunity following treatment, which may mimic the 
death phase of an adaptive immune response in a human cancer scenario, whereby, the 
tumour-specific T cell pool contracts in the absence of cognate antigen.  
 
Much of our knowledge regarding cancer immunology is derived from research using 
animal models of the disease. Studies on TGCT patient samples offer potential data that is 
more readily translatable to clinical therapeutics. Firstly, TGCTs are an ideal model to 
investigate tumour immune evasion, since multiple regulatory mechanisms exist, many of 
which are apparent in other tumour types. Secondly, spontaneous immunity towards 
MAGE antigens is developed and detectable in the peripheral blood of these patients. 
Thirdly, the findings in this study are transferable across many solid tumours that express 
MAGE antigens. Finally, TGCT patients are predominantly young to middle-aged men 
and therefore have an efficiently functioning immune system. This removes the 
complications related to inadequate tumour-specific responses as a consequence of a 
limited naive T cell repertoire and age-related immune senescence. 
 
Testicular cancer is a relatively rare cancer but incidence is rising fast, with an estimated 
doubling over the last 40 years in the UK (Toledano et al., 2001, Swerdlow et al., 1998) and 
USA (McGlynn et al., 2003). Although treatment currently provides a long-term cure in the 
majority of patients, there are a small number that succumb to this disease. Moreover, 
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many adverse side effects including major cardiovascular complications, nephrotoxicity, 
and infertility are commonly associated with cisplatin-based chemotherapy treatment. The 
increasing number of long-term survivors of this disease highlights the long-term side 
effects of such treatments, many of which are more detrimental than cancer recurrence. 
Alternative treatments which may include immunotherapy regimens could be put into 
practice in order to minimise the occurrence and severity of chemotherapy-induced long-
term side effects. 
 
The frequent, concomitant expression of multiple CTAgs in TGCTs, in addition to the 
existence of spontaneous MAGE-specific CD4 and CD8 T cells, demonstrated in this study, 
supports the development of specific vaccination protocols. We observe patients with a 
pre-existing response to MAGE antigens and such patients are more likely to generate a 
further response following vaccination with the same antigen (Reynolds et al., 2003). It 
would be interesting to consider a combination of vaccine strategies to induce a secondary 
MAGE-specific T cell response with PD-1 or TIM-3 blockade, to improve the efficacy of a 
tumour-specific T cell response. Many anti-cancer drugs have been shown to upregulate 
NKG2D ligands on the surface of tumour cells, which induce direct NK cell-mediated 
tumour cell lysis (He et al., 2013, Yang et al., 2013, Wu et al., 2012). However, we show a 
significant downregulation of NKG2D expression on NK cells and T cells, presumably due 
to overexpression or shedding of NKG2D ligands from the tumour surface. Our findings 
do not support this particular rationale for increasing the immunogenicity of TGCTs, 
which may in fact augment immunosuppressive mechanisms by further reducing the 
expression of NKG2D on tumour infiltrating immune cells.  
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Spontaneous humoral immune responses, in addition to cell-mediated immune responses, 
have been detected towards various tumour types (Fossa et al., 2004, Akcakanat et al., 2004, 
Lendvai et al., 2010). Since B cell frequencies in TGCTs are high (Bols et al., 2000), future 
studies should include the examination of antibody responses towards the tumour, 
including those generated towards MAGE antigens. Isolation of tumour-specific B cells 
would allow the generation of therapeutic antibodies, which could be utilised to induce an 
anti-tumour antibody dependent cell cytotoxicity (ADCC) response. 
 
In conclusion, we have found antigen experienced, recently activated and exhausted T 
cells within TGCT lesions. Despite the reversibility of T cell effector function in vitro, 
immune-mediated tumour clearance in these patients is not observed, suggesting multiple 
tumour immune evasion mechanisms operate. Engagement of PD-1 and TIM-3 with their 
respective ligands may account for the lack of an efficient anti-tumour response in vivo. 
The main finding of this study was the demonstration of spontaneous T cell immunity to 
MAGEA family antigens in TGCT patients. MAGE-specific T cell responses may be mere 
markers of exposure to antigen without functional relevance, which is substantiated by the 
fact that low or absent MHC class I expression on testicular tumour cells has been 
reported. Nonetheless, our results suggest that multiple tumour-specific T cell responses 
are generated against primary seminoma tumours, whereas a response to NSGCTT is only 
provoked by the development of a secondary tumour. We have established for the first 
time that elevated frequencies of MAGE-specific T cells diminish over time, which may be 
strongly associated with the loss of cognate antigen following treatment. 
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Combined, our findings lead to the possibility that this family of tumour-specific antigens 
could be manipulated along with inhibitory receptor blockade to enhance the anti-tumour 
response in cancer patients. Further exploration into the interactions between tumour cells, 
stromal cells and TIL in the tumour microenvironment will be important in the design of 
more efficacious cancer immunotherapies, which are widely applicable across many 
tumour types. 
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APPENDIX 
 
  Table 29. Patient Information of Recruited TGCT Patients. 
Patient 
ID 
Age 
Primary Tumour 
Type 
Tumour Stage 
Localised (L) 
or 
Metastatic (M) 
Chemotherapy 
Regimen 
Date of 
Reoccurrence 
(if any) 
Date of 1st 
Sample 
01DB 30 Pure Seminoma Stage 2b M 3 x EP120 
 
24/11/2010 
02PM 52 Pure Seminoma Stage 1 L Carboplatin 
 
07/12/2010 
03RD 35 NSGCTT IGCCCG - Good M 3 x BEP165 
 
07/12/2010 
04SD 41 Pure Seminoma Stage 1 L Carboplatin 
 
07/12/2010 
05TB 23 Pure Seminoma Stage 1 L Carboplatin 
 
11/01/2011 
06JB 32 Pure Seminoma Stage 2a M 3 x EP120 
 
17/01/2011 
07IB 47 Pure Seminoma Stage 1 L Carboplatin 17/01/2013 18/01/2011 
08JP 37 Mixed GCT Stage 1  vi+ L 2 x BEP120 
 
18/01/2011 
09DW 48 Mixed GCT Stage 1  vi- L Surveillance 
 
18/01/2011 
10CP 28 NSGCTT Stage 1  vi- L 2 x BEP120 
 
24/01/2011 
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11DO 20 Pure Seminoma Stage 1 L Carboplatin 
 
22/02/2011 
12AW 30 Pure Seminoma Stage 1 L Carboplatin 
 
15/03/2011 
13SC 24 Pure Seminoma Stage 1 L Carboplatin 
 
15/03/2011 
14AM 39 Pure Seminoma Stage 1 L Carboplatin 
 
29/03/2011 
15SK 47 Pure Seminoma Stage 2a M 3 x EP120 
 
31/03/2011 
16PR 44 Pure Seminoma Stage 1 L Carboplatin 
 
17/05/2011 
17YH 26 NSGCTT IGCCCG - Good M 3 x BEP165 
 
20/05/2011 
18MP 25 NSGCTT Stage 1  vi- L 2 x BEP120 
 
24/05/2011 
20KB 41 Mixed GCT IGCCCG - Good L 2 x BEP120 
 
31/05/2011 
21LW 24 NSGCTT IGCCCG - Good M 3 x BEP165 
 
14/06/2011 
22DG 37 Pure Seminoma Stage 1 L Carboplatin 
 
21/06/2011 
23DW 22 NSGCTT IGCCCG - Good M 3 x BEP165 
 
21/06/2011 
25PM 44 Pure Seminoma Stage 1 L Carboplatin 
 
28/06/2011 
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26MP 55 Pure Seminoma Stage 2b M 3 x EP120 
 
28/06/2011 
27MC 45 Pure Seminoma Stage 1 L Carboplatin 
 
05/07/2011 
31GS 30 Mixed GCT Stage 1  vi- L 2 x BEP120 
 
30/08/2011 
33LH 46 Pure Seminoma Stage 1 L Carboplatin 
 
04/10/2011 
34SR 39 Pure Seminoma Stage 1 L Carboplatin 
 
04/10/2011 
35NM 31 Pure Seminoma Stage 1 L Carboplatin 
 
04/10/2011 
36GC 40 Pure Seminoma Stage 1 L Carboplatin 
 
11/10/2011 
37SR 21 Pure Seminoma Stage 1 L Carboplatin 
 
11/10/2011 
38MT 26 NSGCTT IGCCCG - Good M 3 x BEP165 
 
11/10/2011 
39DT 67 Pure Seminoma Stage 1 L Carboplatin 
 
18/10/2011 
40DC 72 Pure Seminoma Stage 3 L 3 x EP120 
 
18/10/2011 
41ZY 31 Pure Seminoma Stage 1 L Carboplatin 
 
18/10/2011 
42GM 37 Pure Seminoma Stage 1 L Carboplatin 
 
18/10/2011 
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43SJ 35 Pure Seminoma Stage 1 L Carboplatin 
 
25/10/2011 
44SA 43 Pure Seminoma Stage IV M 4 x BEP100 
 
25/10/2011 
45PR 47 Pure Seminoma Stage 1 L Carboplatin 
 
08/11/2011 
47MH 37 Pure Seminoma Stage 2a M 3 x EP120 
 
09/12/2011 
48JL 54 Pure Seminoma Stage 1 L Carboplatin 
 
10/01/2012 
49NC 20 NSGCTT IGCCCG - Good M 3 x BEP165 
 
10/01/2012 
50RN 45 Mixed GCT Stage 1  vi- L 2 x BEP120 
 
10/01/2012 
52RA 42 Pure Seminoma Stage 1 L Carboplatin 
 
24/01/2012 
53LR 33 Pure Seminoma Stage 1 L Carboplatin 
 
24/01/2012 
54SH 23 Mixed GCT Stage 1  vi+ L 1 x BEP165 
 
24/01/2012 
56AP 34 Pure Seminoma Stage 1 L Carboplatin 
 
31/01/2012 
57MV 32 Pure Seminoma Stage 1 L Carboplatin 
 
31/01/2012 
58CL 31 Pure Seminoma Stage 1 L 3 x EP120 
 
02/02/2012 
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59BS 27 Pure Seminoma Stage 1 L Carboplatin 
 
03/02/2012 
61ZQ 25 NSGCTT Stage 1  vi+ L 1 x BEP165 
 
07/02/2012 
62ML 37 Mixed GCT Stage 1  vi- L 2 x BEP120 
 
07/02/2012 
63JL 24 Mixed GCT Stage 1  vi- L 2 x BEP120 
 
21/02/2012 
65FB 32 Pure Seminoma Stage 1 L Carboplatin 
 
21/03/2012 
66MI 36 NSGCTT IGCCCG - Good M 3 x BEP165 
 
18/04/2012 
67TC 22 NSGCTT Stage 1  vi+ L 1 x BEP165 
 
20/04/2012 
68CJ 28 Pure Seminoma Stage 1 L Carboplatin 
 
26/04/2012 
69HB 45 NSGCTT IGCCCG - Inter M 4 x BEP165 16/04/2012 27/04/2012 
70DS 23 Pure Seminoma Stage 1 L Carboplatin 
 
01/05/2012 
71DM 41 Pure Seminoma Stage 1 L Carboplatin 
 
01/05/2012 
72TC 51 NSGCTT IGCCCG - Good M EP 165 
 
04/05/2012 
74SW 24 Embryonal Carcinoma Stage 1  vi- L 2 x BEP120 
 
04/05/2012 
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75NS 43 Pure Seminoma Stage 1 L Carboplatin 
 
04/05/2012 
76AM 20 Mixed GCT Stage 1  vi+ L 1 x BEP165 
 
04/05/2012 
77DS 33 Mixed GCT Stage 1  vi- L 2 x BEP120 
 
08/05/2012 
80JD 28 NSGCTT Stage 1  vi+ L 2 x BEP120 
 
26/06/2012 
82MC 54 Pure Seminoma Stage 1 L Carboplatin 
 
10/07/2012 
83PR 49 Pure Seminoma Stage 1 L Surveillance 
 
10/07/2012 
84JM 23 Embryonal Carcinoma Stage 1  vi+ L n/a 
 
03/08/2012 
85JJ 43 Pure Seminoma Stage 1 L Carboplatin 
 
21/08/2012 
86CE 39 Mixed GCT Stage 1  vi- L 2 x BEP120 
 
21/08/2012 
87AB 82 Pure Seminoma Stage 2b M Radiotherapy 
 
26/09/2012 
89KJ 57 Pure Seminoma Stage 1 L Carboplatin 
 
08/10/2012 
90LS 36 Pure Seminoma IGCCCG - Good L 3 x EP120 
 
16/10/2012 
91PN 39 Pure Seminoma Stage 1 L Carboplatin 
 
19/10/2012 
 
